Chronic and Acute Effects of Green Tea Extract and Catechol-O-methyltransferase Genotype on Body Composition and Obesity-Associated Hormones in Overweight and Obese Postmenopausal Women by Dostal, Allison
  
Chronic and Acute Effects of Green Tea Extract and Catechol-O-methyltransferase 
Genotype on Body Composition and Obesity-Associated Hormones in Overweight and 
Obese Postmenopausal Women 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF  
UNIVERSITY OF MINNESOTA 
BY 
 
Allison M. Dostal 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF  
 DOCTOR OF PHILOSOPHY 
 
Mindy S. Kurzer 
 
 
June 2015 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Allison M. Dostal 2015 
  i 
Acknowledgements 
Thank you to my adviser, Dr. Mindy Kurzer, for her guidance and perspective through 
the rigorous challenges of obtaining my doctoral degree. I would also like to extend an 
immense amount of appreciation to the members of the Minnesota Green Tea Trial team 
– in particular, Hamed Samavat, Sarah Bedell, April Rose, William (Ed) Smith, Jane 
Mobeck-Wilson, and Andrea Arikawa. We navigated this experience together, and I am 
so thankful to have worked with such intelligent, kind, and inspirational individuals. 
I am forever grateful to Luis Espejo, whose statistical expertise and devotion to these 
projects made data analysis understandable and relatable, and who graciously donated his 
time to teach me these important principles. 
I owe an immeasurable amount of gratitude to Drs. Dan Gallaher, Sabrina Trudo, and 
Kristin Anderson. In addition to their service on my doctoral committee, each of these 
individuals has served as my teacher in some capacity, both inside and outside of the 
classroom. I can only hope to achieve the same level of success, respect, and knowledge 
that they possess. 
Thank you to my friends, family, and graduate student peers for their patience and 
unwavering support through this incredibly challenging, but unquestionably rewarding, 
period of my life. I have grown so much in my years at the University of Minnesota, and 
I will forever be thankful to the Department of Food Science & Nutrition and the 
individuals within it for providing the formative experiences that have made me the 
person and professional that I am today. 
 
 
 
 
 
 
 
 
 
 
 
  ii 
Dedication 
 
"i would not trade a single highway or city or moment or person i met for anything. 
i have loved it all." 
 
- St. Vincent 
 
To my parents, for their enduring patience and confidence that I would be done with 
school…someday. Thank you for never losing faith and always giving me strength.  
And to Trevor Webster, for his reassurance, encouragement, and humor through these 
exhilarating and overwhelming years. 
Your support has meant everything to me. 
  iii 
Abstract 
This dissertation details the chronic and acute effects of green tea extract (GTE) 
supplementation (1315 mg green tea catechins/day, 843 mg as (-)-epigallocatechin-3-
gallate, [EGCG]) on body composition, obesity-associated hormones, glucose 
homeostasis, and satiety in overweight and obese postmenopausal women at increased 
risk for breast cancer due to high mammographic density. Participants in the forthcoming 
studies were a subset of participants drawn from the Minnesota Green Tea Trial (MGTT), 
which was a randomized, placebo-controlled, double-blind, phase II clinical trial 
designed to determine the effects of supplementing GTE for one year on breast cancer 
risk factors including mammographic density, reproductive hormones, insulin-like 
growth factor (IGF) axis proteins, and F2-isoprostanes, a recognized biomarker of 
oxidative stress. Effect modification by catechol-O-methyltransferase (COMT), an 
enzyme involved in the metabolism of green tea catechins, estrogens, and norepinephrine, 
was also analyzed for all endpoints, due to its potential role in modulating the impact of 
GTE on breast cancer risk factors.  
Chapter 1 provides a brief introduction to the MGTT and the forthcoming 
chapters. Chapter 2 presents a review of the literature, providing context for the MGTT 
and ancillary studies. Chapter 3 describes the effect of GTE on anthropometric variables, 
obesity-associated hormones (leptin, ghrelin, adiponectin, and insulin) and markers of 
glucose homeostasis (blood glucose concentrations and the homeostasis measure of 
insulin resistance [HOMA-IR]) in 237 participants. In this study, no changes in energy 
intake or anthropometric measurements were observed in women taking GTE or placebo. 
Similarly, no changes were seen in circulating leptin, ghrelin, adiponectin, or glucose 
concentrations. However, among participants with baseline insulin ≥10 µIU/mL, there 
was a reduction in insulin concentration in the GTE group over 12 months compared to 
the placebo group and participants with baseline insulin < 10 µIU/mL in either group (P 
< 0.01). Participants with the homozygous high-activity (G/G) form of COMT showed 
significantly lower adiponectin and higher insulin concentrations at month 12 as 
compared to those with the low-activity (A/A) genotype, regardless of treatment group.  
  iv 
Chapter 4 describes the more specific effects of GTE on body composition as 
measured by dual-energy x-ray absorptiometry (DXA), including total body fat, % body 
fat, region-specific adiposity, and bone mineral density (BMD) in 121 participants. These 
results were correlated with measures of leptin, adiponectin, and insulin. No changes in 
BMI, total fat mass, % body fat, or BMD were observed in women taking GTE compared 
to placebo; however, a reduction in visceral adipose tissue mass in GTE participants as 
compared to the placebo group nearly reached significance. Interactions were observed 
between treatment, time, and baseline BMI for gynoid % fat and tissue % fat, with more 
favorable results seen in the GTE group. No changes were seen in circulating leptin, 
adiponectin, or insulin concentrations. COMT genotype did not modify the effect of GTE 
on any variable.  
Chapter 5 details the acute postprandial effects of GTE administration in 60 
participants who were administered a high-carbohydrate breakfast meal in the final 
months of their participation in the MGTT. Leptin, ghrelin, and adiponectin were not 
different between GTE and placebo at any time point and COMT genotype did not 
modify these results. Participants randomized to GTE with the high-activity form of the 
COMT enzyme (GTE-high COMT) had higher insulin concentrations immediately after 
the test meal (time 0) and at 0.5 and 1.0 hours post-meal compared to all COMT groups 
randomized to placebo. The GTE-high COMT group had higher insulin concentrations at 
times 0, 0.5, 1.0, 1.5, and 2.0 h compared to the GTE-low COMT group. Nine markers of 
satiety and appetite, as measured through comparison of mean area under the curve 
(cm/hr), were not different between GTE and placebo.  
The results of these three studies demonstrate that daily supplementation of 1315 
mg GTE, independent of caffeine, does not influence long-term energy intake, satiety, 
body weight, or obesity-associated hormones, though it may be beneficial for individuals 
with a higher degree of visceral adiposity and with increased circulating insulin 
concentrations. This suggests benefit for those at risk for metabolic syndrome or type 2 
diabetes. Given the association of these conditions with breast cancer risk, GTE may be a 
beneficial dietary supplement for overweight and obese postmenopausal women. 
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Chapter 1 - Introduction 
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Breast cancer is the most common type of non-skin cancer worldwide and is a 
significant cause of cancer-related mortality in women. Results of many epidemiologic 
studies have determined that obesity is a strong risk factor for postmenopausal breast 
cancer, which is concerning given the increasingly widespread epidemic of this metabolic 
condition. While risk factors for breast cancer are both genetic and lifestyle-related, 
recent research has focused on those determinants that may be modifiable, such as body 
weight, adiposity, and dietary intake of certain foods and beverages.  
Green tea catechin consumption has been suggested as a strategy for weight loss 
and weight maintenance in overweight and obese women. While some positive results of 
green tea on body weight and adiposity have been reported, other studies have 
demonstrated null results, making the current data inconclusive. Additionally, it is 
undetermined if any beneficial effects of green tea on body weight are due to its catechin 
content, caffeine (which is naturally present in tea), or a synergistic relationship between 
the two compounds. To date, the number of long-term randomized trials (>12 weeks) 
examining these relationships is few, and clinical relevance of any observed weight loss 
is uncertain. Rate of metabolism of green tea catechins may also have an impact on the 
influence of green tea on these variables. O-methylation, catalyzed by catechol-O-
methyltransferase (COMT) is one pathway of catechin metabolism, and polymorphisms 
of this enzyme may influence the duration of exposure to green tea catechins. 
This dissertation addresses four general questions related to obesity and 
decaffeinated green tea extract (GTE) supplementation. First, does GTE produce 
favorable changes in body weight and body composition in overweight and obese 
postmenopausal women? Second, are circulating concentrations of obesity-associated 
hormones and markers of glucose homeostasis altered with chronic ingestion of GTE? 
Third, does GTE supplementation impact postprandial satiety or concentrations of 
obesity-associated hormones and glucose homeostasis markers? Lastly, are these effects 
modified by COMT genotype? Answers to these four questions will provide a 
comprehensive analysis of the role of long-term green tea catechin consumption and 
COMT genotype on obesity, adiposity, and obesity-associated hormone concentrations in 
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postmenopausal women, which may lead to targeted strategies for prevention of obesity-
related health conditions, including postmenopausal breast cancer. 
Research reported in this dissertation is the result of three ancillary studies that 
were conducted in a subset of overweight and obese participants enrolled in the 
Minnesota Green Tea Trial (MGTT). The MGTT was a randomized, double-blind, 
placebo-controlled, phase II clinical trial investigating the effect of 12 months of daily 
decaffeinated GTE supplementation on breast cancer risk factors in postmenopausal 
women. Participants in the MGTT were healthy women between the ages of 50-70 years 
who were at high risk of breast cancer due to dense breast tissue. The intervention was a 
green tea extract supplement containing a daily dosage of 1315 mg green tea catechins 
(843 mg as (-)-epigallocatechin-3-gallate) or placebo, taken in capsule form for one year. 
The primary outcomes included change from baseline in percent mammographic density, 
circulating endogenous sex hormones, and insulin-like growth factor axis proteins; the 
secondary endpoints were urinary estrogens and metabolites and plasma F2-isoprostanes 
(a recognized biomarker of oxidative stress). The MGTT screened more than 100,000 
mammograms and randomized 1075 participants into 6 groups based on treatment (GTE 
vs. placebo) and COMT genotype (high-, intermediate-, or low-activity). Among enrolled 
participants, 937 women successfully completed the study and 139 withdrew from the 
study (attrition rate: 12.9%).  
Chapter 2 presents a review of the literature on green tea and its associations with 
obesity and breast cancer, which will assemble the framework upon which the rationale 
for the forthcoming chapters will be constructed. Chapter 3 describes in detail a study 
designed to examine the impact of GTE on anthropometric variables, obesity-associated 
hormone concentrations, and glucose homeostasis markers over the 12-month 
intervention period. The second study, comprising Chapter 4, analyzed the effect of GTE 
on specific measures of body composition, adiposity, and skeletal health and correlated 
these results with circulating concentrations of obesity-associated hormones. Chapter 5 
details research that aimed to determine the effect of GTE consumption on acute 
postprandial concentrations of obesity-associated hormones, markers of glucose 
homeostasis, and satiety after a high-carbohydrate breakfast meal. Lastly, Chapter 6 
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summarizes the knowledge gained from these studies and assesses this research in the 
context of the current literature on the relationship between green tea, obesity, and 
postmenopausal breast cancer. 
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I. Breast Cancer 
Breast cancer is the most common type of non-skin cancer in women 
worldwide and is the second leading cause of cancer-related deaths amid women 
in Western countries. In 2015, an estimated 231,840 new cases of breast cancer 
will be diagnosed in the United States and it is projected that 40,290 deaths will 
occur as a result of the disease. Approximately 1 in 8 women in the U.S. will 
develop breast cancer during their lifetime (1).  
A. Risk Factors 
Numerous risk factors for breast cancer have been identified and can be 
classified into modifiable or non-modifiable categories. Non-modifiable risk 
factors, such as increasing age or female gender, cannot be changed. Risk factors 
that are linked to environmental causes or personal health behaviors are 
modifiable and may change over time. Therefore, a woman’s risk of developing 
breast cancer continues to evolve through the life span. 
1. Non-modifiable Risk Factors 
a) Age 
Breast cancer risk increases with increasing age. According to the 
American Cancer Society, approximately 1 in 8 invasive breast cancers are 
diagnosed in women younger than 45 years, while 2 of 3 cases of breast cancer 
are found in women 55 years or older (2).  
b) Gender 
Breast cancer occurs nearly 100 times more often in women than in men, 
likely due to increased exposure to estrogen and progesterone, which are known 
to promote breast carcinogenesis (3).   
c) Race and Ethnicity 
Breast cancer incidence varies by race and ethnicity. In 2011, the most 
recent year for which numbers have been reported for U.S. populations, white 
women had the highest breast cancer incidence rates, followed by black, Hispanic, 
Asian/Pacific Islander, and American Indian/Alaska Native women (4).  
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d) Genetic Factors 
It is estimated that 5 to 10% of all breast cancers can be directly attributed 
to inherited gene mutations, most often to mutations in the BRCA1 or BRCA2 
genes. Mutations in other genes, including ATM, TP53, CHEK2, PTEN, CDH1, 
PALB2, and STK11 can also increase breast cancer risk, though these mutations 
are much more rare and do not increase risk to the same extent as BRCA genes 
(2). 
e) Family History 
A woman’s risk for breast cancer doubles if she has one first-degree 
relative with the disease. If a woman has 2 first-degree relatives with breast 
cancer, her risk is three times higher. However, the number of women diagnosed 
with breast cancer who have a family member with the disease (15%) is relatively 
small compared to those diagnosed without a family history (85%) (3).   
f) Breast Density 
Women classified as having dense breasts on mammogram, indicating an 
increased amount of fibrous or glandular breast tissue as compared to fatty tissue, 
have a 1.2- to 2-fold increased risk of breast cancer as compared to women with 
average breast density. In addition, dense breast tissue can make detecting tumors 
via mammogram more difficult (5).  
2. Lifestyle-related Risk Factors 
a) Reproductive History and Estrogen Exposure 
Lifetime exposure to estrogens is an established risk factor for breast 
cancer. Having several pregnancies, becoming pregnant at a young age, and 
breastfeeding are known to reduce risk, attributed to exposure to lower levels of 
endogenous estrogens during pregnancy and lactation (6). Nulliparous women or 
those who had their first child after the age of 30 have a modestly increased risk 
of breast cancer. Additional risk factors include early age of menarche (before age 
12) and entering menopause after age 55, both of which are associated with longer 
duration of estrogen exposure (3).  
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Hormone therapy after menopause, referred to as menopausal hormone 
therapy (MHT) in this manuscript, is used to relieve adverse symptoms after 
menopause and prevent loss of bone mineral density (BMD). Research has shown 
that using combined MHT (both estrogen and progesterone) increases breast 
cancer incidence and mortality, especially if used for longer than 2 to 3 years. Use 
of estrogen alone has not been associated with these effects (7). Use of oral 
contraceptives may also increase risk, though this association diminishes if a 
woman has discontinued use for over 10 years (8). 
b) Alcohol and Tobacco Use 
Compared with non-drinkers, women who consume 1 alcoholic drink per 
day have an increased risk of breast cancer, and this risk increases with the 
amount of alcohol consumed (9). Both mainstream and secondhand smoke 
contain chemicals that have been shown to cause breast cancer in rodents, and 
chemicals present in tobacco smoke have been found in breast milk (10). Yet, the 
association between tobacco use and breast cancer remains inconclusive, as the 
2014 U.S. Surgeon General’s report concluded that there is “suggestive but not 
sufficient” evidence that smoking increases breast cancer risk (11).  
c) Physical Activity 
Regular physical activity has been shown to have a protective effect 
against postmenopausal breast cancer: risk reduction for physically active 
individuals compared with those who are least active may be as much as 25% 
(12).   
d) Dietary Intake  
The influence of diet on postmenopausal breast cancer risk remains 
inconclusive. While some studies have found that a diet rich in fruits, vegetables, 
poultry, fish, and low-fat dairy is associated with reduced breast cancer risk, 
others have found null effects (9). Intake of foods high in dietary flavonoids, such 
as soy and green tea, may also have preventive effects against breast cancer 
occurrence (9). Epidemiologic studies have mainly determined that breast cancer 
is less common in countries where the typical diet is low in total fat, 
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polyunsaturated fat, and saturated fat (13). Yet, these results have not been seen in 
studies conducted in the United States (14). Reasons for this discrepancy may 
involve variations in typical dietary intake, physical activity, and genetic factors 
when comparing women in the U.S. versus those in other countries. Another 
important consideration is the strong association between dietary and total energy 
intake with body weight and obesity, which itself is an independent risk factor for 
postmenopausal breast cancer. 
e) Obesity 
      A vast body of knowledge has been amassed regarding the epidemiologic 
associations of body weight, body fatness (as measured by body mass index 
[BMI]), and postmenopausal breast cancer risk. It is widely known that obesity 
increases risk for postmenopausal breast cancer (15-23) and is associated with 
poorer prognosis (24). A pooled analysis of seven prospective cohort studies 
comprised of 337,819 women and 4,385 incident breast cancer cases indicated 
that the relative risk of breast cancer was 1.26 (95% CI: 1.09-1.46) when a BMI > 
28 kg/m2 was used as the highest category in the analyses of postmenopausal 
women (21). Interestingly, overweight and obesity have been found to be 
moderately protective in premenopausal women (21). This reversal of effect may 
be explained by differing methods of estrogen production in pre- versus 
postmenopausal women. Estrogen production in premenopausal women mainly 
occurs in the ovaries; in contrast, estrogen is produced primarily by adipose tissue 
after menopause (25). Since epidemiologic studies have suggested that serum 
estrogen concentration is a risk factor for breast cancer in postmenopausal women 
(26) increased body fat, leading to a higher serum estrogen concentration, may be 
an independent risk factor for breast carcinogenesis. Additionally, central 
adiposity increases risk of postmenopausal breast cancer independent of body 
weight (15,20,27). Conversely, maintenance of body weight throughout the adult 
years and weight loss after menopause are associated with decreased risk of 
postmenopausal breast cancer (18,28).  
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        In 2007, the World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) issued the Second Expert Report “Food, Nutrition, 
Physical Activity, and the Prevention of Cancer: a Global Perspective”(29), which 
concluded that adult weight gain, body fatness, and abdominal body fatness are 
causally linked to breast cancer incidence in postmenopausal women. These 
conclusions continue to be supported by the AICR’s Continuous Update Project, 
whose last publication in 2010 classified the evidence of body fatness as a risk 
factor for postmenopausal breast cancer as “convincing” and abdominal fatness 
and adult weight gain as “probable” (30). 
B. Section Summary 
There are a number of modifiable and non-modifiable risk factors for breast 
cancer. While characteristics such as age, gender, race and ethnicity, genetics, and family 
history are unable to be impacted by prevention strategies, several lifestyle modifications 
can be made to reduce postmenopausal breast cancer risk, including decreasing body 
weight and adiposity. 
II. Mechanisms of the Relationship between Obesity, Body Composition and Breast 
Cancer Risk 
A. Introduction and Definitions 
 Over the past several decades, obesity has become a significant public health 
concern due to its association with many chronic diseases and cancers, including 
postmenopausal breast cancer. It is estimated that more than one-third (34.9% or 78.6 
million) of U.S. adults are obese, with the highest rates in middle-age adults (40-59 years 
old, 39.5% obesity rate) as compared to younger adults (20-39 years old, 30.3%) and 
those aged 60 or above (35.4%) (31). As of 2008, the annual burden of obesity on the 
U.S.’s health care system was estimated to be $147 billion; annual medical costs for 
people who are obese are approximately $1,429 higher than those of normal weight (32).  
The World Health Organization defines obesity in terms of the body mass index 
(BMI), measured by weight in kilograms (kg) divided by height in meters squared (m2). 
An adult with a BMI between 25.0 and 29.9 kg/m2 is considered overweight, and a BMI 
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>30.0 kg/m2 is considered obese. While BMI does not directly measure adiposity, its use 
is widespread due to its simple calculation and high correlation with body fatness. Most 
epidemiologic studies use simple measurements such as BMI, waist circumference (WC), 
and waist-to-hip ratio (WHR) as proxies for obesity due to the inherent difficulty and 
expense in gathering more detailed and specific data from large study populations.  
Fat is principally deposited in two compartments; subcutaneously and viscerally. 
Visceral adipose tissue (VAT), which is comprised of intra-abdominal fat, is known to be 
more metabolically active than subcutaneous fat and has multiple endocrine, metabolic, 
and immunological functions. It has also been shown to be central to the pathogenesis of 
the metabolic syndrome, a constellation of disorders diagnosed by possessing 3 of the 5 
following characteristics: WC >88 cm (women); triglycerides ≥ 150 mg/dL; high-density 
lipoprotein (HDL) cholesterol < 50 mg/dL (women); blood pressure ≥ 130/85 mmHg; 
and fasting glucose ≥ 110 mg/dL (33). 
 It is well established that obesity is associated with cancer development at 
numerous sites, including the esophagus, pancreas, colorectum, endometrium, kidney, 
and breast (in postmenopausal women) (29). The AICR has estimated that 38% of all 
breast cancer cases in the U.S. could be prevented with lifestyle modifications including 
maintaining a healthy weight – this amounts to approximately 89,300 women being 
spared of breast cancer every year (30). The mechanisms by which obesity increases 
breast cancer incidence and mortality, and the role of visceral adipose tissue in disease 
pathogenesis, have become the focus of considerable research. 
B. Visceral Adipose Tissue and Breast Cancer Pathogenesis 
The importance of adipose tissue location is evident, as an increased ratio of VAT 
area to subcutaneous fat area has been shown to be strongly related to glucose and lipid 
metabolism disorders in obese subjects (34). VAT has also been identified as an 
independent risk factor for breast cancer, largely attributed to the state of chronic 
systemic low-grade inflammation brought about by excess visceral obesity. As VAT 
expands, it becomes infiltrated with macrophages and T-cells. These immune cells and 
the adipocytes produce adipokines including leptin, interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-α). In addition, increasing visceral adiposity leads to 
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hyperinsulinemia and increased concentrations of free insulin-like growth factor-1 (IGF-
1) (35). Consequently, there is a pro-tumorigenic state of inflammation, angiogenesis and 
insulin resistance, a condition that will be discussed in the forthcoming section.  
C. Obesity- and Appetite-associated Hormones  
Several hormones associated with obesity and markers of glucose homeostasis 
also play a critical role in communicating nutritional status to the central nervous system 
(CNS), such as the hypothalamus and the brainstem. In addition to their involvement in 
obesity, IR, and breast cancer, hormonal regulation of appetite by these peptide hormones 
may play a significant role in appetite control and energy intake. Several hormones have 
demonstrated these dual effects, including leptin, adiponectin, ghrelin, and insulin.  
1. Leptin 
Adipose tissue is a dynamic endocrine organ that releases several adipokines, 
including leptin, which was first identified by Zhang et al. (36) in 1994. Leptin is a 
166-amino acid protein with well-characterized effects on regulation of energy 
balance. Leptin concentrations increase after a meal, resulting in reduced food intake 
(37) and increased energy expenditure (38) to maintain the body’s energy stores. 
This is largely due to increased expression of anorexigenic peptides such as pro-
opiomelanocortin (POMC) and cocaine-amphetamine-regulated transcript (CART) 
modulated by leptin (39). Circulating concentrations of the hormone are proportional 
to fat mass (40); however, obese individuals have demonstrated a resistance to the 
protein’s effects (41). Therefore, its appetite-reductive and satiation effects are 
reduced in individuals with a higher degree of adiposity. 
        Apart from its effects on appetite and metabolic rate, leptin has recently been 
associated with the pro-inflammatory properties of obesity and insulin resistance, 
which have been correlated with breast cancer risk (42). Higher blood leptin 
concentrations have been observed in breast cancer patients as compared to controls 
and Garafalo et al. (43) found overexpression of leptin and its receptors in primary 
and metastatic breast cancer as compared to non-cancer tissues. Potential 
mechanisms for carcinogenic effects of leptin include increasing cancer cell 
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migration and invasion (44), increasing angiogenesis via vascular endothelial growth 
factor (VEGF)(45), and induction of pro-inflammatory cytokines and macrophage 
stimulation(46). Therefore, interventions that reduce circulating leptin concentrations 
may have a risk-reductive effect for breast cancer. 
2. Adiponectin 
Adiponectin is the most abundant adipokine and is secreted mainly from 
adipocytes in visceral fat. In contrast to leptin, circulating concentrations are 
inversely correlated with various measures of obesity, including BMI and abdominal 
adiposity (47). Adiponectin modulates several metabolic processes, including 
glucose regulation (48) and fatty acid metabolism (49). Adiponectin has known 
insulin-sensitizing effects, and circulating concentrations of this hormone have been 
found to predict the development of type 2 diabetes (50). Circulating adiponectin and 
adiponectin gene expression in adipose tissue are reduced in patients with type 2 
diabetes and obese populations (51-53). This hormone may also have centrally 
mediated effects on food intake and energy expenditure, though animal studies 
examining this relationship have shown conflicting results (54,55).  
Adiponectin has been shown to be both anti-angiogenic and anti-
inflammatory, and can inhibit tumor growth in animal models (56). Adiponectin 
concentrations have been shown to be an independent risk factor for breast cancer 
(57). In a prospective case-control study nested within the Nurses’ Health Study 
(NHS) and NHS II cohorts, prediagnostic adiponectin levels were inversely 
associated with the risk of postmenopausal breast cancer (58).  
3. Ghrelin 
Ghrelin is a 28-amino acid peptide produced mainly in the stomach and is a 
potent stimulator of food intake (59). Ghrelin secretion is primarily mediated by an 
individual’s nutritional state – concentrations increase in the fasted state and 
decrease after feeding. After its release into the bloodstream, ghrelin crosses the 
blood brain barrier and exerts its orexigenic effects on the hypothalamus. This 
stimulates the activity of neurons expressing neuropeptide-Y (NPY), agouti-related 
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protein (AgRP), and orexin, leading to increased appetite (60,61). At the same time, 
ghrelin reduces the activity of neurons expressing POMC and CART, which 
normally act to decrease food intake and body weight (62). Increased preprandial 
ghrelin concentrations have been correlated with hunger scores in humans (59), and 
intravenous infusion of ghrelin can induce hunger and food intake in both normal-
weight and obese adults (63,64). Circulating ghrelin concentrations are negatively 
correlated with BMI and typically increase with weight loss (65). 
Several studies have correlated ghrelin levels to breast cancer risk – ghrelin 
treatment has been shown to increase proliferation of breast cancer cell lines in vitro 
(66). Conflicting evidence exists for the association of polymorphisms in the gene 
coding for ghrelin (GHRL) or the ghrelin receptor (GHSR) with breast cancer risk 
(67-69). 
4. Insulin 
       Insulin is a 51-amino acid peptide hormone produced in the beta cells of the 
pancreas. Its primary role is maintaining glucose homeostasis mainly in the 
postprandial period, though it is also an important anorexigenic hormone involved in 
food intake. Animal studies have shown that central administration of insulin 
decreases food intake in primates (70) and rodents (71). Concentrations of insulin 
vary with adiposity (72), and this hormone is known to have growth-stimulatory 
effects (73). 
a) Methods of Assessment of Insulin Sensitivity 
         Though no reference range is established for optimal fasting insulin 
concentrations, objective assessment of insulin sensitivity is important for diagnosis 
of health conditions such as IR and diabetes. Direct measures of insulin sensitivity 
include the euglycemic glucose clamp, which is considered to be the gold standard of 
measurement but is also time-consuming, labor intensive, expensive and impractical 
for large clinical investigations and epidemiologic studies (74). Therefore, indirect 
measurements are typically used to assess insulin sensitivity. The homeostasis model 
assessment of insulin resistance (HOMA-IR), which is equivalent to ([fasting insulin 
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(μIU/mL)] × [fasting glucose (mg/dL)]) / 405, is commonly used in clinical trials. 
The denominator of 405 is the product of a standard fasting plasma insulin (5 
μIU/mL) and fasting plasma glucose (81 mg/dL), typical of a “normal” healthy 
individual (74). Therefore, for an individual with “normal” insulin sensitivity, 
HOMA-IR = 1.  
b) Insulin, IR, and Breast Cancer Risk 
Higher concentrations of fasting insulin have been associated with a 2- to 3-
fold increased risk of breast cancer mortality in several studies (75-78), including a 
Women’s Health Initiative random sample of female participants with a baseline 
measurement for glucose and insulin, in which the risk ratio for the highest tertile of 
insulin was 2.22 (95% CI: 1.39-3.53) (79). Yet, associations between fasting insulin 
concentrations and breast cancer risk are not entirely consistent: one meta-analysis 
(80) provided data from five studies, in which two (81,82) found a direct relationship 
between increased fasting insulin and breast cancer risk and three studies (83-85) 
found no association. A meta-analysis specific to the association between metabolic 
syndrome and postmenopausal breast cancer was published in 2013. The authors 
determined that among 9 articles comprised of 6,417 cancer cases, metabolic 
syndrome was associated with a 52% increased risk for breast cancer, which was 
mainly attributed to the results of case-control studies rather than prospective cohort 
studies (86). Importantly, no single component explained the risk conveyed by the 
full syndrome, indicating that there is a complex, synergistic negative effect of the 
health conditions contributing to the metabolic syndrome. 
D. Obesity and Skeletal Health 
Osteoporosis is a skeletal disorder characterized by low bone mass and bone 
tissue deterioration that results in reduced bone strength and increased fracture risk. 
Several epidemiologic studies have highlighted the correlation between obesity and 
osteoporosis (87-91), with many indicating a significant positive relationship between 
body weight and bone mineral density (BMD). This correlation is largely attributed to 
both the increased mechanical load of excess weight and hormonal changes associated 
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with obesity, including increased estrogen and leptin production by adipose tissue, which 
have been shown to suppress bone resorption and stimulate osteoblastogenesis (92-94). 
However, recent evidence has emerged demonstrating that increased body weight may 
actually be negatively correlated with BMD after correction for the mechanical loading 
effect of excess body weight (95), and that obese individuals with high BMD are still at 
increased risk for fractures (88). Research on the association between obesity and 
metabolic bone diseases such as osteoporosis, a major cause of morbidity and mortality in 
postmenopausal women, remains inconclusive. 
1. Dual-energy X-ray Absorptiometry for Measurement of Bone Mineral 
Density and Body Composition 
Although there are several methods for studying human body composition, 
dual-energy X-ray absorptiometry (DXA) has emerged as one of the most commonly 
used clinical standards (96). Using this technique, an energy source produces photons 
at two different energy levels, 40 and 70 keV, which pass through tissues and 
diminish at rates related to its elemental composition. Bone is rich in calcium and 
phosphorous, which are highly attenuating minerals, and therefore it is easily 
distinguished from soft tissues. The elemental profiles of bone, fat, and non-bone lean 
tissue are different from each other, which allows for visualization and separate 
analysis of each tissue type (97). Most currently marketed DXA instruments use 
standardized calibrations, are able to scan quickly (within 5 to 20 min), and use 
standard software for analyses (97). The ability to study body composition in the 
whole body and individual body segments is useful in determining not only BMD, but 
also body fat distribution. The DXA is considered to be one of the gold standards of 
body composition assessment (98).  
E. Section Summary 
Obesity is a significant public health concern and is associated with insulin 
resistance, the metabolic syndrome, and increased risk for postmenopausal breast cancer. 
Intra-abdominal fat, known as VAT, has been identified as an independent risk factor for 
breast cancer, largely attributed to the state of chronic systemic low-grade inflammation 
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brought about by excess abdominal obesity. Several hormones associated with obesity 
and breast cancer also communicate nutritional status to areas of the central nervous 
system, including leptin, adiponectin, ghrelin, and insulin. Osteoporosis and obesity are 
typically negatively correlated, though research has indicated that obese individuals with 
high BMD are still at increased risk for fractures. DXA has emerged as one of the most 
commonly used methods of body composition assessment in randomized trials. Taken 
together, interventions that reduce body weight and adiposity may reduce risk for 
metabolic diseases, osteoporosis, and postmenopausal breast cancer via several 
mechanisms, including alterations in obesity-associated hormone concentrations and 
reductions in VAT. 
III. Green Tea Catechins 
A. Description and Chemical Composition  
Tea is one of the most widely consumed beverages in the world, second only to 
water (99). There are over 300 types of tea, each derived from the leaves of the Camellia 
sinensis plant, which are commonly divided into three types: green tea (non-fermented), 
oolong tea (semi-fermented), and black tea (fermented). Green tea accounts for 
approximately 20% of the world’s tea production, with black tea comprising 78% and 
oolong teas accounting for the remaining 2%. Green tea is the main tea consumed in 
Japan and China but has been relatively uncommon in western countries, where black tea 
is more frequently consumed (99). Green tea is manufactured by steaming and heating 
fresh tea leaves immediately after harvesting; this process avoids oxidation of the 
naturally occurring polyphenols in the plant, the most abundant of which are known as 
catechins. In contrast, the processing of black tea involves oxidization of dried and 
crushed tea leaves by polyphenol oxidase and peroxidase, which convert catechins to 
other compounds (mainly theaflavins and thearubigens) (99,100). 
Green tea has been associated with myriad health benefits which have been 
attributed mainly to its catechin content. Catechins belong to a specific class of flavonoid, 
the flavan-3-ols, and are characterized by a di- or tri-hydroxyl group substitution of the B 
ring and the meta-5,7-dihydroxy substitution of the A ring (101,102). These compounds 
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account for 30-42% of the dry weight of the solids in brewed green tea. Though there are 
many different forms of catechins, the four predominantly found in green tea are (-)-
epicatechin (EC), (-)-epicatechin gallate (ECG), (-)-epigallocatechin (EGC), and (-)-
epigallocatechin-3-gallate (EGCG). Of these, EGCG accounts for 50-80% of the total 
catechins in green tea, making it the most abundant polyphenol (103). The structures of 
these four major catechins are shown in Figure 2.2 (104). Green tea also contains 
caffeine as 2-5% of the water-extractable solids. The amount of caffeine in a tea beverage 
is determined by leaf size, brewing time, and temperature of the steeping liquid and is 
relatively consistent between types of tea, ranging from 14 to 61 mg per 6-8 ounce 
serving (105). Flavonols and flavones make up a small percentage of the polyphenolic 
content (106); other compounds include gallic acid, theanine, theogallin, theobromine, 
theophyilline, nitrogenous compounds, and several minerals (potassium, calcium, 
magnesium, aluminum, and fluoride) (106). 
B. Green Tea Catechin Biotransformation and Metabolism  
Animal studies have determined that green tea catechins (GTC) and their 
downstream metabolites are widely distributed in a broad range of tissues after oral 
administration (107,108). Catechin metabolites reach peak plasma nanomolar 
concentrations 1.6-2.3 hours after intake, which then rapidly decline - only trace amounts 
remain 8 hours after consumption (109). GTC go through extensive biotransformation 
following ingestion, which is primarily accomplished through methylation, sulfation, 
glucuronidation, and ring-fission metabolism by colonic bacteria (110). EC and ECG 
metabolites are primarily excreted in the urine. In contrast, EGCG appears unmetabolized 
in low concentrations in plasma and its metabolites are typically undetectable in urine 
(111). It is largely believed that enterohepatic recirculation of EGCG occurs and that it is 
primarily excreted in the bile (112). Approximately 69% of GTC and their metabolites 
reach the large intestine, where they are converted into phenylvalerolactones and 
phenylvaleric acids, which then leave the body through urinary excretion (109). Clifford 
et al. have noted that based on 24-hour urinary excretion, gut microflora-associated 
metabolites account for substantially more of the recovered flavan-3-ol dose than from 
strictly sulfated, glucuronidated, or methylated forms of GTC (109). 
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1. Catechol-O-methyltranferase (COMT) 
Catechol-O-methyltransferase (COMT), which catalyzes O-methylation reactions, 
is of considerable research interest as it is known to have widespread influence on several 
physiological processes and disease conditions. COMT is ubiquitously present in human 
tissues, with its highest activity in the liver, kidney, and gastrointestinal tract (113) and 
the enzyme is also known to metabolize catecholamines (dopamine, norepinephrine, and 
epinephrine, which are significantly involved in sympathetic nervous system 
stimulation), catecholestrogens, neurotransmitters, and other dietary flavonoids (114). 
COMT is present in both soluble and membrane-bound forms, with the soluble form 
predominating in most tissues (113). While O-methylation of GTC occurs very rapidly, 
inhibition of the COMT enzyme by EGCG and its metabolites has also been 
demonstrated (113), indicating that (1) ingestion of GTC may decrease the degradation 
rate of catecholamines and other substrates of COMT; and (2) alternate pathways of 
catechin metabolism play a significant role in the biotransformation of green tea 
constituents. Indeed, Zhu and colleagues found that ECG and EGCG were methylated at 
much lower rates as compared to EC and ECG (115), while glucuronidation and sulfation 
may play a larger role in EGCG metabolism (116).  
Genetic variations in COMT enzyme activity have been widely noted. One 
common polymorphism, a guanine (G) to adenine (A) substitution, at codon 108 (rs4680) 
of the soluble form of the enzyme (codon 158 of the membrane-bound form) has been 
identified that produces an amino acid change from valine to methionine, which has been 
shown to reduce the thermostability of the enzyme and is associated with a 3- to 4-fold 
decrease in enzymatic activity (117,118). Given these effects, COMT genotype may 
influence the rate of catechin metabolism, stimulation of the sympathetic nervous system, 
and the functional response to dietary catechins.   
Since the health effects of green tea are largely attributed to catechins, factors that 
modulate the bioavailability of these compounds or their downstream metabolites could 
have a significant impact on the health properties associated with tea consumption. 
Polymorphisms in COMT have also been studied in direct relation to breast cancer risk, 
though conflicting hypotheses exist for this association. Wu et al. have described an 
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interaction between tea intake, COMT genotype, and breast cancer risk, in which the 
protective effect of tea consumption on breast cancer risk was mainly limited to women 
carrying at least one copy of the low-activity (A) allele (119). These results suggest that 
individuals with the low-activity COMT genotype metabolize tea catechins at a slower 
rate than those with the high-activity (G) allele, which increases the in vivo exposure of 
these flavonoids within the body. Therefore, a stronger beneficial effect of catechins may 
be observed. This hypothesis has proven to be inconsistent, as some studies have found 
no evidence that COMT genotype is independently associated with breast cancer risk 
among Caucasian and Asian women (120,121). It has also been suggested that 
individuals who inherit the homozygous low-activity genotype may be at increased risk 
for breast cancer due to an increased accumulation of the catechol estrogen intermediates, 
methoxyestradiols and methoxyestrones (122-124). A meta-analysis completed in 2012 
encompassing 51 case-control studies, with a total of 34,358 cases and 45,429 controls, 
concluded that the COMT Val158Met polymorphism was not associated with breast 
cancer risk in women either overall or among subgroups of ethnicity, menopausal status, 
or sources of the control population (125). Yet, dietary interactions between COMT 
genotype and breast cancer risk remain understudied. 
a) Insulin and COMT 
Immunohistochemical staining has indicated that the COMT enzyme is present in 
the beta cells of the pancreas (126), therefore demonstrating significant potential for 
cross-talk between its enzymatic activity and glucose homeostasis. In an animal model of 
diabetes, COMT activity was markedly decreased in the liver, and correction of 
hyperglycemia restored activity of the enzyme (127). Hyperglycemia is associated with 
beta cell destruction; therefore, high blood glucose or an insulin deficit may account for 
the abnormality in COMT activity. The neurotransmitters norepinephrine and dopamine 
are important regulators of many physiological processes - including glucose homeostasis 
(128) - and are metabolized by COMT, so polymorphisms in COMT and potential 
interactions with dietary intake may impact the insulin response. 
Translation of this body of research to humans has yielded evidence of an 
increased risk of impaired glucose tolerance (IGT) and type 2 diabetes (T2D) in 
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individuals with the homozygous high-activity (G/G) genotype. In a cohort study of 
Danish Caucasian men, an 11.6% increased frequency of the G/G genotype was noted in 
those with IGT and T2D as compared to the homozygous low-activity (A/A) genotype 
(129). Similarly, Miller et al. showed that individuals with the G/G genotype (n = 10) had 
a greater increase from baseline in postprandial insulin concentrations 2 and 3 hours after 
a high-carbohydrate breakfast meal as compared to those with the A/A genotype (n = 10), 
despite similar glucose concentrations at these time points (130). However, an association 
between COMT genotype and circulating insulin concentrations was not seen in a 
crossover study of 64 overweight and obese males who consumed 800 mg decaffeinated 
GTC daily for 6 weeks (131). Notably, there is a lack of research – in both epidemiologic 
and randomized controlled trials - on the role of COMT genotype in insulin sensitivity in 
female subjects, indicating the need for additional research in this area. 
C. Section Summary 
Green tea is a popular beverage and is believed to have health benefits, which 
have been attributed its high content of polyphenolic catechins. Catechins are 
metabolized through methylation, sulfation, glucuronidation, and ring-fission 
metabolism, and the COMT enzyme is known to be involved in degradation of catechins 
as well as catecholamines, including norepinephrine. This duality of effect is believed to 
be vital in green tea’s effects on body weight and adiposity. Polymorphisms in COMT 
are thought to play a role in the functional response to dietary catechins, and may also 
impact green tea’s effect on breast cancer and obesity.  
IV. Effect of Green Tea on Obesity and Body Composition 
Given their modifiable nature, obesity and body composition may be influenced by 
dietary intake of foods and beverages, such as green tea. The following sections will 
detail the biological mechanisms behind green tea’s effects on body weight and body 
composition, results of randomized trials assessing body weight and body composition as 
clinical endpoints, and previous research on the impact of GTC on obesity-associated 
hormone concentrations and insulin sensitivity. 
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A. Biological Mechanisms of Green Tea Catechins on Changes in Body 
Composition 
Specific mechanisms by which GTC may influence body weight and adiposity 
continue to be actively researched. Research in humans has primarily focused on four 
main areas: increases in energy expenditure (EE) with GTC administration; increased fat 
oxidation; decreased nutrient absorption, and modifications to satiety and appetite 
control.  
1. Increased Energy Expenditure 
The sympathetic nervous system (SNS) is highly involved in regulation of EE and 
lipolysis. Norepinephrine, a catecholamine produced in the adrenal glands, is a key 
mediator of SNS activity and is known to increase EE and promote fat oxidation (132). 
As stated previously, degradation of norepinephrine is mediated primarily by COMT, an 
enzyme whose activity may be inhibited by GTC. Therefore, GTC, through inhibition of 
COMT activity, may prolong norephinephrine activity and lead to increases in EE and fat 
oxidation. In addition to catechins, green tea also naturally contains caffeine, which is 
independently known to increase EE. Caffeine inhibits phosphodiesterase (PDE), an 
enzyme that rapidly degrades cyclic adenosine monophosphate (cAMP), which is 
released in response to norepinephrine (133) . Therefore, through the dual actions of GTC 
and caffeine, green tea consumption may increase an individual’s metabolic rate, leading 
to weight loss and reductions in adiposity.  
Many randomized trials examining the acute effects of green tea on EE have been 
conducted, with most using interventions including a combination of GTC + caffeine. 
Most of these studies have demonstrated modest increases (3-4%) in 24-hour EE relative 
to caffeine-free control (134-139). A widely cited paper by Dulloo et al. (138) 
demonstrated a 4% increase in 24-hour EE following treatment with 270 mg GTC + 150 
mg caffeine, while there was no change in the group that received caffeine without GTC. 
This finding suggested that GTC had an independent effect on EE. Yet, these results have 
proven difficult to replicate, as additional studies comparing EGCG + caffeine to caffeine 
only and placebo are notably lacking. Further, randomized trials that include comparisons 
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of placebo, caffeine alone, caffeine + EGCG, and EGCG alone (i.e. a 2 x 2 factorial 
design) have not been conducted. 
There is a scarcity of research of the effects of GTC on EE independent of 
caffeine. Only a few studies in total have examined caffeine-free GTC compared to a 
caffeine-free control (140,141) and they have not included EE assessment. While this is 
certainly an important area of active study, measurement of EE was beyond the scope of 
the current project and will not be addressed in the forthcoming research chapters. 
2. Increased Fat Oxidation 
Green tea may also influence body weight and adiposity through changes in fatty 
acid oxidation and metabolism. Norepinephrine stimulates lipolysis in peripheral tissues 
(including adipose, the liver, and skeletal muscle), which releases fatty acids into the 
circulation and up-regulates hepatic lipid metabolism (142). Inhibition of COMT (by 
GTC) and PDE (by caffeine) is theorized to increase fat oxidation. Animal studies 
support this hypothesis (143,144); yet, human studies have shown mixed results.  
The respiratory quotient (RQ) is an indicator of the ratio of fat to carbohydrate 
oxidation, in which a lower RQ (close to 0.7 to 0.8) indicates greater fatty acid oxidation 
as compared to a higher RQ of 1.0, indicating pure carbohydrate oxidation. In humans, 
this is measured through indirect calorimetry (145) . Dulloo et al. (138)  first 
demonstrated that 375 mg GTC + 150 mg caffeine decreased RQ by 3.4% as compared to 
a caffeine-free placebo in a small sample of young male subjects (n=10), which was 
suggestive of increased fat oxidation. Importantly, they did not see an effect of caffeine 
alone, which suggested that a combination of GTC and caffeine was necessary to elicit 
increased FA oxidation. As highlighted in the section above, the findings of this study 
have been widely cited in the literature in support of synergism between catechins and 
caffeine; yet, despite many attempts to replicate these findings, it is the only acute 
feeding study to show preferential effects of GTC in addition to caffeine on RQ and fat 
oxidation.  
It has also been suggested that the effects of GTC on fat oxidation may be 
cumulative over time – one animal study showed that EGCG upregulated gene expression 
of acyl-CoA oxidase and medium chain acyl-CoA dehydrogenase and downregulated 
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expression of hepatic fatty acid synthase following one month of feeding. This resulted in 
a 285% increase in beta-oxidation as compared to control mice on a low-fat diet. These 
results were not noted 24 hours after feeding (144).   
Human studies of long-term (>4 weeks) effects of GTC on fatty acid oxidation are 
inconclusive, and research using female participants is very limited. Mielgo-Ayuso 
studied the effect of 300 mg/day EGCG on body weight and adiposity in a randomized 
trial of 83 obese pre-menopausal Caucasian women over 12 weeks. They did not find any 
significant difference in change in fat mass or fat metabolism between the EGCG and 
placebo groups at the end of the intervention (146). This agrees with previous work, 
which showed that RQ was not different at baseline or between groups after GTC 
ingestion (141 mg GTC + 87 mg caffeine/day) for 4 weeks versus a caffeine-free control, 
declined at week 8, and returned to baseline levels by week 12 (134).  
Human intervention trials have indirectly demonstrated that GTC may promote 
lipolysis from specific fat depots. Abdominal fat is known to be more lipolytically active 
than lower body adipose; therefore, abdominal adipose tissue could be selectively 
reduced more than peripheral fat stores (142). It is possible that GTC, by enhancing 
sympathetic effects, may have differential influences on lipid storage in various fat 
depots. Several randomized trials have demonstrated reductions in measures of central 
adiposity independent of weight loss in subjects receiving GTC interventions. In a sample 
of Japanese type 2 diabetics (men and women), Nagao et al. noted that while body weight 
did not differ between treatment groups after 12 weeks, WC was significantly reduced (-
3.3 cm) in those consuming GTC (583 mg GTC + 75 mg caffeine/day) as compared to 
the control (96 mg GTC + 75 mg caffeine/day). Similar results were shown in Caucasian 
men and women following a 12-week study with in subjects receiving 624 mg GTC + 39 
mg caffeine along with an exercise program:  Maki et al. (147) determined that total 
abdominal fat area (measured by computed tomography) was significantly reduced (−7.7 
cm2) versus the control group, despite there being no significant difference between 
groups in body weight loss (−2.2 vs. −1.0 kg). More recently, another 12-week study with 
60 healthy Caucasian men and women found no difference between groups receiving 
either placebo or GTE (560 mg EGCG + 280-450 mg caffeine/day) for body weight, fat 
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mass (assessed by BodPod), WC, or RQ (148). While increased fat oxidation and 
mobilization of VAT seems to be a promising mechanism of GTC’s effects on body 
composition, several studies have based their conclusions of a beneficial effect on crude 
measurements such as WC and WHR, while others have used a variety of technology-
based techniques, making aggregation of this data difficult. Research using precise 
measurements of body composition are needed to draw definitive conclusions of the 
effect of GTC on changes in adiposity. 
3. Decreased Nutrient Absorption 
Green tea catechins may inhibit gastrointestinal enzymes involved in nutrient 
absorption. Chan et al. demonstrated that hamsters given GTC produced feces with 
increased concentrations of total fatty acids and sterols compared with a control group 
(149). These results were recently confirmed in another study (150). With regard to 
human studies, Zhong, et al. reported that meals containing 100 mg ECG and 300 mg 
EGCG, black tea, and mulberry tea resulted in malabsorption of carbohydrates of 
approximately 60 calories compared to placebo, as assessed by hydrogen breath test 
(151). However, this same study failed to see any difference in fat malabsorption. 
Another study determined that a single dose of GTE taken with a test meal decreased 
lipid digestion and absorption in 32 healthy subjects (152). Though beyond the scope of 
the forthcoming research chapters in this dissertation, alteration of nutrient absorption by 
GTC remains a topic of current research, and its clinical relevance is in need of further 
study. 
4. Appetite Inhibition 
Green tea consumption may impact body weight through inhibition of appetite, 
though this remains a somewhat understudied area of research. Mechanisms for this 
effect include green tea’s ability to increase hepatic fatty acid oxidation, which has been 
shown to decrease voluntary food intake (153). Early animal studies suggested that 
administration of GTC decreased food intake as compared to controls (154). However, 
the intervention was given intraperitoneally, rendering these results untranslatable to 
humans due to the administration of a catechin dose higher than physiologically 
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achievable through oral intake. When GTC were given orally, there was no difference in 
food intake between treatment and control groups (143). .  
Randomized trials of human subjects have yielded mixed results, dependent on the 
variation in methods of assessing satiety and prospective food intake as well as the 
experimental conditions. Most studies have implemented the 100 mm visual analog scale 
(VAS) to measure satiety parameters, with the test anchored by 0 (“not at all hungry”) 
and 100 (“extremely hungry”), as described by Flint (155). Using this method, 
Auvichayapat et al. measured appetite in subjects taking GTC or placebo for 12 weeks – 
appetite scores did not differ from baseline or between treatment groups over time (134). 
A lack of difference in satiety scores between green tea catechin interventions and 
placebo has been noted in several other randomized trials (139,156). Somewhat 
unexpectedly, Diepvens et al. showed that in a study of 46 overweight women 
randomized to receive 1125 mg catechins + 225 mg caffeine daily for 3 months or 
placebo, those randomized to receive catechins became more hungry over time and 
showed increased prospective food consumption compared with the placebo group (157). 
Other studies have used 3-day diet records to analyze food intake over time (147,158). 
While these studies have failed to show any change in food intake when comparing green 
tea interventions to the control group, self-reported diet recalls may not be sensitive 
enough to detect small changes that may impact long-term body weight and fat mass. 
Further, studies assessing the long-term (>12 weeks) impact of GTC consumption on 
appetite and food intake have not been conducted. 
To date, only three studies have examined the acute postprandial effects of green 
tea catechins on satiety. One of these (159) demonstrated increased satiety after 
consuming a beverage containing 10 g soluble fiber, 167 mg catechins and 100 mg 
caffeine as compared to catechin-free beverage (10 g fiber + 46 mg caffeine), water, or 
no beverage control. These results are similar to those of Josic (160), who found 
increased satiety in a crossover study of 14 healthy volunteers who consumed 300 mL 
green tea beverage (approximately 148 mg catechins) with a breakfast meal as compared 
to water. Lastly, Belza et al. (136), also using a crossover study design, compared satiety 
and next-meal energy intake in 12 healthy men who randomly consumed 400 mg GTE, 
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400 mg tyrosine, 50 mg caffeine, or placebo on 4 separate occasions. They found that ad 
libitum energy intake 4 hours after administration of the intervention was reduced by 96 
calories in the GTE group as compared to the placebo, despite no difference in VAS 
ratings of satiety and prospective food intake. 
B. Epidemiologic Studies of Green Tea Consumption and Body Composition 
A few epidemiologic studies have examined the impact of tea on body weight and 
other obesity-related end points. A 2003 cross-sectional epidemiologic study of 1103 
Taiwanese adults found that habitual tea drinkers (defined as tea consumption at least 
once per week for 6 months) who consumed tea for >10 years had 19.6% lower body fat 
percentage and 2.1% lower WHR compared with non-habitual consumers (161). While 
this study did not separate consumers of different tea types, they did note that green tea 
and oolong tea were consumed more frequently than black tea. A longitudinal analysis 
within The Netherlands Cohort study of 4280 adults aged 55-69 years found an inverse 
relationship between catechin consumption and BMI increase over the 14-year study 
period in women only (162). Women with the highest intake of total flavonols/flavones 
and total catechins experienced a significantly lower increase in BMI of 0.40 and 0.31 
kg/m2, respectively (162). These population-based studies indicate that regular 
consumption of green tea may have beneficial effects on adiposity and body weight. 
C. Randomized Trials and Meta-analyses of Green Tea Interventions and Body 
Weight-Related Endpoints 
Over the last decade, many human intervention studies have assessed the effects 
of green tea catechins on body weight and related outcomes. Four major meta-analyses  
(156,163-165)  have summarized these results, with the most recent being published in 
2012. Since then, several more articles have been published on the subject of green tea 
and body composition. The following section highlights the results of the previous meta-
analyses and describes in more detail the studies that have been published within the last 
3 years. 
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1. Randomized Trials and Meta-analyses of Green Tea Interventions and Body 
Weight-Related Endpoints 
a) Hursel et al., 2009 
      Hursel et al. (156) published the first meta-analysis of green tea and body 
weight in 2009. Their study aim was to determine the effects of EGCG on weight 
loss and weight maintenance and included possible modifiers, including regular 
caffeine intake and ethnicity. Trials were included if they had a randomized, double-
blinded design, compared effects of GTC on weight loss or weight maintenance to 
different catechin doses or no catechins, and were at least 12 weeks in duration. 
Eleven articles fulfilled all criteria, 9 of which were weight loss studies  
(134,157,166-171) and 2 (139,172) were weight maintenance. Their results showed 
that GTC significantly decreased body weight and significantly maintained body 
weight after weight loss (-1.31 kg; 95% CI: -2.05, -0.57). While not reaching 
statistical significance, their results also demonstrated that high habitual caffeine 
intake may inhibit these effects on body weight, and that GTC had a larger effect on 
subjects of Asian ethnicity as compared to Caucasian subjects. Authors speculated 
that this could be due to different distributions of COMT genotype in these two 
populations, with Asian populations known to have a higher proportion of 
individuals with the G/G genotype as compared to Caucasians, who exhibit a higher 
frequency of the low-activity COMT enzyme allele (A/A or A/G) (173). A potential 
explanation for why studies examining the effects of GTC on body weight and 
adiposity -related variables in Asian populations have shown more favorable results 
may be that individuals of Asian descent are more sensitive to the effects of GTC on 
EE and other SNS-mediated outcomes. This outcome was also noted in the meta-
analysis by Jurgens et al., below. 
b) Phung et al., 2010 
       The results of the meta-analysis by Phung et al. were published in 2010 (163). 
Their objective was to characterize the relationship between GTC with and without 
caffeine and changes in anthropometric variables, including BMI, body weight, WC, 
and WHR. To account for possible confounding with caffeine in the results, they 
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conducted 3 separate analyses: (1) trials with GTC + caffeine compared to a 
caffeine-matched control; (2) GTC + caffeine compared with a caffeine-free control; 
and (3) caffeine-free GTC compared with a caffeine-free control. A total of 15 trials 
(n = 1243) met their inclusion criteria, 7 of which evaluated GTC + caffeine 
compared with caffeine-matched control (147,167,174-178), 6 that evaluated GTC + 
caffeine compared with caffeine-free control (134,157,170,179-181), and 2  
(140,141) with caffeine-free GTC compared with a caffeine-free control. The authors 
determined that administration of catechins with caffeine significantly decreased 
body weight (-1.38 kg, 95% CI: -1.70, -1.06), BMI (-0.55; 95% CI: -0.65, -0.40), and 
WC (-1.93 cm; 95% CI: -2.82, -1.04) when compared with caffeine alone, suggesting 
an independent beneficial effect of catechins on body weight and central and total 
adiposity. This contrasts with the literature highlighted above on the effect of GTC 
on EE and fat oxidation, as most studies of specific mechanisms have failed to show 
positive results of GTC administration apart from the effects of caffeine. A 
significant reduction in body weight was observed in studies that compared GTC + 
caffeine to a caffeine-free control (-0.44 kg; 95% CI: -0.72, -0.15), but had no effect 
on BMI, WC, or WHR. The two studies that compared caffeine-free catechins with 
placebo did not find a significant effect of green tea alone on body weight or related 
outcomes. This lack of effect may be due to the small number of studies, small 
sample sizes (n=38 and n=81), short duration of supplementation (12 weeks), and 
moderate catechin dose provided (280 mg EGCG/day, equal to 2-3 four-ounce cups 
of green tea per day). Aside from the study by Matsuyama (176), which was 
conducted in children, the longest study duration was 12 weeks, so any effect of 
GTC extending past this point was unable to be determined.  
c) Jurgens et al., 2012 
      A comprehensive review of green tea’s effects on weight loss and weight 
maintenance specific to overweight or obese adults was conducted in 2012 (164). 
This meta-analysis used Cochrane methodology and looked at 15 weight loss studies  
(134,140,141,147,157,158,166-168,170,182-186) and 3 weight maintenance studies 
(139,172,187) (total n = 1945). Each of the included randomized trials was at least 
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12 weeks in duration and study size ranged from 19 to 270 participants. Nine of the 
18 took place in Japan (140,166-168,182-186), which were separated from the 
remaining 9 studies due to significant heterogeneity between Japanese and non-
Japanese studies. Daily dose of GTC ranged from 141 to 1207 mg, with 16 of the 18 
doses ranging from 270 to 646 mg. Overall, more favorable changes in body weight, 
BMI, WC, and WHR were seen in Japanese populations as compared to those from 
other countries. In studies conducted outside of Japan, the mean difference in weight 
loss when comparing the green tea intervention to control was -0.04 kg (95% CI: -
0.5, 0.4; P = 0.88), whereas mean difference in weight loss in Japanese populations 
ranged from -0.2 kg to -3.5 kg in favor of green tea preparations (results could not be 
pooled for Japanese studies, so a mean difference and 95% CI could not be 
calculated). When assessing BMI, mean difference in studies conducted outside of 
Japan was -0.2 kg/m2 (95% CI: -0.5, 0.1, P = 0.21), while the range for Japanese 
studies was from no effect to -1.3 kg/m2 in favor of green tea over control. WC 
showed similar findings, in that a small but insignificant reduction was seen in 
groups both inside (range from -3.3 cm to +1 cm) and outside of Japan (mean 
difference = -0.2 cm, 95% CI: -1.5, 0.9; P = 0.70; 404 participants). In the three 
studies that measured WHR, no significant change was seen (mean difference = 0; 
95% CI: -0.02, 0.01). Authors concluded that green tea preparations appeared to 
induce a small, though statistically non-significant weight loss in overweight and 
obese adults. They further stated that because the amount of weight loss was small, it 
was unlikely to be clinically significant. While this meta-analysis included a large 
number of subjects and addressed a number of body weight-related variables, they 
did not separate out studies that included caffeine in the intervention from those that 
did not, therefore rendering the results incomparable to those of Phung et al. 
Additionally, they used crude measurements of abdominal adiposity (WC and WHR) 
that are prone to measurement error, so precision in these measurement is uncertain. 
Lastly, only 5 (141,157,170,184,185) of the 18 studies included only women, while 
10 included both males and females, making it impossible to separate any gender-
specific differences on weight and adiposity variables.  
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d) Baladia et al., 2014 
      Baladia et al. conducted a meta-analysis (165) whose aim was to evaluate 
the magnitude of the effect of green tea or its extracts on body weight and body 
composition in overweight or obese individuals. In the 5 studies that were included 
in their analysis (134,158,170,172,187), authors concluded that there was not a 
statistically significant mean difference in weight loss, BMI, WC, or hip 
circumference in the overall sample or in Caucasian or Asian subgroups when 
comparing green tea interventions to control. Despite a lack of statistically 
significant change in body fat percentage in either Asian or Caucasian subgroups, a 
small, statistically significant decrease was seen in those randomized to green tea 
intervention as compared to control when the subgroups were pooled (mean 
difference = -0.76% [95% CI: -1.44% to -0.09%; P = 0.03]; n = 260). Though this 
analysis is limited by the small number of studies included, it is the only review to 
date that has included measurement of percent body fat, which contributes added 
precision to adiposity measurement as compared to WC or WHR. In support of this, 
assessment of WC and hip circumference did not yield significant mean differences 
between treatment and control groups despite a significant reduction in % fat mass. 
2. Studies Conducted since 2013 
     Since the last meta-analysis was conducted, two studies (146,148) examining 
the effect of GTC on body weight and adiposity have been conducted. One of these 
measured changes in body composition in an energy-restricted diet intervention in 83 
obese pre-menopausal women (146). Subjects consumed 300 mg/d of EGCG or 
placebo for 12 weeks. Body weight and adiposity were assessed through DXA. 
Authors did not find any significant difference in the changes in body weight (-0.3 kg, 
95% CI -5.0, 4.3) between the EGCG and control groups. Janssens et al. (148)  
measured body composition in 60 healthy subjects (50 female, 10 male) who received 
560 g EGCG + 280-450 g caffeine/day for 12 weeks. No significant differences 
between groups and no changes over time (baseline vs. week 12) were observed for 
body weight, body fat percentage, and WHR. There were no significant differences in 
the response to EGCG between subjects with a BMI of 18–25 kg/m2 and subjects 
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with a BMI >25 kg/m2, and no differences were seen when comparing men and 
women. 
D. Green Tea and Adiposity Measurements 
Several randomized trials have examined the impact of GTC on measures of 
adiposity. Overall, most studies have observed a small effect of GTC interventions on 
total body and abdominal fat reduction, which supports the hypothesis that GTC may 
selectively reduce VAT through SNS-mediated increases in fat oxidation. However, 
comparisons between studies have been difficult to draw, due to the wide variety in 
measurement techniques. Westerterp-Platenga, using the deuterium (2H2O) dilution 
technique, determined that subjects randomized to the GTC intervention lost significantly 
more body fat after an energy-restricted diet as compared to the control group (139). 
Similar results were obtained by another study using the same technique (157). Nagao et 
al. (177) used computed tomography to measure total, abdominal, visceral, and 
subcutaneous fat area in a 12-week study including 240 obese participants. Decreases in 
body weight, BMI, body fat mass, visceral fat area, and subcutaneous fat area were found 
to be greater in the catechin group than in the control group. Another 12-week study 
(175) used bioimpedance techniques and determined that a significant time effect was 
detected for percent body fat: in the control group, percent body fat had significantly 
increased at week 12 compared with weeks 0, 4, and 8; no significant within-group 
changes in percent body fat were detected in the catechin group. No significant 
differences between the two groups were noted. More recently, DXA technology has 
been used in randomized trials to measure changes in adiposity. Maki et al. (147) found 
that while percent changes in fat mass did not differ between the catechin (625 mg 
catechins + 39 mg caffeine) and control groups after 12 weeks, percent change in total 
abdominal fat area were greater in the catechin group (-7.7 [-11.7, -3.8] vs. -0.3 [-4.4, 
3.9]; P = 0.013). In contrast, another more recent study found that consumption of 300 
mg EGCG/day for 12 weeks did not lead to significant loss of fat mass as compared to 
the control in a sample of obese premenopausal women (-0.7 kg, 95% CI -3.5, 2.1) (146). 
However, this dose of catechins is lower than seen in other interventions and may not 
have been high enough to induce an effect.  
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E. Effects of Green Tea on Bone Mineral Density and Skeletal Health 
1. Pre-Clinical Studies of Green Tea and Bone 
    Evidence from in vitro and animal studies strongly suggests that green tea 
polyphenols are effective in preventing osteoporosis. This is mainly mitigated 
through the ability of GTCs to enhance osteoblastogenesis (188) (leading to bone 
formation) and inhibit osteoclastic activity (189), thereby reducing bone resorption. 
These in vitro effects have been replicated in animal studies using various models for 
bone loss. Supplementation of 3.4 mg/kg/day EGCG has been shown to reduce the 
rate of decrease in BMD and improve parameters of bone volume in ovariectomized 
rats, which serve as an animal model for osteoporosis (190). Song, et al. (191) 
confirmed these results and further demonstrated that 10 mg/kg/day EGCG had a 
positive effect on reducing - though not entirely eliminating - bone loss in recently 
ovariectomized rats as compared to those without EGCG supplementation and rats 
who had undergone a sham operation.  
2. Human Studies of Green Tea Intake and Bone 
      While evidence from animal studies indicates a positive relationship between 
tea consumption and skeletal health, results of human studies have been less 
consistent, yet suggestive of a beneficial effect. A positive association between tea 
drinking and BMD has been reported among postmenopausal women in epidemiologic 
studies in several countries, including the United States (192), United Kingdom (193), 
Australia (194), and Japan (195). Another large case-control study showed that tea 
drinking was associated with a 30% reduced risk for hip fractures in women >50 years 
old (196). Yet, no association was seen in a study that examined tea consumption 
patterns in postmenopausal Turkish women (197). These discrepant results may be 
due to several challenging features of epidemiologic studies, including variation in 
study designs, inconsistent dietary intake methods, and incomplete adjustment for 
confounding lifestyle characteristics, as well as measurement of BMD at different 
skeletal sites. Further, several of these studies failed to differentiate between types of 
tea, which makes it impossible to know the specific association of green tea to BMD.  
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      To date, only one randomized trial has examined green tea’s effects on bone 
health. Shen, et al., conducted a study with a 2 x 2 factorial design of green tea 
supplementation and tai chi exercise in 150 postmenopausal osteopenic women (198) 
and found that compared to the control group, subjects assigned to receive 500 mg 
GTC/day for 6 months had significantly increased bone-specific alkaline phosphatase 
(BAP), a glycoprotein found on the surface of osteoblasts that is indicative of bone 
biosynthesis. However, this research group did not correlate serum biomarkers of bone 
metabolism with measurements of BMD, so the clinical relevance of these results is 
uncertain. 
F. Section Summary 
Obesity and body composition may be influenced by green tea consumption. 
Biologic mechanisms of this effect include increases in EE, increased fat oxidation, 
decreased nutrient absorption, and appetite inhibition. Many randomized trials have noted 
a small beneficial effect of GTC on body weight and measures of adiposity, while others 
have reported null results. Four meta-analyses of green tea’s effect on body weight and 
adiposity have been conducted; however, several challenges make aggregation of the 
results difficult. Most studies have used different inclusion criteria, with many failing to 
separate the effects of GTC from that of caffeine, which is naturally present in green tea. 
This makes it difficult to determine whether the responsible agent is the GTC or caffeine 
- which by itself is known to increase EE – or if a synergistic relationship exists between 
the two compounds. Many studies have included both men and women of various ages in 
their participant pool, which limits the generalizability to specific age and gender groups. 
Lastly, the intervention periods have been mainly 12 weeks or less, so any longer-term 
effect of GTC on body weight and adiposity remains unclear. The shortcomings of the 
literature published to date indicate a need for studies that specifically address the impact 
of GTC – independent of caffeine - on body weight and adiposity, use sophisticated 
techniques for body composition analysis, include specific population groups (such as 
postmenopausal women), and are longer in duration.  
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V. Green Tea’s Effects on Obesity-related Peptide Hormone Concentrations 
GTC may influence body weight and breast cancer risk through modifying 
concentrations of obesity- and appetite-associated hormones, including leptin, 
adiponectin, ghrelin, and insulin. 
A. Leptin 
Animal studies have shown that green tea catechins can lower leptin 
concentrations (154,199-201). However, these reductions in leptin were associated with 
corresponding reductions in body fat. Therefore, green tea has not demonstrated an effect 
on leptin independent of the hormone’s relationship with changes in fat mass. Human 
studies have demonstrated similar results. Basu et al. (202) randomized 35 obese subjects 
to receive either green tea beverage (4 cups/day), GTE (2 capsules and 4 cups water/day), 
or no treatment (4 cups water/day) with similar dosing of EGCG in both green tea 
treatment groups. Leptin concentrations did not change from baseline to the end of the 8-
week intervention. Another study showed that a 4-week weight loss period reduced leptin 
concentrations, though this reduction did not differ between treatment (270 mg EGCG + 
150 mg caffeine/day) and placebo groups, since all groups lost weight (203). These 
results correlate with Diepvens et al., who observed a reduction in leptin with a 
corresponding decrease in body fat in 46 overweight female subjects assigned to follow a 
low-energy diet and either 402 mg GTC + 78 mg caffeine/day or placebo for 12 weeks; 
no differences were observed between those assigned to GTC and those assigned to 
placebo (204). The acute postprandial response of leptin concentrations after a meal has 
not been studied, so it is unclear if leptin secretion and its related appetite-control effects 
are influenced by GTC. 
B. Adiponectin 
Since adiponectin has been investigated as a biomarker of breast cancer risk and 
insulin resistance, an association between green tea intake and adiponectin may have 
implications for prevention of these conditions. GTC have been shown to up-regulate 
adiponectin expression in mouse preadipocytes (205), and animal studies have confirmed 
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that administration of EGCG can increase adiponectin concentrations (206,207). 
However, results of studies involving human subjects are mixed.  
1. Epidemiologic Studies 
    The relationship between adiponectin levels and green tea intake in humans has 
been studied in four cross-sectional studies. One study of Japanese males (n = 665) 
showed that adiponectin levels did not differ by green tea intake after adjusting for 
age, smoking, BMI, and other covariates (Ptrend = 0.55) (208). Similarly, green tea 
consumption was not associated with adiponectin in a multi-ethnic Asian population 
(n = 4139) (209). Recently published results of a cross-sectional survey of Japanese 
workers (ages 20-68 years) reported no association of green tea with adiponectin 
concentrations (210). In contrast, a study conducted in Asian American women (211) 
(n = 219) demonstrated that regular weekly or daily green tea drinkers had 25% 
higher adiponectin concentrations than non-green drinkers (P = 0.03). This difference 
remained after adjustment for age, Asian ethnicity, parity, BMI, and other covariates. 
     Results from a large nested case-control study within the NHS involving 1477 
breast cancer cases and 2196 matched controls reported risk reduction (Odds Ratio = 
0.73, 95% CI=0.55–0.98) comparing postmenopausal women in the highest versus 
lowest quartile of adiponectin levels (58) but this result was not confirmed in two 
smaller nested case-control studies (212,213).  
2. Human Interventions  
    To date, 6 randomized trials examining the effect of GTC on adiponectin 
concentrations have been conducted (170,175,202,214-216). Four of these studies  
(170,202,214,216) found no difference in adiponectin between treatment and control 
groups at the end of the intervention. In a study of type 2 diabetics not receiving 
insulin therapy, Nagao et al. found that adiponectin concentrations increased in the 
group receiving 583 g GTC/day for 12 weeks (n = 23) as compared to the control 
group (n=20, who received 96.3 mg catechins daily). This increase was correlated 
with a reduction in WC (175). In contrast, a study conducted in 103 postmenopausal 
women concluded that adiponectin non-significantly decreased in the GTE groups 
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(400 mg or 800 mg EGCG) as compared to the placebo (P = 0.084) (215), despite no 
change in weight or anthropometric measurements. These 6 studies ranged from 4 to 
16 weeks in duration, administered different amounts of GTC in various preparations, 
and subjects were of disparate clinical and demographic groups, making it difficult to 
draw conclusions on any impact that GTC may have on adiponectin. In addition, the 
postprandial response of adiponectin has not been studied, independent of or together 
with administration of GTC. 
C. Ghrelin 
There is a paucity of research on green tea’s effect on circulating ghrelin 
concentrations. One randomized, double blind, placebo-controlled clinical trial in 78 
obese women found a significant within-group increase in ghrelin after 12 weeks of daily 
supplementation with 1200 mg GTE (170). However, increased ghrelin was also 
observed in the placebo group, which may be related to the modest weight loss 
demonstrated for both groups. This same effect was seen in another study of 68 
overweight subjects with type 2 diabetes (217). No postprandial studies with GTC 
administration have measured circulating ghrelin concentrations after a meal and its 
relationship to appetite and hunger. 
D. Insulin and the Glycemic Response 
Green tea ingestion has demonstrated an association with modulating blood 
glucose homeostasis, and inclusion of this beverage in the diet may promote reductions in 
glucose and insulin concentrations among people at risk for or with diagnosed diabetes or 
insulin resistance. Proposed mechanisms include inhibition of hepatic gluconeogenesis  
(218), inhibition of glucose uptake in the intestine (219), enhanced insulin sensitivity 
(220), and protection of pancreatic beta cells by inhibiting nuclear factor-ĸB (221). 
Epidemiologic evidence of a beneficial effect was noted by Iso et al., who found a dose-
dependent, inverse relationship between green tea intake and diabetes risk in Japanese 
women (222) . These results were corroborated by a cross-sectional study in Japan that 
revealed an inverse correlation between daily green tea consumption and fasting glucose 
concentrations in males, though associations were not seen in mean blood glucose or 
 38 
 
glycated hemoglobin (HbA1c), a form of hemoglobin measured primarily to identify 
average plasma glucose concentrations over time (223).   
In vitro and animal studies have shown beneficial effects of green tea 
consumption on glucose and insulin sensitivity (224,225), but results of human studies 
are inconsistent and based on short-term intervention studies with small sample sizes. 
Decreased glucose concentrations have been observed in several studies with green tea 
catechin interventions (168,202,214,215), while others showed no effect of green tea 
consumption on blood glucose (170,226). Inconclusive results have also been presented 
for insulin (160,170,214,226). Wu et al. (215) demonstrated reductions in insulin 
concentrations (P = 0.010) and glucose concentrations (P = 0.008) in postmenopausal 
women given either 400 mg GTE or 800 mg GTE for 8 weeks as compared to placebo, 
whose insulin concentrations increased over the intervention period. A trial of obese adult 
males was unable to demonstrate a significant change in oral glucose tolerance test in 
response to 8 weeks of supplementation with 800 mg EGCG compared to placebo (227), 
while a trial involving type 2 diabetics showed a significant improvement in insulin 
secretion and blood glucose concentrations in patients who received green tea (583 mg 
catechins) versus placebo tea (96 mg catechins) daily for 12 weeks (177). Many studies 
have not shown a benefit of green tea consumption on insulin sensitivity independent of 
reductions in body weight or carbohydrate intake (146,180,203,228,229). However, one 
study found a significant reduction in fasting insulin concentrations and HOMA-IR in 
subjects randomized to receive 379 mg GTE for 12 weeks, despite non-significant 
differences in BMI change from baseline as compared to placebo (230).   
 Research is very limited on the effect of GTC on the acute postprandial insulin 
response. No significant differences were found in serum insulin concentrations or the 
AUC for insulin or glucose after administration of a high-carbohydrate meal in 14 
healthy volunteers with either 300 mL green tea or water (160).    
1. Interaction between GTC, Insulin, and COMT Genotype 
     COMT genotype has also been suggested as a modifier of insulin sensitivity 
and the acute postprandial response. Miller et al. (130), whose primary aim was to 
investigate the impact of green tea and COMT genotype on vascular reactivity, 
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discovered that participants with the homozygous G/G genotype showed greater 
postprandial insulin concentrations as compared to those with the homozygous A/A 
genotype, irrespective of the green tea intervention. Further, Kring et al. (129), found 
that the frequency of the G/G genotype was 11.6% higher in males with insulin 
resistance and type 2 diabetes as compared to the G/A and A/A genotypes (n = 451). 
They suggested that this may be a result of the role of catecholamines in energy and 
glucose homeostasis. Therefore, it is very plausible that GTC and COMT genotype 
may both have a clinically meaningful physiologic effect on insulin sensitivity, 
though additional studies in humans are needed to confirm this hypothesis. 
E. Section Summary 
Green tea may influence body weight and breast cancer risk through modifying 
concentrations of leptin, adiponectin, ghrelin, and insulin. Green tea has not demonstrated 
an effect on leptin independent of the hormone’s relationship with changes in fat mass, 
and a limited body of knowledge has not shown a benefit of GTC on ghrelin 
concentrations. In contrast, green tea has demonstrated beneficial effects on adiponectin 
and insulin concentrations in both epidemiologic and human intervention studies. COMT 
genotype may also modify the insulin response to GTC administration, though this 
remains inconclusive. With the exception of insulin, the acute postprandial effects of 
GTC on these hormones has not been studied, indicating the need for further research. 
VI. Literature Review Summary and Dissertation Rationale 
It is well known that postmenopausal breast cancer, obesity, and metabolic 
diseases are inextricably linked, and that this relationship is exceedingly complex. Green 
tea consumption may aid in preventing these conditions through a variety of different 
mechanisms, including reducing body weight and adiposity, altering concentrations of 
obesity- and appetite-associated hormones, inducing postprandial satiety, and reducing 
food intake. Further, polymorphisms in COMT are thought to play a role in the functional 
response to dietary catechins and may also impact green tea’s effect on breast cancer and 
obesity. A vast body of literature detailing the impact of green tea and GTC on body 
weight and adiposity has been amassed. Yet, research gaps still remain. Most studies 
conducted to date have not separated catechins from caffeine, so it remains to be seen if 
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GTC have an independent effect on obesity-related endpoints. Research specific to 
overweight and obese postmenopausal women is particularly important, given that this 
population is at increased risk not only for breast cancer, but also for osteoporosis, IR, 
and other metabolic conditions. Since much of the literature behind green tea’s health 
effects has come from studies less than 12 weeks in duration, it is critical that the long-
term implications of GTC consumption be assessed. Lastly, the postprandial response to 
GTC administration has not been studied in obesity- and appetite-related hormones such 
as leptin, ghrelin, and adiponectin, and the acute glycemic effects of GTC with a meal 
remains inconclusive.  
The MGTT is the first long-term clinical intervention to evaluate the effects of 
GTC, independent of caffeine, on parameters related to body composition, glucose 
homeostasis, and appetite regulation in overweight and obese postmenopausal women. 
The ultimate goal of this research is to gain a full understanding of the anti-obesity 
effects of GTC. The findings of the forthcoming chapters in this dissertation will 
contribute extensively to our understanding of the role of green tea in risk reduction for 
obesity, metabolic disorders and breast cancer.
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VII. Figures 
Figure 2.1. Female Breast Cancer Incidence Rates by Race and Ethnicity, U.S., 
1999-2011, reprinted from the Centers for Disease Control and Prevention. 
 
Incidence source: Combined data from the National Program of Cancer Registries as submitted to 
CDC and from the Surveillance, Epidemiology and End Results program as submitted to the 
National Cancer Institute in November 2013. 
*Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups 
– Census P25-1130). Incidence rates are for state registries that meet USCS publication criteria 
for all years, 1999–2011. Incidence rates cover about 99% of the U.S. population. 
†Hispanic origin is not mutually exclusive from race categories (white, black, Asian/Pacific 
Islander, American Indian/Alaska Native). 
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Figure 2.2. Structure of Green Tea Catechins (104) 
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Chapter 3 - Effect of Green Tea Extract on Anthropometric Variables, Obesity-
Associated Hormones, and Glucose Homeostasis in Overweight and Obese 
Postmenopausal Women: a Randomized, Controlled Clinical Trial 
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I. Overview 
Background: Green tea consumption has been associated with favorable changes in 
body weight and obesity-related hormones, though it is unknown if this is due to green 
tea polyphenols or caffeine. Objective: We examined the impact of decaffeinated green 
tea extract (GTE) containing 843 mg (-)-epigallocatechin-3-gallate (EGCG) on 
anthropometric variables, obesity-associated hormones, and glucose homeostasis. 
Methods: The Minnesota Green Tea Trial was a 12-month randomized, double-blind, 
placebo-controlled clinical trial of 937 healthy postmenopausal women assigned to either 
GTE or placebo based on catechol-O-methyltransferase (COMT) genotype. This study 
was conducted in a subset of 237 overweight and obese participants. Results: No changes 
in energy intake, body weight, BMI, or waist circumference (WC) were observed in 
women taking GTE (n=117) or placebo (n=120). No changes were seen in circulating 
leptin, ghrelin, adiponectin, or glucose concentrations. Among participants with baseline 
insulin ≥10 µIU/mL, there was a reduction in insulin concentrations in the GTE group 
over 12 months compared to the placebo group and participants with baseline insulin < 
10 µIU/mL in either group (P < 0.01). Participants with the homozygous high-activity 
(G/G) form of COMT showed significantly lower adiponectin (5.97 ± 0.50 vs. 7.58 ± 
0.53 µg/mL, P = 0.03) and increased insulin concentrations (7.63 ± 0.53 vs. 6.18 ± 0.36 
µIU/mL, P = 0.02) at month 12 as compared to those with the low-activity (A/A) 
genotype, regardless of treatment group. Conclusions: Decaffeinated GTE was not 
associated with reductions in body weight, BMI, or WC and did not alter energy intake or 
mean hormone concentrations over 12 months. GTE decreased fasting insulin 
concentrations in those with elevated baseline fasting concentrations. The high-activity 
form of the COMT enzyme may be associated with elevations in insulin and reduction in 
adiponectin concentrations over time. This clinical trial was registered at 
http://www.clinicaltrials.gov as NCT00917735. 
 
  
  
45 
II. Introduction 
     Excess adiposity, especially visceral adiposity, has been accepted as a risk factor 
for both postmenopausal breast carcinogenesis and insulin resistance, a condition 
associated with development of the metabolic syndrome and type 2 diabetes mellitus 
(231). Numerous studies have indicated that green tea consumption may have beneficial 
effects on weight loss and weight maintenance as well as breast cancer risk 
(119,163,232,233). Catechins, a class of flavan-3-ol polyphenols, are major constituents 
of green tea; these include epicatechin (EC), epicatechin gallate (ECG), epigallocatechin 
(EGC), and (-)-epigallocatechin-3-gallate (EGCG) (154). Among these, EGCG is the 
most abundant and is thought to be a major contributor to many of the beneficial effects 
of green tea, including its anti-obesity and anti-diabetic properties (234,235). Green tea 
also contains caffeine (99), and it remains unclear if green tea’s health benefits are due to 
its catechin content, caffeine content, or synergism between the two compounds.  
One of the major metabolic pathways of green tea catechin degradation is O-
methylation, catalyzed by catechol-O-methyltransferase (COMT). At the same time, 
flavanolic compounds such as catechins reduce the activity of COMT. This enzyme also 
metabolizes a number of other compounds, including catecholamines. One of the 
proposed mechanisms by which green tea consumption may influence body weight is 
through inhibition of COMT and the resulting increased and/or prolonged effects of 
norepinephrine, including increased energy expenditure and fat oxidation (236). Genetic 
variability may also have an impact on this relationship, since the COMT enzyme is 
polymorphic - a single nucleotide polymorphism (SNP) at codon 108/158 (rs4680) results 
in a guanine (G) to adenine (A) transition which results in a 3- to 4-fold decrease in 
enzymatic activity (20, 21). Individuals with the low-activity COMT genotype may 
metabolize tea catechins slower than those with the high-activity genotype, allowing the 
bioactive components to be retained longer and resulting in greater benefits from green 
tea intake.  
    Though there has been significant focus on green tea’s regulation of energy 
expenditure (237) and fat oxidation (132,238), less research has been directed toward its 
potential effects on glucose homeostasis and adiposity-associated hormones, such as 
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leptin, ghrelin, and adiponectin, in postmenopausal women. This study aimed to clarify 
the effects of 12 months of caffeine-free green tea extract (GTE) supplementation on 
obesity-related hormones, anthropometrics, and glucose homeostasis in postmenopausal 
women in the absence of other lifestyle–related changes (diet and physical activity). We 
hypothesized that GTE supplementation would cause reduced body weight, body mass 
index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR), and parallel 
changes in obesity-related hormones and glucose homeostasis. We also hypothesized that 
participants with the low-activity COMT genotype would experience greater effects than 
those with the high-activity genotype. 
III. Methods 
A. Study Design 
The Minnesota Green Tea Trial (MGTT) is a 12-month randomized, double-
blinded, placebo-controlled study designed to examine the effect of high-dose GTE on 
breast cancer risk factors. Details of the study design, eligibility criteria, randomization, 
blinding, study conduct, and patient flow through the trial will be published separately 
(Samavat, et al, Cancer Causes and Control). Briefly, healthy postmenopausal women 
aged 50 to 70 years and classified as having high mammographic density (a breast cancer 
risk factor) were recruited via mailed letter (example in Appendix 1) from 2009 to 2013 
after having a routine screening mammogram at one of 8 clinical centers in the 
Minneapolis-St. Paul metropolitan area. If interested in participation, women contacted 
the study through telephone or online screening questionnaire.  
Exclusionary criteria included: any history of breast cancer, proliferative breast 
disease, or ovarian cancer; any cancer diagnosis within 5 years; regular consumption of 
>7 alcoholic drinks per week; regular consumption of green tea (>1 cup per week); BMI 
< 25.0 or >40 kg/m2; weight change >4.5 kg during the previous year; current or recent 
use (within 6 months) of menopausal hormone therapy or chemopreventive agents; 
current use of methotrexate or Enbrel (etanercept) (anti-inflammatory agents); current 
smoking; history of breast augmentation; positive serology for Hepatitis B or C 
antibodies; or alanine aminotransferase higher than 1.5 times the upper limit of normal 
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(defined as 60 U/L). The blood chemistry variables were determined by a blood sample 
taken at the screening clinic visit prior to randomization. The telephone/online screening 
questionnaire used to determine eligibility is included in Appendix 1.   
Of 1075 randomized women, 538 were assigned to receive four oral GTE 
capsules containing a total of 1315 mg ± 116 total catechins per day (843 ± 44 mg as 
EGCG) and 537 were randomized to receive placebo. Nine hundred thirty-seven women 
(87.2%) completed the study. Of these, 162 overweight (BMI = 25.0-29.9 kg/m2) and 
obese (BMI = 30.0-40.0 kg/m2) women were randomly selected for appetite hormone 
analysis through a computer-generated random number sequence; an additional 75 
overweight and obese participants enrolled in another MGTT ancillary study of body 
composition variables were included in this analysis. The final sample size was n (GTE) 
= 117 and n (placebo) = 120 (total n = 237). Of these, 5 from GTE and 5 from the 
placebo groups discontinued the intervention at some point during the study period, 
though they remained in the study in accordance with the intention to treat (ITT) analytic 
model, wherein all participants originally randomized into the study were included in the 
analyses, regardless of if they consumed the study supplement for the full 12-month 
duration.  
B. Randomization and Blinding 
Participants were randomly assigned to receive oral GTE or placebo for 12 
months. Randomization was performed by the Investigational Drug Services (IDS) 
pharmacy at University of Minnesota Medical Center-Fairview using a computer-
generated permuted block randomization scheme with blocks of 8 stratified by COMT 
genotype activity: low (A/A), intermediate (A/G), or high (G/G). Participants and study 
staff were blind to treatment allocation throughout the trial.  
C. Ethics 
Institutional Review Board (IRB) approval was obtained at each clinical center 
and all participants provided written informed consent. This trial was registered at 
clinicaltrials.gov as NCT00917735. 
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D. COMT Genotyping 
COMT genotype was determined by the University of Minnesota Genomics Center. 
DNA was extracted from buffy coat samples by the Qiagen DNAeasy Blood and Tissue 
Kit method (Qiagen Inc., Gaithersburg, MD, USA). A TaqMan assay was developed for 
defining the COMT H/L polymorphism using a TaqMan PCR Core Reagent kit (Applied 
Biosystems, Foster City, CA). Corriell cell lines with known COMT genotype were used 
as quality controls with each PCR run.  
E. Study Supplement 
Decaffeinated Green Tea Extract Catechin Complex (GTE) and placebo capsules 
were supplied by Corban Laboratories (Eniva Nutraceutics, Plymouth, MN) and 
dispensed by the IDS Pharmacy in 3-month increments. Mean total catechin content of 
each GTE capsule was 328 ± 30 mg, including 211 ± 11 mg EGCG. The total daily 
catechin dose was 1315 ± 116 mg, with 843 ± 44 mg as EGCG, which is equivalent to 
five 8-ounce (240 mL) cups of brewed green tea/day (239) (Table 3.1). Placebo capsules 
were identical in appearance to GTE and contained 816 mg maltodextrin, 808 mg 
cellulose, and 8 mg magnesium stearate as a flow agent. Each GTE capsule contained 
less than 4 mg caffeine. GTE ingredients were analyzed by high-performance liquid 
chromatography (HPLC) (Rutgers University, Piscataway, NJ) to demonstrate 
comparability with the stated catechin contents of the manufacturer. Participants were 
instructed to consume two capsules, twice daily with morning and evening meals (4 
capsules/day). 
F. Anthropometry and Body Composition 
Body weight was recorded at screening, baseline, and months 3, 6, 9, and 12 
using a stand-on, calibrated digital scale (Scale-Tronix Inc., White Plains, NY). Standing 
height was assessed by wall-mounted stadiometer (Seca, Hanover, MD) to the nearest 0.1 
cm at the screening clinic visit and month 12 following standard protocols. BMI was 
calculated by dividing weight in kg by height in meters squared (kg/m2). Waist and hip 
circumference were recorded to the nearest 0.1 cm in duplicate using a flexible body tape 
at baseline and month 12. WC was measured at the uppermost lateral border of the iliac 
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crest at the narrowest point of torso. Hip circumference was measured at the widest part 
of the buttocks. WHR was calculated by dividing WC by hip circumference.  
G. Dietary Assessment 
Participants completed a food frequency questionnaire (FFQ) at the beginning and 
end of the study to capture dietary patterns from the previous 12 months. The Diet 
History Questionnaire (DHQ) is a FFQ that consists of 124 food items and includes both 
portion size and dietary supplement questions. The food list and nutrient database used 
with the DHQ are based on national dietary data (USDA's 1994-96 Continuing Survey of 
Food Intakes by Individuals, available from the USDA Food Surveys Research Group). 
FFQ data was analyzed using Diet*Calc software developed at the National Cancer 
Institute (NCI). 
H. Physical Activity 
Recreational physical activity was assessed at baseline and month 12 by a health 
history questionnaire (Appendix 1), in which participants were asked about frequency 
and duration of several types of physical activity. Metabolic equivalent hours (MET-
hours), defined as the ratio of work metabolic rate to a standard resting metabolic rate, 
were computed as the product of average hours per week of each activity multiplied by 
its MET-hour equivalent. All recorded activities were summed to obtain the total MET-
hours of activity performed per week for a given participant.  
I. Obesity-associated Hormone and Glucose Homeostasis Marker Analysis 
Blood samples for obesity-associated hormone and glucose homeostasis marker 
assessment were collected at baseline and month 12 by a research nurse or licensed 
phlebotomist after an overnight fast of >10 hours. Whole blood samples were separated 
into plasma and serum, aliquoted in 1.5 mL volumes, and stored at -80°C until sample 
analysis was performed. Plasma leptin, ghrelin, and adiponectin were measured using 
radioimmunoassay kits manufactured by EMD Millipore (Billerica, MA) [inter-assay % 
coefficient of variation (% CV): leptin = 7.1%, ghrelin = 7.8%; adiponectin = 8.9%; 
intra-assay % CV: leptin = 6.6%; ghrelin = 5.5%; adiponectin = 7.4%]. Serum insulin 
was measured via a simultaneous one-step immunoenzymatic, chemiluminescent assay 
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(Access Ultrasensitive Insulin assay, Quest Diagnostics, Wood Dale, IL, intra-assay % 
CV: 3-5.0%; inter-assay % CV = 3.9%). Serum glucose concentrations were measured 
using a hexokinase enzymatic reference method (Quest Diagnostics, Wood Dale, IL, 
monthly % CV = 1.4%). Homeostasis model assessment for insulin resistance (HOMA-
IR) was used to evaluate insulin resistance: (fasting insulin [μIU/mL] x fasting glucose 
[mg/dL]) / 405.  
J. Adverse Event Reporting 
 Information on adverse events (AEs) occurring during the study was obtained at 
clinic visits or by self-report via phone or e-mail. Hepatic function was measured 
monthly during the first six months of the study and at months 9 and 12 due to GTE’s 
association with hepatotoxicity (240,241). AE information was coded and graded using 
the National Cancer Institute’s Common Terminology Criteria for Adverse Events 
(CTCAE), version 4.03 (242). The clinical course of each event was tracked in an 
ongoing AE record in the study clinic and each event was followed until resolution. 
K. Statistical Analyses  
Differences in baseline demographic and anthropometric characteristics between 
groups and baseline, month 12 and changes from baseline in dietary intake and 
anthropometrics were assessed by non-paired Student's t tests. Change from baseline was 
calculated by subtracting the baseline from the month 12 values. A repeated measures 
linear regression was used to assess within-treatment group and within-COMT genotype 
differences in anthropometric variables between baseline and month 12. Obesity-
associated hormones, glucose, and HOMA-IR were natural log-transformed and a 
repeated measures 2-way ANOVA was used to compare geometric means between and 
within groups at baseline and month 12. The pairwise differences between groups were 
used to compute the P-values. Similar analysis was performed to compare geometric 
means between and within COMT genotype at baseline and month 12.  
Mean change in the obesity-associated hormones, glucose, and HOMA-IR at 12 
months was analyzed using linear regression and was calculated by subtracting the 
baseline value from the value at 12 months from the baseline value. The explanatory 
variables included treatment, baseline value of the variable, change in BMI, and all 2-way 
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interactions. Main effects were kept in the model. Model reduction was considered using 
backward elimination for 2-way interactions having P-values > 0.05. All-randomized 
(intention-to-treat) and per-protocol analyses were performed and data are reported for 
the all-randomized data set unless otherwise noted. To examine the difference in baseline 
characteristics and AEs by treatment group and AE status, the Chi-square test or Fisher’s 
exact test was used for categorical variables and Student’s t-test was used for continuous 
variables. Data are presented as arithmetic or geometric means and standard errors of the 
mean (SEM) or 95% confidence intervals for continuous variables or as counts and 
percentages for categorical variables. Sample size calculations were done using power 
analysis based on previous obesity study reports. The present study had greater than 80% 
power to detect a 0.5 kg difference in body weight and 0.5 kg/m2 difference in BMI 
between treatment groups, and sufficient power to detect an adiponectin increase of 0.62 
μg/mL in participants randomized to GTE as compared to placebo. There was also 
sufficient power to detect an interaction effect between GTE and COMT genotype with 
>81 participants per group. All analyses were performed using the Mixed procedure of 
SAS, version 9.3 (SAS, Inc.). 
IV. Results 
A. Participant Characteristics 
Demographic and baseline characteristics were similar for both groups ( 
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Table 3.2). The mean age of the study sample was 60.8 years and most subjects 
were of non-Hispanic white race/ethnicity (94.0%). Mean BMI did not differ between 
groups (P = 0.13), though the GTE group had a higher proportion of obese participants at 
baseline as compared to placebo (32.4% vs. 19.2%, P = 0.02). Mean total energy intake 
and intake of caffeine and macro- and micronutrients were similar at baseline.  
B. Change in Dietary Intake and Anthropometric Variables 
Comparison of dietary intake and anthropometric changes from baseline to month 
12 is shown in Table 3.3. Total energy intake non-significantly decreased similarly in 
both groups from baseline to month 12 (-115 ± 505 vs. -108 ± 416 kcal/day in GTE and 
placebo, respectively). Caffeine intake did not appreciably change from baseline to 
month 12 in either group. Weight change from baseline to month 12 was not significantly 
different between GTE and placebo, though slightly greater weight loss was observed in 
GTE participants (-0.28 ± 2.2 vs. -0.14 ± 3.2 kg, respectively; P = 0.13). Similarly, a non-
significant reduction in BMI was seen in GTE participants as compared to placebo (-0.10 
± 0.8 vs. -0.05 ± 1.2 kg/m2, P = 0.14). We did not observe any differences in WC or 
WHR change between GTE and placebo groups. No differences in within-treatment 
group comparisons of baseline and month 12 values were observed for any 
anthropometric variable. Results did not differ when analyzed by COMT genotype. These 
anthropometric outcomes for this subset of participants are consistent with those seen for 
the full study population (n=937, data not shown). 
C. Comparison of Obesity-associated Hormones and Glucose Homeostasis Markers 
No baseline or month 12 differences were observed in measurements of leptin, 
ghrelin, adiponectin, insulin, glucose, or HOMA-IR between treatment groups (Table 
3.4). There were also no significant within-group differences from baseline at month 12 
for any of the hormones or glucose homeostasis variables. Changes in the obesity-
associated hormones, glucose, and HOMA-IR after 12 months were not associated with 
treatment, change in BMI or baseline values. An interaction was observed between 
treatment group and insulin concentration at baseline, such that baseline insulin was 
significantly correlated with change in insulin in GTE participants only (Figure 3.1, P < 
0.01). When analyzed categorically, participants randomized to GTE with baseline 
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fasting serum insulin ≥10 µIU/mL (n=23) showed a reduction in fasting serum insulin 
from baseline to month 12 (-1.43 ± 0.59 µIU/mL), while those randomized to placebo 
with baseline fasting serum insulin ≥10 µIU/mL (n=19) showed an increase in fasting 
insulin over the same time period (0.55 ± 0.64 µIU/mL) (P < 0.01 for comparison of GTE 
(high insulin) to all other categories). Similarly, participants with baseline fasting insulin 
< 10 µIU/mL in either study group (GTE: n = 97; placebo: n=101) increased fasting 
insulin concentrations from baseline to month 12 (0.53 ± 0.30 and 0.24 ± 0.29 µIU/mL in 
GTE and placebo, respectively). When compared to participants with insulin < 10 
µIU/mL, those with baseline insulin concentrations ≥10 µIU/mL had significantly higher 
body weight, BMI, fasting glucose concentrations, and HOMA-IR at baseline (data not 
shown).  
No treatment by genotype interactions were observed. To examine the effect of 
COMT genotype independent of GTE supplementation, an exploratory analysis was 
conducted in which participants were stratified into three groups based on their COMT 
genotype (high-, intermediate-, or low-activity). When analyzed by COMT genotype 
irrespective of treatment group, participants with the homozygous high-activity (G/G) 
form of the enzyme showed lower adiponectin concentrations at month 12 compared to 
participants with the low (A/A) genotype (5.97 ± 0.50 vs. 7.58 ± 0.53 µg/mL, P = 0.03) 
(Table 3.5). Adiponectin concentrations at month 12 also differed between low and 
intermediate (G/A) participants (7.58 ± 0.53 vs. 6.34 ± 0.37 µg/mL, P = 0.05). Mean 
insulin concentrations were significantly higher in participants with the high-activity 
COMT genotype compared to those with the low-activity genotype in the all-randomized 
model (7.63 ± 0.53 vs. 6.18 ± 0.36 μIU/mL; P = 0.02); this comparison was only 
marginally significant in the per-protocol analysis (n = 107, GTE; n=110, placebo) (7.56 
± 0.53 vs. 6.32 ± 0.38 μIU/mL; P = 0.06). HOMA-IR was significantly different at month 
12 when comparing G/G vs. G/A (1.82 ± 0.14 vs. 1.52 ± 0.08, P = 0.05) and G/G vs. A/A 
(1.82 ± 0.14 vs. 1.44 ± 0.09, P = 0.02) genotypes. Mean baseline glucose concentrations 
were significantly different between participants with high- and intermediate-activity 
COMT genotypes (99.75 ± 1.78 vs. 95.11 ± 1.16 mg/dL; P = 0.03) at baseline but not at 
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month 12. No significant differences were observed at month 12 for fasting leptin, 
ghrelin, or glucose concentrations among COMT genotypes. 
D. Tolerability/AEs 
Adverse events (AEs) in MGTT participants have been previously reported 
(Dostal, et al., under review). In this subset of participants, no difference was seen in 
numbers of participants experiencing any AE (22 vs. 25 in GTE and placebo, 
respectively; P = 0.70) or in numbers of AEs per participant (P = 0.74) (data not shown).  
V. Discussion 
The aim of this study was to evaluate the effects of decaffeinated GTE containing 
1315 mg total catechins (843 mg as EGCG) on anthropometric variables, obesity-
associated hormones, and glucose homeostasis markers in overweight and obese, free-
living, postmenopausal women. Our results indicate that oral decaffeinated GTE 
supplementation for one year does not alter total energy intake, anthropometric variables, 
or obesity-associated hormones, though GTE was shown to reduce fasting insulin 
concentrations in participants with higher insulin at baseline. Additionally, women with 
the high-activity form of the COMT enzyme showed reductions in fasting plasma 
adiponectin and increased insulin over 12 months compared to participants with an 
intermediate- or low-activity form of the enzyme regardless of treatment group.  
Green tea and GTEs have recently gained popularity as dietary aids for weight 
reduction and weight maintenance. Several randomized trials have examined the 
association between GTE and body weight and results have been largely inconclusive, 
likely due to differences in study design, short durations of intervention, variable study 
populations, and differences in green tea preparations and caffeine content. The GTE 
used in this study contained a high amount of catechins and less than 16 mg of caffeine 
per day, with the intention of testing the independent effects of green tea catechins. 
Results indicated that decaffeinated GTE did not significantly reduce energy intake, body 
weight, WC, or WHR as compared to placebo, although there was a trend toward 
decreased body weight and BMI. These results are comparable to those of a recent 
Cochrane review of effects of green tea on weight loss in overweight and obese adults 
(164), which concluded that green tea was associated with small, non-significant 
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decreases in body weight. Since weight loss of 5% to 10% of body weight is considered 
to be beneficial for reducing several disease risk factors associated with overweight and 
obesity (243), small losses resulting from green tea preparations are not likely to be 
clinically meaningful.  
A significant association between high baseline insulin concentrations and 
reduction in insulin in GTE participants only was observed, suggesting that GTE is most 
effective at lowering insulin in those with baseline fasting insulin ≥10 µIU/L. Given that 
women with baseline insulin >10 µIU/mL tended to have higher fasting glucose 
concentrations, increased body weight, and increased BMI at baseline as compared to 
those with baseline insulin < 10 µIU/mL, it could be hypothesized that they may be at 
risk for developing metabolic syndrome or may already meet criteria for diagnosis. 
Further studies are needed on this group of participants to combine the present results 
with lipid profiles (triglycerides and high-density lipoprotein cholesterol, HDL-C) and 
blood pressure measurements to gain a full picture of the prevalence of metabolic 
syndrome in this population.  
GTE supplementation has been associated with reductions in fasting insulin in 
several high-quality randomized trials (215,230,244), though this study is the largest, 
with the longest duration of intervention that has demonstrated an association specifically 
in overweight or obese postmenopausal women. Lending strength to the observed results, 
animal studies have suggested that green tea catechins may prevent hyperglycemia by 
enhancing insulin activity (245,246), and epidemiologic studies have noted lower 
incidence of type 2 diabetes in individuals with longer duration of green tea consumption 
and in women consuming > 3 cups of tea/day (222,247). It should be noted that the 
proportion of participants in the present study with fasting insulin >10 µIU/mL was small 
(n = 23 [19.7%] and n = 19 [15.8%] in GTE and placebo, respectively) compared to those 
with concentrations < 10 µIU/mL. Further research in participants with insulin resistance 
or those with obesity-associated metabolic abnormalities is needed to confirm this effect.   
The effect of COMT genotype on hormone concentrations and glucose 
homeostasis both independently and in interaction with GTE supplementation was also 
investigated. No treatment by genotype effects were seen. Although there were no 
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differences in hormones by COMT genotype at baseline, aside from fasting glucose 
concentrations at baseline between participants with high- and intermediate-activity 
COMT genotypes, it was noted that fasting insulin increased and fasting plasma 
adiponectin decreased in women who were homozygous for the high-activity (G) allele of 
the COMT enzyme, when compared to women with the intermediate- (G/A) and low-
activity (A/A) forms of the enzyme, a direction consistent with development of insulin 
resistance and increased risk for type II diabetes (248,249). These results are consistent 
with the findings of Kring, et al. (129), who noted that the frequency of the COMT G/G 
genotype was 11.6% higher in insulin-resistant and type 2 diabetics compared with that 
of the COMT A/A and G/A genotypes. To our knowledge, this is the first study that has 
correlated COMT genotype with change in insulin and adiponectin concentrations over 
time. Since this adipose-derived hormone has notable insulin sensitizing actions 
(250,251), it is possible that the observed relationship of COMT genotype with insulin 
sensitivity could be mediated through the enzyme’s interaction with adiponectin. 
However, since this analysis was done irrespective of the intervention, it represents a 
cross-sectional reporting of differences between COMT genotypes and it is unclear if the 
changes we observed from baseline to month 12 were already on this trajectory prior to 
the study, and if they would continue in the same direction after conclusion of the 
intervention.  
The MGTT is the first long-term randomized trial to evaluate the effects of green 
tea catechins, independent of caffeine, on obesity-associated hormones, glucose 
homeostasis markers, and anthropometric variables. In addition to having the longest 
study duration to date (12 months), this intervention provided the highest catechin dose 
and randomized the largest number of subjects as compared to previous trials. Since 
study participants were in free-living conditions and were encouraged to maintain typical 
dietary and physical activity habits, the results observed likely represent translatable 
effects for a wider population of postmenopausal, Caucasian women. Given that this 
group is one of the largest users of dietary supplements (252), this research is of 
particular importance. This study was also powered to detect an effect of COMT 
polymorphisms on response to GTE supplementation. Genetic variation in response to 
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dietary intake is increasingly becoming a topic of interest in nutrition research, and this 
study is one of the first to suggest a relationship between GTE supplementation and 
possible insulin-reductive effects for those with higher fasting insulin concentrations and 
of different COMT genotypes. However, since a specific reference range has not been set 
for this hormone, additional research is needed to confirm these results and determine 
which individuals might benefit most from GTE supplementation.  
Several limitations of this study should be addressed. Aside from being 
categorized as overweight or obese, participants were generally healthy, Caucasian 
women free of diagnosed diabetes or other metabolic diseases and average circulating 
hormones and glucose concentrations were within normal ranges. Therefore, 
extrapolation of results to diabetic populations or those with metabolic syndrome cannot 
be confirmed, though several studies in diabetic populations have noted similar results 
(217,253). Assessment of the variables of interest at time points in addition to baseline 
and month 12 would lend strength to these results and allow for the determination of the 
short-term effects of GTE on anthropometrics or peptide hormones. However, the 
importance of the long-term impact of dietary interventions, in contrast to those of shorter 
durations, cannot be underscored.  
VI. Conclusion 
In conclusion, these results show that decaffeinated GTE is not associated with 
reductions in WC, or WHR and did not alter energy intake or obesity-associated hormone 
concentrations. GTE may result in small changes in body weight and BMI that are 
unlikely to be of clinical significance. However, these data suggest that GTE 
supplementation may decrease fasting insulin concentrations in those with high 
circulating concentrations and that possessing a high-activity form of the COMT enzyme 
may result in decreased adiponectin and increased fasting insulin concentrations over 
time. Thus, GTE supplementation may be particularly beneficial for individuals with 
elevated insulin concentrations and those possessing the high-activity COMT genotype. 
Additional research is needed to confirm these results and to identify the feasibility of 
incorporating GTE supplementation into treatment and prevention strategies for breast 
cancer and obesity-related metabolic disorders.
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VII. Tables and Figures 
Table 3.1. Catechin and caffeine content of GTEa 
Component  
Quantity per 
Capsuleb (mg) 
Dose per Day 
(mg) 
Quantity 
per 
Capsule 
(%) 
Total catechins 328.8 ± 28.9 1315.3 80.7 
   Epigallocatechin (EGC) 26.7 ± 29.7 106.8 6.6 
   Catechin 3.8 ± 2.1 15.2 0.9 
   Epicatechin (EC) 26.8 ± 5.9 107.2 6.6 
   Epigallocatechin Gallate 
(EGCG) 
210.7 ± 11.0 842.8 51.7 
   Gallocatechin Gallate (GCG) 8.4 ± 1.8 33.6 2.1 
   Epicatechin Gallate (ECG) 50.6 ± 18.5 202.4 12.4 
   Catechin Gallate (CG) 1.1 ± 0.5 4.2 0.3 
   Gallocatechin (GC) 1.3 ± 1.4 5.1 0.3 
Caffeine  3.9 15.8 1.0 
aValues are presented as means ± SD from eight supplement batches. Catechin composition 
analyses were conducted by Covance Laboratories (Madison, WI) and results were 
confirmed by the lab of CS Yang lab (Rutgers University, Piscataway, NJ). 
bEach capsule's entity fill weight equal to 407.3 mg. 
Abbreviation: GTE, green tea extract. 
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Table 3.2. Baseline characteristics of study participants. 
Characteristica GTE (n=117) Placebo (n=120) P-value 
Age at baseline, y 60.9 (0.45) 60.6 (0.47) 0.64 
Race/ethnicity, n (%)  0.52 
Non-Hispanic White 111 (46.8) 112 (47.2) 
African American 2 (0.8) 5 (2.1) 
Hispanic 1 (0.4) 0 (0) 
Other 3 (1.3) 3 (1.3) 
COMT Genotype, n (%)   0.65 
Low (A/A) 38 (16.0) 37 (15.6)  
Intermediate (A/G) 51 (21.6) 59 (24.9)  
High (G/G) 28 (11.8) 24 (10.1)  
Weight, kg 75.6 (0.87) 74.3 (0.86) 0.27 
Height, cm 162.9 (0.59) 163 (0.53) 0.94 
BMI, kg/m2 28.5 (0.28) 27.9 (0.25) 0.13 
BMI, kg/m2, n (%)   0.02 
25.0-29.9         79 (67.6)         97 (80.8) 
30.0-40.0 38 (32.4) 23 (19.2) 
Waist circumference, cm 91.9 ± 0.8 90.5 ± 0.8 0.23 
Waist-hip ratio 0.86 (0.01) 0.86 (0.01) 0.43 
Age at menopause, y 47.2 (46.0, 48.4) 48.3 (47.1, 49.6) 0.20 
Physical Activity, MET-hr/week 26.1 (21.6, 31.6) 28.3 (23.5, 34.1) 0.55 
Alcohol consumption, n (%)  0.79 
Yes 96 (40.5) 100 (42.2) 
No 21 (8.9) 20 (8.4) 
Alcohol, drinks/week (drinkers only) 2.0 (1.6, 2.4) 1.8 (1.5, 2.2) 0.53 
Energy intake, kcal/day 1386 (1297, 1480) 1397 (1309, 1491) 0.87 
Caffeine, mg/day 152 (112, 207) 202 (149, 273) 0.20 
aBaseline age, weight, height, BMI, waist circumference, waist-hip ratio are presented as 
arithmetic mean (SEM); Age at menopause, physical activity, alcohol drinks/wk, energy intake, 
and caffeine intake are presented as geometric mean (95% confidence interval). 
Abbreviations: COMT, catechol-O-methyltransferase; GTE, green tea extract; MET-hr/week, 
metabolic equivalent hours per week. 
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Table 3.3. Change in energy intake and anthropometric variables over 12 months, 
by treatment group.  
Variable 
GTE 
(n=117) 
Placebo 
(n=120) 
P-value 
Total energy intake, 
kcal/day    
Baseline 1477 (52.3)  1499 (51.7)  0.77 
Month 12 1362 (52.3)  1392 (51.9) 0.69 
Change from baseline -115 (505) -108 (416) 1.0 
Body weight, kg 
  
 
Baseline 75.6 (0.9) 74.3 (0.9) 0.27 
Month 12 75.4 (0.9) 74.3 (0.9) 0.39 
Change from baseline -0.28 (2.2) -0.14 (3.2) 0.13 
BMI, kg/m2  
Baseline 28.5 (0.3) 27.9 (0.3)  0.13 
Month 12 28.5 (0.3) 27.9 (0.3)  0.14 
Change from baseline -0.10 (0.8) -0.05 (1.2) 0.14 
Waist circumference, cm  
Baseline 91.9 (0.8)  90.5 (0.8)  0.24 
Month 12 93.2 (0.8)  91.6 (0.8)  0.17 
Change from baseline 1.45 (0.5) 1.29 (0.5) 0.82 
Waist-to-Hip Ratio  
Baseline 0.86 (0.01)  0.86 (0.01)  0.41 
Month 12 0.86 (0.01)  0.86 (0.01)  0.34 
Change from baseline -0.001 (0.005) -0.001 (0.005) 0.98 
Data presented as arithmetic mean (SEM).  
Abbreviation: GTE, green tea extract. 
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Table 3.4. Unadjusted mean concentrations of obesity-associated hormones, glucose, 
and HOMA-IR, by treatment group.  
Variable 
GTE 
(n=117) 
Placebo 
(n=120) 
P-
value1 
Insulin, µIU/mL   
Baseline 6.66 (6.05, 7.27) 6.23 (5.66, 6.80) 0.31 
Month 12 6.82 (6.19, 7.45) 6.45 (5.86, 7.04) 0.44 
Glucose, mg/dL   
Baseline 97.17 (94.94, 99.40) 96.44 (94.23, 98.65) 0.65 
Month 12 95.06 (92.83, 97.29) 94.52 (92.34, 96.70) 0.74 
HOMA-IR   
Baseline 1.60 (1.44, 1.76) 1.48 (1.34, 1.62) 0.30 
Month 12 1.60 (1.44, 1.76) 1.51 (1.35, 1.67) 0.43 
Adiponectin, µg/mL   
Baseline 6.29 (5.58, 7.00) 6.72 (5.98, 7.46) 0.41 
Month 12 6.60 (5.87, 7.33) 6.66 (5.93, 7.39) 0.91 
Ghrelin, pg/mL   
Baseline 1131 (1019.65, 1242.35) 1117 (1007.89, 1226.11) 0.87 
Month 12 1126 (1015.08, 1236.92) 1161 (1047.14, 1274.86) 0.67 
Leptin, ng/mL   
Baseline 32.14 (28.59, 35.69) 29.87 (26.62, 33.12) 0.36 
Month 12 30.86 (27.45, 34.27) 30.86 (27.49, 34.23) 0.57 
Data presented as geometric mean (95% confidence interval). 
1P-value for the comparison of the means between GTE and placebo.  
Abbreviations: GTE, green tea extract; HOMA-IR, homeostatic model assessment for insulin 
resistance.  
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Table 3.5. Unadjusted geometric means of obesity-associated hormones, insulin, and 
glucose, by COMT genotype.  
Variable 
High (G/G)  
(n=52) 
Intermediate (G/A) 
(n=110) 
Low (A/A)  
(n=75) 
Insulin, µIU/mL   
Baseline 6.65 (5.75, 7.55) 6.36 (5.77, 6.95) 6.41 (5.68, 7.14) 
Month 12 7.63a (6.59, 8.67) 6.53ab (5.92, 7.14) 6.18b (5.47, 6.89) 
Glucose, mg/dL   
Baseline 99.75a (96.26, 103.24) 95.11b (92.84, 97.38) 97.32ab (94.52, 100.12) 
Month 12 96.37 (93.0, 99.74) 94.17 (91.94, 96.40) 94.61 (91.87, 97.35) 
HOMA-IR   
Baseline 1.64 (1.40, 1.88) 1.49 (1.33, 1.65) 1.54 (1.34, 1.74) 
Month 12 1.82a (1.55, 2.09) 1.52b (1.36, 1.68) 1.44b (1.26, 1.62) 
Adiponectin, μg/mL   
Baseline 6.64 (5.54, 7.74) 6.19 (5.48, 6.90) 6.89 (5.95, 7.83) 
Month 12 5.97a (4.99, 6.95) 6.34a (5.61, 7.07) 7.58b (6.54, 8.62) 
Ghrelin, pg/mL   
Baseline 1062 (906.63, 1217.37) 1101 (989.79, 1212.21) 1205 (1058.31, 1351.69) 
Month 12 1092 (932.30, 1251.70) 1093 (982.12, 1203.88) 1261 (1107.41, 1414.59) 
Leptin, ng/mL   
Baseline 30.36 (25.36, 35.36) 31.16(27.63, 34.69) 31.12 (26.85, 35.39) 
Month 12 30.03 (25.07, 34.99) 30.55 (27.08, 34.02) 29.71 (25.63, 33.79) 
Data presented as geometric mean (95% confidence interval). Within a row, values with different 
superscripts are significantly different (P < 0.05). 
Abbreviations: COMT, catechol-O-methyltransferase; GTE, green tea extract; HOMA-IR, 
homeostatic model assessment for insulin resistance. 
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Figure 3.1. Effect of GTE on mean change in fasting serum insulin, by baseline 
insulin concentration. 
 
High insulin at baseline defined as ≥10.0 µIU/mL; low insulin < 10.0 µIU/mL. Low insulin, 
GTE: n = 97; low insulin, placebo: n = 101. High insulin, GTE: n = 23; high insulin, placebo: n = 
19.  
*P < 0.01 for comparison between high insulin-GTE group and all other groups. P-value > 0.2 for 
comparison between all other groups. 
Abbreviations: GTE, green tea extract. 
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Chapter 4 - Effect of Green Tea Extract on Adiposity, Obesity-Associated 
Hormones, and Bone Mineral Density in Overweight and Obese Postmenopausal 
Women 
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I. Overview 
Background: Green tea extract (GTE) consumption has been linked to favorable changes 
in adiposity and bone mineral density (BMD), though it is unknown if these effects are 
due to green tea catechins or caffeine. Catechol-O-methyltransferase (COMT) genotype 
may also be a modifier of these associations. Objective: We examined the impact of 
decaffeinated GTE containing 843 mg (-)-epigallocatechin-3-gallate (EGCG) on body 
composition (using dual-energy x-ray absorptiometry [DXA]) and obesity-associated 
hormones. Design: The Minnesota Green Tea Trial was a 12-month randomized, double-
blind, placebo-controlled clinical trial of 937 healthy postmenopausal women at elevated 
risk for breast cancer assigned to either GTE or placebo. This sub-study was conducted in 
121 overweight and obese participants. Results: No changes in BMI, total fat mass, % 
body fat, or BMD were observed in women taking GTE (n=61) compared to placebo 
(n=60). A non-significant reduction in visceral adipose tissue mass was observed in GTE 
participants as compared to the placebo group (-0.02 ± 0.02 vs. 0.03 ± 0.02 kg; P = 0.13). 
Interactions were observed between treatment and time for gynoid % fat and tissue % fat. 
Tissue % fat and gynoid % fat increased from baseline to month 12 in the placebo group 
as baseline BMI increased. Conversely, in the GTE group, tissue % fat and gynoid % fat 
decreased during the intervention as baseline BMI increased (Pinteraction=0.04 and 
Pinteraction=0.02, respectively). No changes were seen in circulating leptin, ghrelin, 
adiponectin, or insulin concentrations. COMT genotype did not modify the effect of GTE 
on any variable. Conclusions: Decaffeinated GTE was not associated with overall 
reductions in adiposity or improvements in BMD. However, GTE may be more beneficial 
for body fat reduction in individuals with higher BMI. 
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II. Introduction 
Despite significant research efforts and public health campaigns, overweight and 
obesity remain prevalent worldwide (254). Excess adiposity is associated with increased 
risk for serious health conditions such as cardiovascular disease, type 2 diabetes, and 
cancer. Conversely, loss of excess fat mass and/or maintenance of a healthy body weight 
are known to reduce risk for these diseases (255,256).  
Research on the associations between obesity and metabolic bone diseases such as 
osteoporosis, a major cause of morbidity and mortality in postmenopausal women, 
remains inconclusive. Several epidemiologic studies have highlighted the correlation 
between these conditions (87-91), with many indicating a significant positive relationship 
between body weight and bone mineral density (BMD). This correlation is largely 
attributed to both the increased mechanical load of excess weight and hormonal changes 
associated with obesity, including increased estrogen and leptin production by adipose 
tissue, which have been shown to suppress bone resorption and stimulate 
osteoblastogenesis (92-94). However, recent evidence has emerged demonstrating that 
increased body weight may actually be negatively correlated with BMD after correction 
for the mechanical loading effect of excess body weight (95), and that obese individuals 
with high BMD are still at increased risk for fractures (88).  
The etiologies of obesity and metabolic bone disorders involve factors that are 
both modifiable and non-modifiable. Dietary intake of natural bioactive foods and 
beverages, such as green tea, is an adaptable habit that may play a role in reducing risk of 
these chronic diseases. Epidemiologic research has suggested that tea intake is associated 
with both reductions in adiposity and increased BMD (195,238). Green tea’s anti-obesity 
effects are thought to be due to increases in thermogenesis and fat oxidation through 
inhibition of the catechol-O-methyltransferase (COMT) enzyme by GTC, resulting in 
prolonged sympathetic nervous system (SNS) stimulation (132,257). Proposed 
mechanisms for improving and/or maintaining bone health include reducing chronic 
inflammation and oxidative stress, conditions that are also tightly linked with obesity and 
excess adipose tissue (258).   
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Genetic variations in COMT enzyme activity have been widely noted. One 
common polymorphism, a guanine (G) to adenine (A) substitution at position rs4680 of 
the enzyme has been identified that produces an amino acid change from valine to 
methionine. The homozygous low-activity (A/A) genotype is associated with a 3- to 4-
fold decrease in enzymatic activity when compared to the high-activity (G/G) genotype 
(117,118). Given these effects, COMT genotype may influence the rate of catechin 
metabolism and the functional response to dietary catechins, wherein individuals with the 
low-activity form of the enzyme may have increased thermogenesis, reduced adiposity, 
and lower body weight due to prolonged SNS effects as compared to individuals with the 
high-activity genotype. Yet, those with the high-activity form of COMT may benefit 
more from interventions that inhibit the enzyme, since the higher rate of substrate 
metabolism would be reduced to a greater degree.   
Most of green tea’s benefits are attributed to its high concentration of 
polyphenolic catechins, of which (-)-epigallocatechin-3-gallate (EGCG) is the most 
abundant and also believed to be the most bioactive (154). On the basis of its potential 
anti-obesity effects, extracts of green tea catechins (GTC) have been marketed as herbal 
supplements for the control of body weight. However, its efficacy has not been 
consistently proven, and the potential beneficial effects of EGCG on obesity, adipose-
related hormone concentrations, and skeletal health remain controversial. Additionally, 
most randomized trials using green tea have included caffeine in the intervention, which 
is independently known to increase energy expenditure and fat oxidation (259).  
Therefore, the independent effects of green tea catechins on these end points remain 
unclear. 
The aim of the present study was to determine the effect of caffeine-free green tea 
extract (GTE) consumption on body composition and BMD in free-living, overweight 
and obese postmenopausal women, a population at risk for both excess weight gain and 
rapid bone loss. Secondary aims included measurement of the effects of GTE on obesity-
related hormones (insulin, leptin, and adiponectin), correlation of these hormones with 
body composition parameters, and testing for effect modification by COMT genotype. 
We hypothesized that GTE supplementation would (1) cause favorable changes in body 
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composition, (2) enhance or maintain measures of BMD, (3) suppress insulin and leptin 
concentrations and (4) increase adiponectin concentrations as compared to placebo. We 
also proposed that GTE supplementation would be particularly beneficial in those with 
the high-activity form of COMT, due to the inhibitory effects of GTC on this enzyme. 
Determining the impact of GTE on body composition, BMD, and obesity-related 
hormones will advance the understanding of the potential health benefits of green tea 
catechins as well as the complex relationship between obesity and skeletal health. 
III. Methods 
A. Study Design 
The Minnesota Green Tea Trial (MGTT) was a randomized, double-blinded, 
placebo-controlled study designed to examine the effect of GTE on breast cancer risk 
factors, including obesity. Details of the study design, eligibility criteria, randomization, 
blinding, study conduct, and patient flow through the trial have been previously published 
(Samavat, et al., under review). Briefly, postmenopausal women aged 50 to 70 years and 
classified as having high breast density (a breast cancer risk factor) were recruited from 
2009 to 2013 at clinical centers in the Minneapolis-St. Paul metropolitan area. Baseline 
health status was assessed by standardized questionnaire (Appendix 1) and a blood 
sample taken at the initial screening clinic visit. Exclusionary criteria included: any 
history of breast cancer, proliferative breast disease, or ovarian cancer or any cancer 
diagnosis within 5 years; consumption of >7 alcoholic drinks per week; consumption of 
>1 cup per week of green tea; BMI < 25.0 or >40 kg/m2; >4.6 kg weight change during 
the previous year; current use of menopausal hormone therapy (MHT) or use within past 
6 months; use of methotrexate or Enbrel (etanercept); current smoking; history of breast 
augmentation; positive serology for Hepatitis B or C antibodies; or alanine 
aminotransferase higher than 1.5 times the upper limit of normal (defined as 60 U/L).  
Of 937 women who completed the full study duration, 214 women classified as 
overweight (BMI = 25.0-29.9 kg/m2) or obese (BMI = 30.0-40.0 kg/m2) at the screening 
clinic visit were additionally consented for body composition analysis beginning in May 
2013. Of these, 146 were randomized into the study (GTE: n=76; placebo: n = 70). 
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Fifteen women allocated to GTE and 10 allocated to placebo withdrew from 
participation; 121 completed the duration of the study (GTE: n = 61; placebo: n = 60).  
B. Randomization and Blinding 
Participants were randomly assigned to receive oral GTE or placebo in 4 capsules 
daily for 12 months. Randomization was performed by the Investigational Drug Services 
(IDS) pharmacy at University of Minnesota Medical Center-Fairview, who used a 
computer-generated permuted block randomization scheme with blocks of 8 stratified by 
COMT genotype activity: low (A/A), intermediate (A/G) or high (G/G). Participants and 
study staff were blind to treatment allocation throughout the trial. Sample size 
calculations were done using power analysis based on previous reports of GTE’s effect 
on body fat parameters. The present study has greater than 80% statistical power to detect 
a 1.5% difference in body fat percentage between GTE and placebo groups. Institutional 
Review Board (IRB) approval was obtained at each clinical center. All participants 
provided written informed consent. This trial was registered at clinicaltrials.gov as 
NCT00917735. 
C. COMT Genotyping 
COMT genotype analysis was completed at the University of Minnesota Genomics 
Center. DNA was extracted from buffy coat samples by the Qiagen DNAeasy Blood and 
Tissue Kit method (Qiagen Inc., Gaithersburg, MD, USA). A TaqMan assay was 
developed for defining the COMT rs4680 polymorphism using a TaqMan PCR Core 
Reagent kit (Applied Biosystems, Foster City, CA). Cell lines with known COMT 
genotype were used as quality controls with each PCR run.  
D. Study Supplement 
Decaffeinated Green Tea Extract Catechin Complex and placebo capsules were 
supplied by Corban Laboratories (Eniva Nutraceutics, Plymouth, MN) in 8 batches. Mean 
daily catechin content was 1315 ± 116 mg/day (843 ± 44 mg as EGCG). Placebo capsules 
were identical in appearance to GTE and contained 816 mg maltodextrin, 808 mg 
cellulose, and 8 mg magnesium stearate (Table 3.1). GTE ingredients were analyzed by 
high-performance liquid chromatography (HPLC) (Rutgers University, Piscataway, NJ) 
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to demonstrate comparability with the stated catechin contents of the manufacturer. 
Participants consumed 4 capsules of GTE or placebo daily, and were advised to ingest 2 
capsules in the morning hours and 2 in the evening to maintain circulating catechin 
concentrations throughout each day. 
E. Anthropometry and Body Composition 
Body weight was measured to the nearest 0.1 kg at baseline and months 3, 6, 9, 
and 12 using a stand-on digital scale (Scale-Tronix Inc., White Plains, NY). Standing 
height was assessed by wall-mounted stadiometer (Seca, Hanover, MD) to the nearest 0.1 
cm at the screening clinic visit and month 12. BMI was calculated by dividing weight in 
kilograms by height in meters squared (kg/m2).  
DXA scans were completed using a GE Healthcare Lunar iDXA (GE Healthcare 
Lunar, Madison, WI, USA) and analyzed using Encore software version 13.6, revision 2. 
Total body fat was expressed as percent of total body mass and android and gynoid were 
expressed as percent of total body fat. Subcutaneous fat was determined using an 
algorithm and measurements of total abdominal thickness and the width of the 
subcutaneous fat layer along the lateral extent of the abdomen along with empirically 
derived geometric constants to estimate the subcutaneous fat in the android region. 
Visceral adipose tissue (VAT) was determined in the android region by subtracting 
subcutaneous fat from total fat. The android region was defined as the caudal limit placed 
at the top of the iliac crest and its height set to 20% of the distance from the top of the 
iliac crest to the base of the skull. The upper limit of the gynoid region was set below the 
iliac crest a distance 1.5 times the height of the android region. The lower limit was set a 
distance of 2 times the height of the android region. Central fat distribution was assessed 
by the android:gynoid fat ratio, calculated as android fat divided by gynoid fat. 
Areal BMD was expressed as g/cm2. T-scores were expressed in standard 
deviations using the peak bone mass from the manufacturer’s reference population. Z-
scores were measured as the deviation from the normal age- and sex-matched mean and 
SD. Osteoporosis was defined in accordance with the World Health Organization as 
BMD at any site greater than 2.5 standard deviations below the young adult mean and 
osteopenia as BMD 1.0-2.5 standard deviations below the young adult mean (260).   
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F. Obesity-associated Hormone and Glucose Homeostasis Analysis 
Blood samples for obesity-associated hormone and glucose assessment were 
collected at baseline and month 12 after an overnight fast of >10 hours. Whole blood 
samples were separated into plasma and serum. Plasma leptin, adiponectin, and ghrelin 
were measured using radioimmunoassay kits manufactured by EMD Millipore (Billerica, 
MA) [inter-assay % coefficient of variation (% CV): leptin = 7.1%, adiponectin = 8.9%, 
ghrelin = 7.8%; intra-assay % CV: leptin = 6.6%; adiponectin = 7.4%, ghrelin = 5.5%]. 
Serum insulin was measured using a simultaneous one-step immunoenzymatic, 
chemiluminescent assay (Access Ultrasensitive Insulin assay, Quest Diagnostics, Wood 
Dale, IL, intra-assay % CV: 3-5.0%; inter-assay % CV = 3.9%). Serum glucose 
concentrations were measured using a hexokinase enzymatic reference method (Quest 
Diagnostics, Wood Dale, IL, monthly % CV = 1.4%). Homeostasis model assessment for 
insulin resistance (HOMA-IR) was calculated as fasting insulin (μIU/mL) x fasting 
glucose (mg/dL) / 405. 
G. Dietary Assessment 
Participants completed a food frequency questionnaire (FFQ) at baseline and 
month 12 for dietary intake assessment over the previous 12 months. The Diet History 
Questionnaire (DHQ) is a FFQ consisting of 124 food items and includes portion size and 
dietary supplement questions. The food list and nutrient database used with the DHQ are 
based on national dietary data (USDA's 1994-96 Continuing Survey of Food Intakes by 
Individuals, available from the USDA Food Surveys Research Group). FFQ data was 
analyzed using Diet*Calc software developed at the National Cancer Institute (NCI). 
H. Physical Activity 
Recreational physical activity was assessed at baseline and month 12 by a 
validated physical activity questionnaire (261), in which participants were asked about 
frequency and duration of several types of physical activity. Metabolic equivalent hours 
(MET-hours), defined as the ratio of work metabolic rate to a standard resting metabolic 
rate, were computed as the product of average hours per week of each activity multiplied 
by its MET-hour equivalent. All recorded activities were summed to obtain the total 
MET-hours of activity performed per week for a given participant. This sub-study used a 
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separate physical activity questionnaire from the parent study in order to gather more 
specific data than the original questionnaire, since changes in activity habits from 
baseline to the end of the intervention could have an impact on body composition. See 
Appendix 2 for a sample questionnaire. 
I. Statistical Analyses 
Differences in baseline demographic and anthropometric characteristics between 
treatment groups at baseline were assessed by non-paired Student's t-test for continuous 
variables and Chi-square test for categorical variables. Two-way repeated measures 
ANOVA was used to compare BMI, adiposity measures and bone density variables 
between GTE and placebo groups and within group at baseline and at month 12. Change 
from baseline was calculated by subtracting the baseline from the month 12 values for 
each participant. Linear regression was used to compare the mean change from baseline 
in GTE and placebo groups after adjusting by baseline value, change in BMI, years since 
menopause and MHT use. The same analyses were used to compare adiposity measures 
and bone density variables between COMT genotype groups.  
Obesity-associated hormones, glucose, and HOMA-IR were natural log-
transformed and a repeated measures 2-way ANOVA was used to compare geometric 
means at baseline and month 12. The pairwise differences between groups were used to 
compute the P-values between and within treatment groups. Similar analyses were 
performed to compare geometric means between and within COMT genotype at baseline 
and month 12. Mean changes in obesity-associated hormones, glucose, and HOMA-IR at 
12 months were calculated by subtracting the baseline value from the value at month 12 
and analyzed using linear regression. The explanatory variables included treatment group, 
baseline value of the variable, change in BMI, COMT genotype, and all possible 2-way 
interactions. Main effects were kept in the model. Model reduction was considered using 
backward elimination for 2-way interactions having P-values > 0.05. Pearson’s 
correlation was used to evaluate the association between leptin, adiponectin and insulin, 
and BMI, adiposity measures and bone density variables at baseline.   
Data are presented as arithmetic or geometric means and standard errors of the 
mean (SEM) or 95% confidence intervals for continuous variables or as counts and 
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percentages for categorical variables. All analyses were performed using the Mixed, 
GLM and Freq procedures of SAS, version 9.3 (SAS, Inc.). Cook’s distance was used to 
evaluate influential outliers and residual plots were used to evaluate model assumptions. 
IV. Results 
A. Participant Characteristics 
Demographic and baseline characteristics were similar for both groups (Tables  
Table 4.1). The mean age of the study sample was 60.4 years and most subjects 
were of non-Hispanic white race/ethnicity (94.2%). Mean BMI was 27.8 kg/m2 and waist 
circumference was 91.5 cm. Approximately 50% of participants regularly consumed 
calcium supplements in both groups and only a small number of women were taking 
medication to inhibit bone resorption. Physical activity, total energy intake and intake of 
caffeine and macro- and micronutrients did not differ at baseline or at month 12. 
Prevalence for osteopenia (n = 3) was 2.5%. No participants met criteria for osteoporosis. 
Baseline characteristics did not differ between participants who completed the study and 
those who withdrew (data not shown). 
B. Comparison between Groups for Body Composition and Adiposity Variables 
Body composition and adiposity variables are presented in Table 4.2. Groups 
were similar at baseline for most body composition and adiposity variables, though 
participants in the GTE group had significantly higher android % fat (48.6 ± 0.8% vs. 
45.5 ± 0.8%, P = 0.01) and android/gynoid ratio (1.06 ± 0.02 vs. 0.99 ± 0.02, P = 0.01). 
No significant differences in change from baseline to month 12 were seen in any 
parameter of body composition. Non-significant reductions from baseline in VAT mass (-
0.01 ± 0.02 vs. 0.03 ± 0.02 kg, respectively; P = 0.11) and estimated VAT volume (-0.02 
± 0.02 vs. 0.02 ± 0.02 cm3; P = 0.18) were observed in the GTE group as compared to 
placebo. Interactions were observed between treatment, time, and baseline BMI for 
gynoid % fat and tissue % fat. While the gynoid % fat increased from baseline to month 
12 in the placebo group as baseline BMI increased, gynoid % fat decreased over time as 
baseline BMI increased in the GTE group (P for interaction = 0.02). Similarly, while 
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tissue % fat increased from baseline to month 12 in the placebo group as baseline BMI 
increased, the opposite occurred in the GTE group - as baseline BMI increased, tissue % 
fat decreased during the intervention (P for interaction = 0.04). Android:gynoid ratio did 
not change from baseline in either study group. 
No treatment by genotype interactions were observed, so we conducted an 
exploratory analysis of baseline body composition variables by COMT genotype, 
independent of treatment group. A statistically significant difference in lean weight at 
baseline was observed between participants with the high-activity COMT genotype 
(n=34) as compared to the intermediate-activity group (n=46) (41.9 ± 0.82 kg vs. 39.1 ± 
0.77 kg, respectively; P = 0.02). No differences were seen between genotype groups for 
any other body composition variable. 
C. Comparison between Groups for Bone Mineral Density Variables  
 No differences were observed between or within groups when comparing change 
from baseline to month 12 in BMD, T-score, or Z-score ( 
Table 4.3). Mean T-score and Z-scores were positive in both groups at both time points. 
Results did not differ by COMT genotype. 
D. Comparison of Obesity-associated Hormone Concentrations 
 Mean fasting concentrations for obesity-associated hormones and glucose 
homeostasis markers at baseline and month 12 are presented in Table 4.4. Concentrations 
did not differ between treatment group at either time point for any variable, aside from 
differences in baseline adiponectin (P = 0.05), and there were no significant differences 
in change from baseline for any variable. No interaction was observed between GTE and 
COMT genotype for change from baseline in these variables.  
E. Associations between obesity-associated hormones and body composition 
variables 
 Table 4.5 reports Pearson correlations between baseline concentrations of leptin, 
adiponectin, and insulin and body composition and BMD measurements from the pooled 
group of all participants (n = 121). Fasting plasma leptin concentrations were positively 
correlated with BMI and body fat measurements and were negatively correlated with 
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tissue % lean (r = -0.270; P < 0.001) and Z-score (r = -0.314; P < 0.001). Concentration 
of adiponectin was positively correlated with gynoid % fat (r = 0.264; P = 0.004) and 
negatively correlated with VAT mass (r = -0.342; P < 0.001). Insulin concentration was 
positively correlated with BMI and body fat measurements and was negatively correlated 
with tissue % lean (r = -0.188; P = 0.04). Adiponectin and insulin concentrations were 
not correlated with BMD. These relationships remained similar at month 12. 
V. Discussion 
The results of the present study indicate that intake of 1315 mg green tea 
catechins daily (843 mg as EGCG) for one year did not affect overall adiposity, fat-free 
mass, or BMD in postmenopausal overweight or obese women. Similarly, GTE did not 
alter concentrations of obesity-associated hormones or glucose homeostasis markers as 
compared to placebo. However, reductions in visceral adiposity in GTE participants 
nearly reached significance and participants with higher baseline BMI randomized to 
GTE reduced tissue % fat to a greater degree than those randomized to placebo.  
Epidemiologic evidence has demonstrated that individuals with the highest degree 
of tea consumption may have reduced risk for obesity-related diseases (262,263), and 
several randomized trials (typically ≤ 12 weeks in duration) have demonstrated that GTC 
supplementation may lead to modest decreases in body weight and adiposity. However, 
results are inconsistent and the clinical relevance of these reductions is a topic of debate 
(163,164). Further, most studies examining this relationship have included caffeine as 
part of the intervention, making it impossible to measure the independent effects of green 
tea catechins. While we did not see a change in BMI, total fat mass, or % body fat 
between treatment groups, trends toward reductions in total VAT mass and volume in the 
GTE group suggest that green tea catechins may inhibit accumulation of abdominal fat 
when consumed over the life span. These effects are notable, given that central adiposity 
is associated with higher risk of metabolic disorders, cardiovascular disease, and some 
forms of cancer (264). Though we are not able to extrapolate our results beyond the 12-
month intervention period, our results are consistent with evidence from other 
randomized trials that have found an influential effect of green tea catechins on 
abdominal and visceral fat (158,177). In addition, our results show that participants with 
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higher baseline BMI randomized to GTE reduced tissue % fat to a greater extent over 
time as compared to those randomized to placebo, indicating that GTE supplementation 
may be especially beneficial for individuals with a higher degree of adiposity.  
As previously stated, the effect of green tea catechins on body composition has 
not been consistent across all study populations and trial designs. Genetic variations may 
at least partially explain these differences in outcomes. The G to A polymorphism at 
position 4680 of the COMT gene is often cited as playing a potential role in sensitivity to 
GTC with respect to energy expenditure and fat oxidation. EGCG has been suggested to 
inhibit COMT, an enzyme responsible for metabolizing both green tea catechins and 
catecholamines such as norepinephrine (265). Reduced activity of COMT may lead to 
extended effects of these compounds, with resulting increases in SNS activity, fat 
oxidation, and energy expenditure. Additionally, the A/A form of the COMT enzyme is 
associated with a 3- to 4-fold reduction in enzymatic activity as compared to the G/G 
genotype (117), suggesting that those with the A/A form of COMT may have prolonged 
circulating concentrations of green tea catechins which would translate into prolonged 
physiologic effects. Since people with the high-activity form of COMT metabolize GTC 
and norepinephrine at a faster rate, it was hypothesized that GTE supplementation would 
be most beneficial in these individuals due to the inhibitory effects of GTC on the 
enzyme. However, the results of the present study do not indicate a modifying effect of 
COMT genotype on body composition variables. Indeed, there is little in vivo evidence to 
support a role of COMT in relation to clinically meaningful reductions in body weight 
and adiposity. Hodgson et al. (266), using targeted catecholamine profiling techniques, 
determined that GTE did not increase concentrations of norepinephrine, suggesting that 
GTE supplementation may not alter COMT activity. Further, Lorenz et al. (267). 
determined that administration of 750 mg EGCG did not impair the in vivo activity of 
COMT.  
Epidemiologic studies have linked green tea consumption to increased bone 
density (195) and reduced risk for hip fractures (268). Biologic mechanisms are thought 
to involve the weak estrogenic effect of green tea catechins (269) and induction of 
osteoclast apoptosis by EGCG (189), therefore inhibiting bone resorption and leading to 
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increased BMD. We did not observe an effect of GTE on measures of BMD in this study 
population. This is in contrast to Shen et al. (198), who found that supplementation of 
500 mg/d of green tea polyphenols (233 mg as EGCG) for 6 months increased bone-
specific alkaline phosphatase (BAP), a glycoprotein found on the surface of osteoblasts 
that is indicative of bone biosynthesis, in postmenopausal women with osteopenia. 
However, since their trial design did not include diagnostic markers of bone health (i.e., 
T-score), it is difficult to determine the clinical relevance of these physiologic changes. 
The women in the present study had high T-scores and Z-scores in comparison to the 
respective reference populations, so it is possible that any favorable effect of GTE on 
bone density may be best observed in individuals with low bone density.  
In addition to being a fat storage depot, adipose tissue secretes inflammatory 
markers and adipokines, such as leptin and adiponectin. Leptin concentrations are 
proportional to fat mass, while adiponectin concentrations are negatively correlated with 
degree of adiposity. Adiponectin is known to play important roles in energy homeostasis 
and insulin sensitivity. Recent research has shown that receptors for adiponectin are 
present on osteoblasts and may influence proliferation, differentiation, and the 
mineralization effects of these bone remodeling cells (270,271). However, correlational 
analysis has not proven a consistent positive association between adiponectin and BMD  
(272). The impact of leptin on bone metabolism has also been studied, but results remain 
controversial. However, we did not observe significant changes in obesity-associated 
hormone concentrations between treatment groups and these hormones did not correlate 
with bone-related end points. These results are in contrast to other studies that have 
shown increases in adiponectin concentrations and improvements in insulin sensitivity 
with GTE supplementation (215,253). This could be largely attributed to the lack of 
change in BMI and body fat mass in our study participants, as well as their general good 
health status – no participant had been previously diagnosed with diabetes or any other 
metabolic disorder. Hormone analysis and correlations to other end points were largely 
exploratory in this data set and we may not have had sufficient power to detect an effect 
of GTE on these variables.  
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 Pearson correlations confirmed established positive associations between leptin 
and adiponectin with BMI and measurements of adiposity. No relationship was seen 
between adiponectin or insulin concentrations and BMD. Interestingly, we observed a 
negative correlation between leptin concentration and Z-score (P < 0.0001), though not 
with BMD or T-score. As Z-scores compare BMD measurements to a reference 
population of the same age, it is possible that age may have been a confounder in this 
association. However, this correlation is in agreement with Morcov et al., who observed 
that leptin was an independent predictor of bone mass in postmenopausal but not 
premenopausal women (273).   
It is important to note that the GTE used in this study was decaffeinated (< 16 mg 
caffeine/day), therefore demonstrating the effect of green tea catechins independent of the 
well-understood effects of caffeine on fat oxidation and energy expenditure (274). While 
modest, non-significant reductions in VAT were observed, the overall lack of effect of 
decaffeinated GTE on body composition and adiposity aligns with the results of a 
previous randomized trial examining the effect of a 12-week caffeine-free green tea 
intervention on body weight in 38 obese postmenopausal subjects (141). This suggests 
that any beneficial effect of green tea on improvements in body weight and adiposity is 
largely due to its caffeine content or synergism between catechins and caffeine. The latter 
combination may have the greatest effect: a meta-analysis by Phung et al. (163) 
determined that in studies using interventions incorporating both green tea catechins and 
caffeine, a significant decrease in body weight, BMI, and waist circumference was 
observed as compared to individuals randomized to a caffeine-only placebo. 
The MGTT is the largest and longest clinical trial investigating the impact of GTE on 
health outcomes in postmenopausal women, including body composition and bone health. 
We used the highest daily dosage of green tea catechins in comparison to other published 
articles of GTE interventions (1315 mg/d, 843 mg as EGCG) and have previously proven 
the overall safety of our intervention supplement (Dostal et al., in press, Food and 
Chemical Toxicology). An additional strength of the current study is our use of accurate 
methods of assessing regional adiposity, which eliminates intra- and inter-examiner 
variation in measurements as compared to manual measurements such as waist and hip 
  
79 
circumference. Limitations of the current study include the lack of measurements of 
resting energy expenditure and respiratory quotient, which would have allowed us to 
form relationships between the observed changes in central adiposity, energy 
expenditure, and substrate utilization. Lastly, our genotypic analysis was limited to just 
one polymorphism of one enzyme involved in green tea catechin metabolism. It is 
possible that other enzymes and physiologic pathways may play a role in green tea’s 
effect on body composition. 
VI. Conclusion 
Daily consumption of decaffeinated GTE containing 843 mg EGCG for 12 
months was not associated with changes in adiposity, BMD, or obesity-associated 
hormones. COMT genotype did not modify these results. However, GTE may be 
beneficial for reduction of visceral fat, as well as total body fat in individuals with higher 
BMI.  
  
  
80 
VII. Tables  
Table 4.1. Baseline characteristics of study participants. 
Characteristic 
GTE  
(n = 61) 
Placebo  
(n = 60) 
P-
value 
Age at baseline, y 60.7 (0.60) 60.0 (0.65) 0.45 
Race/ethnicity     0.72 
Non-Hispanic white, n (%) 57 (93.4) 57 (95.0)   
African American, n (%) 2 (3.3) 2 (3.3)   
Other, n (%) 2 (3.3) 1 (1.7)   
Weight, kg 74.9 (1.12) 74.1 (1.25) 0.63 
Height, cm 163.7 (0.01) 163.5 (0.01) 0.89 
BMI, kg/m2 27.9 (0.34)  27.6 (0.35)  0.53  
COMT genotype, n (%)     0.49 
Low (A/A) 20 (32.8) 21 (35.0)   
Intermediate (A/G) 21 (34.4) 25 (41.7)   
High (G/G) 20 (32.8) 14 (23.3)   
Years since menopause, y 9.8 (8.1, 11.8) 8.5 (7.0, 10.3) 0.31 
MHT use (ever), n (%)     0.80 
Yes 22 (36.1) 23 (38.3)   
No 39 (63.9) 37 (61.7)   
Length of MHT use, y 3.5 (1.9, 6.5) 2.9 (1.6, 5.4) 0.66 
n 21 21   
Use of bone resorption inhibitors, n 
(%)     0.66 
Yes 3 (4.9) 2 (3.3)   
No 57 (93.4) 57 (95.0)   
Use of calcium supplements, n (%)     0.65 
Yes 30 (49.2) 27 (45.0)   
No 31 (50.8) 33 (55.0)   
Physical activity, MET-hr/week 13.8 (10.7, 17.7) 16.8 (13.1, 21.7) 0.27 
Alcohol consumption, n (%)     0.78 
Yes 51 (83.6) 49 (81.7)   
No 10 (16.4) 11 (18.3)   
Alcohol, drinks/week (drinkers only) 2.08 (1.54, 2.82) 2.07 (1.52, 2.82) 0.98 
Energy intake, kcal/day 
1384 (1262, 
1517) 
1426 (1300, 
1564) 0.65 
Caffeine, mg/day 141 (89, 222) 161 (102, 254) 0.68 
Data reported as arithmetic mean (SEM) or geometric mean (95% confidence interval) for 
continuous variables or n (%) for categorical variables. 
Abbreviations: BMI, body mass index; COMT, catechol-O-methyltransferase; GTE, green tea 
extract; MET-hr. metabolic equivalent hours; MHT, menopausal hormone therapy. 
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Table 4.2. Comparison of BMI and adiposity measures between GTE and placebo 
groups.  
  
GTE  
(n = 61) 
Placebo 
(n = 60) P-value 
BMI, kg/m2 
Baseline 28.0 ± 0.34 27.6 ± 0.35 0.30 
Month 12 27.9 ± 0.34 27.5 ± 0.35 0.37 
Change from baseline -0.13 ± 0.11 -0.05 ± 0.11 0.61 
Total fat mass, kg 
Baseline 32.2 ± 0.8 30.9 ± 0.8 0.25 
Month 12 31.7 ± 0.8 30.9 ± 0.8 0.45 
Change from baseline -0.30 ± 0.16 -0.12 ± 0.15 0.40 
% Total body fat 
Baseline 42.5 ± 0.5 41.5 ± 0.5 0.21 
Month 12 42.3 ± 0.5 41.4 ± 0.6 0.29 
Change from baseline -0.15 ± 0.17 -0.15 ± 0.16 0.99 
VAT mass, kg 
Baseline 1.06 ± 0.07 0.88 ± 0.07 0.06 
Month 12 1.04 ± 0.07 0.91 ± 0.07 0.17 
Change from baseline -0.01 ± 0.02 0.03 ± 0.02 0.11 
Estimated VAT volume, cm3 
Baseline 1.12 ± 0.07 0.93 ± 0.07 0.06 
Month 12 1.10 ± 0.07 0.96 ± 0.07 0.17 
Change from baseline -0.01 ± 0.02 0.02 ± 0.02 0.18 
Android % fat 
Baseline 48.6 ± 0.8 45.5 ± 0.8 0.01 
Month 12 47.4 ± 0.9 45.4 ± 0.9 0.09 
Change from baseline -0.92 ± 0.43 -0.27 ± 0.43 0.29 
Gynoid % fata 
Baseline 45.6 ± 0.6 45.8 ± 0.6 0.80 
Month 12 45.5 ± 0.6 45.7 ± 0.6 0.81 
Change from baseline -0.06 ± 0.18 -0.15 ± 0.17 0.71 
Android/gynoid ratio 
Baseline 1.06 ± 0.02 0.99 ± 0.02 0.01 
Month 12 1.05 ± 0.02 0.99 ± 0.02 0.03 
Change from baseline -0.009 ± 0.007 -0.003 ± 0.006 0.52 
Lean weight, kg 
Baseline 40.6 ± 0.6 40.7 ± 0.6 0.99 
Month 12 40.7 ± 0.5 40.7 ± 0.5 0.97 
Change from baseline 0.10 ± 0.11 0.09 ± 0.11 0.91 
Tissue % lean 
Baseline 54.4 ± 0.5 55.3 ± 0.5 0.18 
Month 12 54.6 ± 0.5 55.5 ± 0.5 0.26 
Change from baseline 0.19 ± 0.17 0.18 ± 0.16 0.95 
Tissue % fata    
Baseline 32.2 ± 0.8 30.9 ± 0.8 0.25 
Month 12 31.7 ± 0.8 30.9 ± 0.8 0.45 
Change from baseline -0.30 ± 0.16 -0.12 ± 0.15 0.40 
Data presented as arithmetic mean ± SEM. BMI change from baseline adjusted for baseline value, years 
since menopause, and MHT use. All subsequent change from baseline data adjusted for baseline value, 
change of BMI from baseline, years since menopause and MHT use.  
aStatistically significant time x treatment interaction 
Abbreviations: BMI, body mass index; GTE, green tea extract; MHT, menopausal hormone therapy; VAT, 
visceral adipose tissue.  
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Table 4.3. Comparison of bone density measurements between GTE and placebo. 
  
GTE  
(n = 61) 
Placebo 
(n = 60) P-value 
BMD, g/cm2 
Baseline 1.17 ± 0.01 1.14 ± 0.01 0.07 
Month 12 1.17 ± 0.01 1.14 ± 0.01 0.09 
Change from baseline -0.006 ± 0.002 -0.003 ± 0.002 0.49 
T-score 
Baseline 0.95 ± 0.12 0.62 ± 0.12 0.06 
Month 12 0.88 ± 0.12 0.59 ± 0.12 0.09 
Change from baseline -0.07 ± 0.03 -0.03 ± 0.02 0.31 
Z-score 
Baseline 1.37 ± 0.12 1.10 ± 0.12 0.11 
Month 12 1.40 ± 0.12 1.12 ± 0.12 0.10 
Change from baseline 0.02 ± 0.03 0.02 ± 0.03 0.99 
Data presented as arithmetic mean ± SEM. Change from baseline data adjusted for, BMI change 
from baseline, years since menopause, baseline value of the variable, and menopausal hormone 
therapy use.  
Abbreviations: BMD, bone mineral density; GTE, green tea extract. 
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Table 4.4. Mean concentrations of obesity-associated hormones, glucose, and 
HOMA-IR, by treatment group. 
Variable 
GTE 
(n=61) 
Placebo 
(n=60) 
P-
value1 
Insulin, µIU/mL   
Baseline 6.8 (6.0, 7.8) 5.9 (5.2, 6.7) 0.12 
Month 12 7.5 (6.6, 8.5) 6.4 (5.7, 7.3) 0.09 
Change from baseline 0.72 (0.12, 1.32) 0.50 (-0.11, 1.10) 0.61 
 
Glucose, mg/dL 
 
 
Baseline 101.5 (98.3, 104.8) 99.0 (95.9, 102.3) 0.29 
Month 12 97.4 (94.3, 100.6) 95.7 (92.6, 98.8) 0.45 
Change from baseline2 -3.1 (-5.6, -0.69) -4.32 (-6.78, -1.85) 0.56 
 
HOMA-IR 
 
 
Baseline 1.71 (1.50, 1.96) 1.44 (1.27, 1.66) 0.09 
Month 12 1.81 (1.57, 2.07) 1.52 (1.32, 1.74) 0.08 
Change from baseline 0.13 (-0.3, 0.29) 0.07 (-0.09, 0.24) 0.61 
 
Adiponectin, µg/mL 
 
 
Baseline 6.6 (5.5, 7.8) 8.4 (7.1, 10.0) 0.05 
Month 12 6.9 (5.8, 8.2) 8.1 (6.8, 9.7) 0.21 
Change from baseline 0.54 (-0.32, 1.41) -0.05 (-0.93, 0.84) 0.35 
 
Ghrelin, pg/mL 
 
 
Baseline 1061.9 (935.1, 1205.9) 1119.8 (985.0, 1273.0) 0.57 
Month 12 1057.5 (931.2, 1201.0) 1194.6 (1050.9, 1358.1) 0.19 
Change from baseline3 -31.1 (-119.2, 56.9) 84.2 (-5.98, 174.2) 0.16 
 
Leptin, ng/mL 
 
 
Baseline 31.1 (27.2, 35.6) 30.9 (27.0, 35.3) 0.93 
Month 12 30.4 (26.6, 34.8) 30.1 (26.3, 34.4) 0.90 
Change from baseline 0.002 (-2.68, 2.68) -0.59 (-3.33, 2.15) 0.76 
Baseline and month 12 data presented as geometric mean (95% confidence interval). Change 
from baseline data presented as arithmetic mean (95% confidence interval). 
1P-value for the comparison of the means between GTE and placebo. Within-group comparisons 
of baseline and month 12 values were not significant. 
2Significant interaction of change of BMI and treatment. 
3Significant interaction of baseline value and treatment. 
Abbreviations: GTE, green tea extract; HOMA-IR, homeostatic model assessment for insulin 
resistance.  
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Table 4.5. Baseline Pearson correlations between leptin, adiponectin, and insulin concentrations with BMI, adiposity, and 
BMD. 
 
aP < 0.0001 
bP < 0.05
BMI 
Total 
fat 
mass, kg 
% Total 
body fat 
VAT 
mass, 
kg 
Android 
% fat 
Gynoid 
% fat 
A/G 
Ratio 
Lean 
weight, 
kg 
Tissue 
% lean 
Tissue 
% fat 
BMD 
(g/cm2) 
T-
score 
Z-
score 
Leptin, ng/mL 0.515a 0.508a 0.495a 0.386a 0.378a 0.159 0.007 0.037 -0.270b 0.486a -0.089 -0.080 
-
0.314a 
Adiponectin, 
ug/mL -0.146 -0.080 0.060 
-
0.342a -0.109 0.264b 
-
0.086 -0.125 -0.087 0.059 -0.143 -0.146 -0.056 
Insulin, uIU/mL 0.427a 0.429a 0.322a 0.578a 0.39a -0.023 0.034 0.185b -0.188b 0.320a 0.052 0.059 -0.136 
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Chapter 5 - Acute Postprandial Effects of Green Tea Extract Administration with a 
High-Carbohydrate Meal on Appetite-Associated Hormones, Glucose Homeostasis, 
and Satiety
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I. Overview 
Background: Green tea extract (GTE) may be involved in a favorable postprandial 
response to a high-carbohydrate meal. Suggested mechanisms include increases in insulin 
sensitivity and satiety. COMT genotype may modify these effects. Objective: We 
examined the acute effects of GTE supplementation on postprandial response to a high-
carbohydrate meal through assessing appetite-associated hormone concentrations and 
glucose homeostasis markers in women who had consumed GTE (1315 mg total 
catechins/day, 843 mg as (-)-epigallocatechin-3-gallate [EGCG]) or placebo capsules for 
11-12 months. Methods: Sixty Caucasian postmenopausal women (BMI ≥ 25.0 kg/m2) 
were included in a randomized, double-blind feeding study. GTE capsules were 
consumed with a breakfast meal (665.4 kcal; 67.2% carbohydrate). Blood samples were 
drawn pre-meal, post-meal, and every 30 minutes for 4 h. Participants completed six 
satiety questionnaires (pre-meal, post-meal, and hourly). Results: Leptin, ghrelin, and 
adiponectin were not different between GTE and placebo at any time point; COMT 
genotype did not modify these results. Participants randomized to GTE with the high-
activity form of the COMT enzyme (GTE-high COMT) had higher insulin concentrations 
at time 0, 0.5, and 1.0 h post-meal compared to all COMT groups randomized to placebo. 
Insulin remained higher in the GTE-high COMT group at 1.5, 2.0, and 2.5 h compared to 
Placebo-low COMT group (P < 0.02). GTE-high COMT had higher insulin 
concentrations at times 0, 0.5, 1.0, 1.5, and 2.0 h compared to the GTE-low COMT group 
(P ≤ 0.04). AUC measurements of satiety were not different between GTE and placebo at 
any time. Conclusions: GTE supplementation and COMT do not alter the acute 
postprandial response of leptin, ghrelin, adiponectin, or satiety after consumption of a 
high-carbohydrate meal, but may be involved in the post-meal glycemic response. 
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II. Introduction 
Overweight and obesity are major public health concerns with worldwide obesity 
rates having doubled since 1980 (275). Obesity is associated with several serious health 
conditions, including cardiovascular disease, diabetes, and some forms of cancer, 
including postmenopausal breast cancer (276-278). Studies have suggested that green tea 
and its high content of polyphenolic catechins may reduce risk for these diseases in part 
via beneficial effects on body weight, as green tea consumption has been shown to 
modestly reduce body weight and adiposity in many randomized trials 
(134,156,163,175). Among the catechins present in green tea, the four most prominent 
types are epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and (-)-
epigallocatechin-3-gallate (EGCG). EGCG has been the most widely studied and is also 
thought to be the most bioactive catechin (154). However, these results have not been 
consistent across all study designs and populations, as several studies have shown no 
weight loss or weight maintenance effects with green tea supplementation (163,164)  
(Dostal et al., under review).  
Numerous mechanisms have been proposed for the anti-obesity effects of green 
tea catechins (GTC), including increases in β-oxidation and thermogenesis (138,259,266) 
and reductions in adipocyte differentiation and proliferation, lipogenesis, and nutrient 
absorption (132,150,154,279). Another mechanism by which GTC may reduce body 
weight or promote weight maintenance is through modification of several hormones 
associated with energy balance, the postprandial glycemic response, and satiety. The gut-
derived hormone ghrelin, as well as hormones derived from adipose tissue, including 
adiponectin and leptin, have been shown to be involved in appetite cues and satiety after 
ingestion of a meal, respectively. Insulin has also been associated with energy balance 
(280), and several randomized trials have demonstrated increased insulin sensitivity with 
consumption of green tea catechins (217,230,244). However, few randomized 
intervention studies examining the immediate postprandial effects of green tea catechins 
on these hormones have been conducted (130, 160) and results are overall inconclusive. 
The proposed beneficial effects of GTC on body weight and adiposity may be 
further modulated by the catechol-O-methyltransferase (COMT) enzyme, one of the main 
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enzymes responsible for catechin degradation as well as metabolism of the 
catecholamines, including norepinephrine. The gene encoding COMT is polymorphic and 
its alleles correspond to different activity levels of the enzyme: A/A = homozygous low-
activity, A/G = heterozygous intermediate-activity, and G/G = homozygous high-activity. 
A specific allele consisting of an amino acid change from valine to methionine at codon 
108 of the soluble form of the enzyme/158 of the membrane-bound form reduces the 
thermostability of the enzyme and lowers its enzymatic activity by 3- to 4-fold (117,118). 
These differences in activity are thought to affect individual variation in metabolism of 
GTC, thus potentially influencing the biological effects of green tea consumption on 
weight loss and weight control. In addition, GTC have been shown to inhibit the action of 
COMT in vitro, which is significant given that COMT is also responsible for the 
metabolism of catecholamines including norepinephrine, a potent sympathetic nervous 
system stimulant. Reduced activity of COMT, therefore, may prolong the effects of 
catecholamines on increasing thermogenesis and satiety (157,281). The polymorphic 
nature of the COMT enzyme indicates that the low-activity form of the COMT enzyme 
may further potentiate these actions, resulting in even greater increases in thermogenesis 
and satiety and possibly translating into improved weight loss or weight maintenance.  
The primary aim of the present study was to determine the effect of a 
decaffeinated green tea extract (GTE) containing 1315 mg total catechins/day (843 mg as 
EGCG) on postprandial concentrations of appetite-related hormones and blood glucose as 
well as measures of satiety in a population of healthy overweight and obese 
postmenopausal women at high risk for breast cancer. A secondary aim was to evaluate 
the modification of these effects by COMT genotype. We hypothesized that GTE 
supplementation would cause favorable changes in hormone concentrations and increase 
postprandial satiety, and that women with the low-activity genotype (A/A) would have a 
more favorable response to GTE consumption than those with the intermediate- (A/G) or 
high-activity (G/G) COMT genotypes, due to greater exposure to GTC.  
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III. Methods 
A. Study Design 
 This acute postprandial feeding study was conducted in a subset of overweight 
and obese women enrolled in the Minnesota Green Tea Trial (MGTT), a phase II, 
randomized, double blind, placebo-controlled, intervention study which is described in 
detail elsewhere (Samavat, et al., under review). In the parent study, healthy 
postmenopausal women at high-risk of breast cancer due to increased mammographic 
density were randomized by COMT genotype into one of six groups: GTE, low COMT 
activity (A/A); GTE, intermediate COMT activity (A/G); GTE, high COMT activity 
(G/G); placebo, low COMT activity (A/A); placebo, intermediate COMT activity (A/G); 
or placebo, high COMT activity (G/G). The subjects consumed either four decaffeinated 
(< 16 mg caffeine/day) GTE capsules containing a total of 1315 ± 116 mg GTC (843 ± 
44 mg as EGCG) or placebo capsules daily for 12 months to determine the effects of 
GTE exposure on a number of breast cancer biomarkers including mammographic 
density, reproductive hormones, oxidative stress, and insulin-like growth factor (IGF) 
axis proteins.  
To evaluate the postprandial effects of GTE consumption following a 
standardized meal, 60 subjects (10 from each treatment/genotype group) were invited to 
participate in the postprandial study during month 11 or 12 of the 12-month parent study. 
The postprandial study was designed to assess the acute effects of GTE ingestion 
(independent of caffeine) and COMT genotype on energy balance-related measures. This 
research took place during a half-day clinic visit. For the half-day visit, subjects were 
instructed to adhere to their normal energy intake and to refrain from exercise and alcohol 
the day before the test day. They arrived at the research unit between 07:00 and 08:00 
after a 10-hour fast. Baseline satiety questionnaires were completed and fasting blood 
drawn for assessment of the energy-related hormones. After a standardized high-
carbohydrate breakfast (consisting of a bagel with cream cheese, orange juice, and low-
fat, fruit-flavored yogurt or 2% milk), blood was drawn immediately post-meal and every 
30 minutes over a period of 4 hours for evaluation of change in energy- and obesity-
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related hormones. Satiety questionnaires were completed before the meal, immediately 
after consumption of the meal, and every hour thereafter for a total of six questionnaires. 
B. Participant Recruitment and Eligibility Criteria 
Participant eligibility, screening, and recruitment followed the same protocol as 
the parent study (Samavat, et al., under review). Inclusion criteria included healthy, non-
smoking postmenopausal women aged 50-70 years who were classified as having 
“heterogeneously dense” or “extremely dense” breast tissue by a trained radiologist after 
a routine screening mammogram. Additional inclusion criteria included: no use of 
systemic menopausal hormone therapy (MHT) or chemopreventive agents, no history of 
breast cancer or proliferative breast disease, alcohol consumption < 7 drinks/week, stable 
weight in the past year (< 4.6 kg change), no positive serology for Hepatitis B or C 
antibodies or elevated concentrations of liver enzymes (defined as alanine 
aminotransferase (ALT) above 1.5 times the upper limit of normal, 60 U/L) at the 
screening clinic visit, and willingness to avoid green tea beverage consumption for the 
12-month intervention period. Specific criteria for this sub-study included: 
overweight/obese (BMI: ≥25 to ≤40 kg/m2), no use of weight loss medications, and no 
history of bariatric surgery.  
Recruitment for the parent study took place through the Fairview and Park 
Nicollet hospital systems through identification of postmenopausal women at high risk of 
breast cancer due to high mammographic density (assessed by routine screening 
mammogram). Of 1075 women randomized into the parent study, 230 women classified 
as overweight (BMI = 25.0-29.9 kg/m2) or obese (BMI = 30.0-40.0 kg/m2) at the 
screening clinic visit were additionally invited to participate in this acute feeding study 
beginning in September 2012. Of these, 149 participants responded to the invitation, 50 
of whom were excluded due to the need for equal numbers in each COMT genotype 
group. An additional 33 women declined to participate, and 5 did not participate for 
various other reasons. Ultimately, 61 participants were randomized into the study (GTE: 
n=30; placebo: n=31). One participant in the placebo group was excluded at the end of 
the half-day study due to not consuming the intervention product with the breakfast meal, 
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so the final sample size was 30 participants per treatment group (n=10 for each COMT 
genotype within each treatment group).  
C. Randomization, Blinding, and Participant Consent 
Randomization of subjects was performed by the University of Minnesota 
Medical Center-Fairview’s Investigational Drug Service (IDS) pharmacy using a 
computer-generated permuted block randomization scheme with blocks of 8 stratified by 
COMT genotype activity: low (A/A), intermediate (A/G) or high (G/G), assuring both 
participants and investigators were blinded to the treatment of a subject. Institutional 
Review Board (IRB) approval was obtained at each clinical center. All participants 
provided additional written informed consent for this ancillary study (see Appendix 3). 
This trial was registered at clinicaltrials.gov as NCT00917735. 
D. Determination of COMT Genotype 
DNA was purified from buffy coats of peripheral blood samples using a PureGene 
Blood kit (Gentra Systems, Minneapolis, MN). A TaqMan assay was developed for 
determining the COMT G/A polymorphism using a TaqMan PCR Core Reagent kit 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. PCR 
amplification using ~10 ng of genomic DNA was performed in a thermal cycler (MWG 
Biotech, High Point, NC) with an initial step of 95°C for 10 min followed by 50 cycles of 
95°C for 25 s and 62°C for 1 min. The fluorescence profile of each well was measured in 
an ABI 7900HT Sequence Detection System and the results analyzed with Sequence 
Detection Software (Applied Biosystems). Experimental samples were compared with 12 
controls to identify the three genotypes at each locus (G/G, G/A, and A/A). Any samples 
that fell outside the parameters defined by the controls were identified as non-informative 
and retested. 
E. Green Tea Extract Composition 
This study used decaffeinated Green Tea Extract Catechin Complex (GTE) in 
capsule form, provided by Corban Laboratories, (Eniva Nutraceutics, Plymouth, MN). 
Mean daily catechin content was 1315 ± 116 mg/day (843 ± 44 mg as EGCG). Placebo 
capsules were identical in appearance to GTE and contained 816 mg maltodextrin, 808 
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mg cellulose, and 8 mg magnesium stearate (flow agent). See Table 3.1 for detailed 
information on the GTE composition. GTE ingredients were analyzed by high-
performance liquid chromatography (HPLC) (Rutgers University, Piscataway, NJ) to 
demonstrate comparability with the stated catechin contents of the manufacturer. 
Participants were required to consume four capsules daily and were advised to ingest 2 
capsules in the morning hours and 2 in the evening to maintain circulating catechin 
concentrations throughout each day, and to take the capsules with meals to reduce any 
potential gastrointestinal discomfort associated with consuming GTE in the fasted state. 
For this specific sub-study, participants were asked to consume the morning dose of GTE 
with the breakfast meal. 
F. Demographics Data Collection 
All participants completed a health history questionnaire (Appendix 1) upon 
entry into the parent study that included comprehensive data of demographics, lifestyle 
factors (physical activity, smoking history, and alcohol intake), and information about 
medical history, medication use (current and former), and full reproductive history. 
G. Dietary Intake  
 To evaluate dietary intake participants were asked to record food intake on two 
assigned weekdays and one weekend day prior to the half-day visit. Recording errors 
were minimized by providing the subjects detailed instructions on how to keep accurate 
diet records (see Appendix 3 for example). Subjects were encouraged to measure foods 
eaten using measuring spoons and cups whenever possible. Diet records were then 
reviewed for accuracy and completeness during the clinic visit by a Registered Dietitian 
Nutritionist and later analyzed for nutrient content using the Food Processor Diet 
Analysis and Fitness software, version 10.10 (ESHA Research, Salem, OR). The average 
of the three days was used to represent typical food and nutrient intake.   
H. Test Meal Composition 
 The high-carbohydrate test meal consisted of a plain bagel (300 kcal, 59.4 g 
carbohydrate, 11.6 g protein, 1.8 g fat), 1 ounce cream cheese spread (84 kcal, 0.1 g 
carbohydrate, 2 g protein, 8.1 g fat), 8 ounces orange juice (122 kcal, 28.7 g 
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carbohydrate, 1.7 g protein, 0.3 g fat), and choice of 6 ounces low-fat fruit yogurt (183 
kcal, 34.5 g carbohydrate, 7.4 g protein, 2.1 g fat) or one cup 2% milk (138 kcal, 13.5 g 
carbohydrate, 9.7 g protein, 4.9 g fat). Mean total energy content was 665.4 kcal; 
macronutrient content was as follows: carbohydrate = 113.3 g (67.2%); protein = 23.9 g 
(14.3%); and fat = 10.0 g (18.5%). Appendix 3 details the dietary analysis of the test 
meals. Participants were instructed to take two GTE or placebo capsules with the test 
meal. 
I. Biological Sample Analyses 
Plasma adiponectin, leptin, and ghrelin were measured using radioimmunoassay 
kits manufactured by EMD Millipore (Billerica, MA) (inter-assay % coefficient of 
variation [% CV]: leptin = 9.8%, adiponectin = 8.6%, ghrelin = 6.2%; intra-assay % CV: 
leptin = 10.1%; adiponectin = 7.7%, ghrelin = 8.1%). Serum insulin was measured using 
a simultaneous one-step immunoenzymatic, chemiluminescent assay (Access 
Ultrasensitive Insulin assay, Quest Diagnostics, Wood Dale, IL, intra-assay % CV: 3-
5.0%; inter-assay % CV = 3.9%). Serum glucose concentrations were measured using a 
hexokinase enzymatic reference method (Quest Diagnostics, Wood Dale, IL, monthly % 
CV = 1.4%).  
J. Assessment of Satiety 
To test satiety, we used a set of nine visual analogue scale (VAS) ratings 
associated with the standardized high-carbohydrate test meal. Participants were asked to 
answer each separate VAS question relating to hunger, fullness, desire to eat, prospective 
consumption, perceived satiety, contentedness, irritability, sleepiness, and mental 
alertness in a continuous linear scale from 0 to 100 millimeters, where 0 represented 
“not/none at all” and 100 represented “extremely/very” (example included in Appendix 
3). These scores were then converted to centimeters. The VAS is considered to be a valid 
and reliable assessment tool for monitoring the effects of energy, palatability, and 
macronutrient manipulations on subjective ratings in appetite studies (155,282). . 
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K. Statistical Analyses 
Power calculations were unable to be performed for the half-day postprandial sub-
study, since there was no data available on these outcomes at that time. We chose 60 
participants as a feasible number that is large in comparison to similar studies examining 
appetite-related hormones in response to a specific dietary component.  
Demographic characteristics of participants at baseline were compared between 
treatments using a one-sample t-test for continuous variables. Natural logarithmic 
transformation was considered to normalize the distribution of these variables. Chi-
square and Fisher exact tests were used to compare the distribution of categorical 
variables between treatments. Change in hormones (leptin, ghrelin, adiponectin, and 
insulin) and blood glucose over time was evaluated using linear regression with repeated 
measurements. Hormones and blood glucose were transformed using natural logarithms 
to normalize their distribution. The model included time, treatment, COMT genotype and 
the 2-way and 3-way interactions as explanatory variables. Interactions were excluded 
from the model if non-significant at P-value < 0.05, using backward elimination. When 
statistically significant differences were detected, a post hoc pairwise comparison across 
treatment and COMT genotype groups was performed. Results are expressed as means 
and 95% confidence interval. An unstructured working correlation matrix was fitted to 
model the correlation between time points within participants; this was chosen based on 
Akaike’s information criterion. The area under the curve (AUC) for insulin and glucose 
was calculated using the trapezoidal rule and pairwise compared within genotypes 
between treatment groups using repeated measurements linear regression. The AUC of 
the satiety VAS at different time points before and after the meal was calculated for each 
participant and each VAS question using the trapezoid method. The AUC of each 
question and participant were used as dependent variables in a linear mixed model to 
evaluate the effect of treatment on the AUC of each question. Baseline VAS (pre-meal) 
was used as a random effect in the model. Model assumptions were evaluated using 
residual plots and Cook’s distance greater than 0.5 was used to evaluate possible 
influential outliers for both hormones and VAS measures. Significance was set at P ≤ 
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0.05 for all comparisons. All analyses were conducted using SAS system version 9.4 
(The SAS system for Windows, 2005, Cary NC, SAS Institute, Inc.). 
IV. Results 
A. Baseline Characteristics 
 Participants randomized to GTE and placebo were similar with respect to baseline 
demographics and characteristics, as presented in Table 5.1. Groups differed in the 
distribution of level of education, in that the GTE group had a greater number of 
participants who had obtained education beyond high school (P = 0.001). Mean intake of 
macro- and micronutrients as assessed by 3-day diet records did not differ by treatment 
group. 
B. Postprandial Hormone and Glucose Response 
 Postprandial concentrations of leptin, ghrelin, and adiponectin are presented in 
Figure 5.1. Baseline fasting concentrations of all variables were similar between 
treatment groups. These hormone concentrations were not different between GTE and 
placebo at any time point, and COMT genotype did not modify these results. 
 There was a statistically significant interaction between treatment and COMT 
genotype for insulin and glucose that varied across time (
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Figure 5.2). Participants randomized to GTE with the high-activity form of the COMT 
enzyme (GTE-high COMT) had significantly higher insulin concentrations at time 0 
(post-meal), 0.5, and 1.0 h post-meal as compared to all COMT genotype groups 
randomized to placebo. Insulin concentrations remained significantly higher in the GTE-
high COMT group 1.5, 2.0, and 2.5 h as compared to the Placebo-low COMT group (P < 
0.02). The GTE-high COMT group also had higher insulin concentrations at time 0, 0.5, 
1.0, 1.5, and 2.0 h after the meal as compared to the GTE-low COMT group (P ≤ 0.04). 
No differences between treatment groups and COMT genotypes existed 3.0, 3.5, or 4.0 h 
after the meal. With respect to glucose, the GTE-high COMT group had significantly 
higher glucose concentrations at time 0 as compared to Placebo-high COMT (P = 0.05) 
and the GTE-low COMT group (P = 0.004). The GTE-low COMT group had higher 
serum glucose 3.5 h post-meal as compared to the GTE-high COMT and Placebo-low 
COMT groups (P = 0.01 and P = 0.05, respectively). Insulin AUC comparisons within 
genotypes between treatment groups are listed in Table 5.2.  The insulin AUC for GTE-
high COMT was significantly higher as compared to Placebo-high COMT at all time 
points, though the overall mean AUC comparison failed to reach significance (P = 0.06). 
Mean insulin AUCs between intermediate- and low-COMT groups did not differ at any 
time point, and glucose AUCs did not differ within any COMT genotype between 
treatment groups (data not shown). 
C. Appetite Sensations 
AUC measurements of satiety-related variables did not show any significant 
difference between treatments at baseline or over the 4-h time period between GTE and 
placebo groups (Table 5.3). COMT genotype did not modify these results.  
V. Discussion 
The results of the present study indicate that GTE supplementation does not alter the 
acute postprandial response of leptin, ghrelin, or adiponectin after consumption of a high-
carbohydrate meal, and that COMT genotype does not modify this relationship. However, 
GTE supplementation and COMT genotype may both be involved in the post-meal 
glycemic response, as significant interactions were observed between COMT genotype 
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and glucose and insulin concentrations over the 4-h test period. No effect of GTE or 
COMT genotype was seen on measures of postprandial satiety.  
To our knowledge, this is the first study to examine the effect of GTE 
supplementation on acute postprandial concentrations of the appetite-associated peptide 
hormones leptin, ghrelin, and adiponectin. Ghrelin is a peptide produced mainly in the 
stomach and has been shown to influence feeding behavior, energy metabolism, and 
gastrointestinal function (283). Ghrelin concentrations typically increase prior to a meal 
and decrease after feeding (284). Leptin exerts an anorectic effect resulting in reduced 
food intake (37) and increased energy expenditure (38). Circulating levels of leptin are 
proportional to fat mass (40); however, obese individuals have demonstrated a resistance 
to the protein’s effects (41). Adiponectin modulates several metabolic processes 
including glucose regulation (48) and fatty acid metabolism (49), and also has centrally 
mediated effects on food intake and energy expenditure (54,55). Concentrations of 
adiponectin are negatively correlated with body fat percentage in adults (51). We did not 
find significant differences between treatment groups in these hormones prior to the meal 
or at any time point thereafter, indicating that GTE did not modify fasting concentrations 
of ghrelin, leptin, and adiponectin in these participants. This is consistent with our 
previous work, which demonstrated that GTE did not modify concentrations of these 
hormones over the MGTT’s 12-month intervention period in larger samples of 
overweight and obese study participants (Chapters 3 and 4). We did observe a somewhat 
unexpected leptin response, in which plasma leptin concentrations decreased moderately 
from pre-meal to 1.5 h in both groups before increasing to the end of the 4 h period. Yet, 
these results correlate with other studies that have examined leptin concentrations in 
overweight and obese women after a high-carbohydrate meal (285,286), affirming that 
obesity is associated with an impaired postprandial leptin response. When correlated to 
the AUC analysis of satiety-related endpoints, satiety and prospective food intake were 
not differentially influenced by the effect of GTE on energy-related hormones. Together, 
the results of these studies indicate that any effect of GTE supplementation is not 
mediated through alteration of leptin, ghrelin, or adiponectin concentrations.  
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We observed a significant interaction between GTE, COMT genotype, and time, 
in which participants randomized to GTE with the high-activity (G/G) form of the COMT 
enzyme demonstrated increased postprandial insulin concentrations as compared to the 
Placebo-high COMT and GTE-low (A/A) COMT groups, despite similar glucose profiles 
at most time points. The significance of an increased insulin response to a high-
carbohydrate meal in participants with the G/G genotype taking GTE is unclear, though it 
could be indicative of the need to secrete additional insulin to manage blood glucose 
concentrations over time, as compared to individuals with other forms of the COMT 
genotype and those not taking GTE. The sample size of this group was small, thus 
making it difficult to draw definitive conclusions. Yet, our results are in agreement with 
those of another study (130) that found greater postprandial insulin concentrations after 
consumption of GTE (836 mg catechins) in individuals with the G/G genotype as 
compared to those with the G/A or A/A COMT genotypes. Similarly, Kring, et al. (129), 
determined that there was an 11.6% increased frequency of the G/G COMT genotype in 
individuals with impaired glucose tolerance or type 2 diabetes. These studies seem to 
suggest that the high-activity form of the COMT enzyme is associated with increased risk 
for glycemia-related health conditions, and that GTE consumption may potentiate an 
exaggerated insulin response after a meal. These results coincide with our previous 
findings in a larger sample of postmenopausal overweight and obese women (n = 237) 
(Dostal, et al., under review), in which participants with the G/G form of COMT showed 
significantly higher insulin concentrations at month 12 as compared to those with the 
A/A genotype irrespective of treatment group (GTE and placebo groups combined); yet, 
among participants with baseline fasting insulin ≥10 µIU/mL, reductions in fasting 
insulin concentrations were seen in the GTE group over 12 months compared to both the 
placebo group and all participants with baseline insulin < 10 µIU/mL. It is plausible that 
GTE consumption may elicit a higher immediate postprandial insulin response, 
particularly in those with the G/G COMT genotype, while at the same time acting to 
reduce fasting insulin concentrations over time. Additional research is needed to 
determine the specific mechanisms of the COMT enzyme on insulin concentrations after 
administration of GTE and how this may affect short- and long-term glycemic response. 
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Early animal studies demonstrated reduced food intake with administration of 
green tea catechins (154,199), which generated interest in the idea that green tea may 
increase satiety. However, this effect has not been confirmed in human subjects. One 
study found that inclusion of 167 mg green tea catechins and 100 mg caffeine in a 
beverage containing 10 g soluble fiber created lower hunger and higher fullness ratings 
and was associated with the lowest energy intake in the next meal as compared to fiber-
only (46 mg caffeine), isocaloric control beverage (no caffeine), and no beverage 
conditions (159). In contrast, Diepvens, et al. showed that women randomized to receive 
green tea (1125 mg catechins + 225 mg caffeine/day) for nearly 3 months with a low-
energy diet became hungrier over time and showed increased prospective food 
consumption as compared to placebo (157). The authors suggested that this could be due 
to down-regulation of the leptin response through stimulation of the sympathetic nervous 
system by green tea, as leptin is known to reduce appetite. However, leptin 
concentrations were not measured in their study, so this conclusion could not be 
confirmed. Several other randomized trials examining the effect of GTC on acute 
measures of satiety (136,287) or long-term changes in energy intake (134,147) (Dostal, et 
al., under review) have shown null results, including the present study, in which we did 
not observe differences between treatment groups in any of the 9 questions related to 
hunger, satiation, and prospective food intake in the 4 hours following a high-
carbohydrate breakfast meal. Taken together with the existing evidence, it is unlikely that 
oral GTE consumption is independently associated with increased satiety or reduction in 
voluntary food intake.  
The results of this research contribute depth not only to the growing body of 
research on the effects of GTC on insulin sensitivity, but also to the association between 
COMT genotype and risk for glycemia-related health conditions. Our results also 
strongly indicate that GTE does not induce appetite inhibition or satiety, thus weakening 
the argument for these effects as mechanisms behind green tea’s association with 
reductions in body weight and adiposity. However, our research has several limitations. 
We conducted this analysis after just one meal and were unable to compare each 
participant’s response to that of a reference meal. There was no measure of hedonic 
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liking of the meal, which may have influenced satiety and prospective food intake. 
Standardization of the diets of participants 24 hours prior to the breakfast meal could 
have increased similarity of the glycemic response. Lastly, the sample size in this study 
may have been too small to yield significant results.  
VI. Conclusion 
These results indicate that supplementation of 1315 mg GTE per day for 12 
months did not influence pre- or postprandial concentrations of appetite-associated 
hormones or measures of satiety after a high-carbohydrate breakfast meal. Yet, GTE and 
COMT genotype may have specific influences on post-meal insulin and glucose 
concentrations, and these findings warrant additional research to determine the specific 
impact of GTE on the postprandial glycemic response.  
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VII. Tables and Figures 
Table 5.1. Baseline characteristics and mean 3-day dietary intake of study 
participants, by treatment group 
  GTE (n=30) Placebo (n=30) 
P-
value 
Age, y 61.0 (59.2, 62.8) 60.8 (59.0, 62.6) 0.88 
White, non-Hispanic, n (%) 29 (96.7) 30 (100) 1.00a 
Weight, kg 74.2 (71.1, 77.4) 75.3 (72.1, 78.4) 0.64 
Body mass index, kg/m2 28.2 (27.1, 29.4) 28.3 (27.2, 29.5) 0.91 
Waist-to-hip ratio 0.87 (0.83, 0.89) 0.85 (0.82, 0.87) 0.31 
Years postmenopausala 8.8 (6.3, 12.2) 7.8 (5.6, 10.8) 0.60 
Type of menopause, n (%) 0.75 
Natural 23 (76.7) 24 (80.0) 
Surgical 7 (23.3) 6 (20.0) 
Education, n (%) 0.001a 
Masters/PhD/Professional 10 (33.3) 8 (26.7) 
College degree 8 (26.7) 15 (50.0) 
Some college 12 (40.0) 2 (6.7) 
High school or below 0 5 (16.7) 
Physical activity, MET-hr/week 39.5 (26.2, 52.7) 43.8 (30.6, 57.1) 0.64 
Dietary variables       
Total energy, kcal 1761.9 (1589.7, 1934.0) 1849.9 (1677.8, 2022.0) 0.48 
Protein, g 73.4 (65.7, 81.0) 78.6 (70.9, 86.2) 0.35 
Total fat, g 67.5 (57.6, 77.4) 73.9 (64.0, 83.8) 0.37 
Dietary cholesterol, mg 230.0 (189.6, 270.5) 237.8 (197.3, 278.2) 0.79 
Saturated fat, g 23.4 (19.9, 26.9) 24.5 (21.0, 28.0) 0.66 
MUFAb, g 11.9 (9.7, 14.6) 13.4 (10.9, 16.4) 0.44 
PUFA, g 7.0 (5.0, 9.0) 8.5 (6.5, 10.5) 0.31 
Omega-3 FAb, g 0.5 (0.4, 0.7) 0.6 (0.5, 0.8) 0.65 
Omega-6 FAb, g 1.2 (1.0, 1.5) 1.3 (1.1, 1.7) 0.38 
Total carbohydrate, g 216.7 (192.1, 241.2) 215.6 (191.0, 240.1) 0.95 
Dietary fiber, g 19.0 (16.8, 21.2) 20.6 (18.4, 22.9) 0.31 
Soluble fiber, g 1.8 (1.4, 2.2) 1.6 (1.2, 2.0) 0.42 
Alcoholb, g 0.1 (0.0, 0.3) 0.1 (0.0, 0.4) 0.75 
Caffeineb, mg 36.8 (13.6, 99.9) 46.2 (17.0, 125.3) 0.75 
Continuous data expressed as arithmetic mean (95% confidence interval) unless otherwise 
indicated by superscript. Categorical variables compared using Chi-square test and expressed as n 
(%).  
aFisher’s exact test used for comparison. 
bData expressed as geometric mean (95% confidence interval). 
Abbreviations: FA, fatty acid; GTE, green tea extract; MET-hr, metabolic equivalent hours; 
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 
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Table 5.2. Mean insulin area under the curves in participants after the ingestion of a 
meal with or without GTE, by COMT genotype (expressed in μIU/(mL-h))  
Placebo (n=30) GTE (n=30) 
Time 
(h) High (G/G) 
Intermediate 
(G/A) Low (A/A) High (G/G) 
Intermediate 
(G/A) Low (A/A) 
0-0.5 14.0 ± 4.9 14.6 ± 4.9 21.2 ± 4.9 35.4 ± 4.9* 25.4 ± 5.1 16.4 ± 4.6 
0-1 31.9 ± 11.4 37.6 ± 11.4 51.1 ± 11.4 81.1 ± 11.4* 55.1 ± 12.0 45.0 ± 10.9 
0-1.5 48.1 ± 18.5 58.9 ±18.5 70.5 ± 18.5 120.0 ± 18.5* 83.9 ± 19.5 73.3 ± 17.6 
0-2 65.8 ± 25.8 79.0 ± 25.8 84.1 ± 25.8 155.9 ± 25.8* 120.1 ± 27.2 99.3 ± 24.6 
0-2.5 82.9 ± 32.9 95.0 ± 32.9 96.1 ± 32.9 190.1 ± 32.9* 148.1 ± 34.7 123.7 ± 31.4 
0-3 98.7 ± 38.7 105.6 ± 38.7 105.6 ± 38.7 216.3 ± 38.7* 167.6 ± 40.8 143.1 ± 36.9 
0-3.5 109.1 ± 42.8 113.6 ± 42.8 112.5 ± 42.8 231.1 ± 42.8* 183.5 ± 45.1 156.3 ± 40.8 
0-4 114.6 ± 45.7 119.7 ± 45.7 117.9 ± 45.7 241.4 ± 45.7 195.8 ± 48.2 165.5 ± 43.6 
Data presented as arithmetic mean ± SEM. Time 0 indicates post-meal. 
*Statistically significant difference between COMT genotypes, GTE vs. placebo (P ≤ 
0.05).  
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Table 5.3. Mean satiety and fullness AUCs after ingestion of a high-carbohydrate 
meal (expressed in cm/h). 
Question 
GTE 
(n=30) 
Placebo 
(n=30) P-value 
1. Hunger 7.5 ± 2.2 9.1 ± 2.0 0.37 
2. Fullness 24.7 ± 1.4  25.3 ± 1.5 0.77 
3. Desire to eat 6.8 ± 1.8 7.6 ± 1.8 0.59 
4. Prospective consumption 3.1 ± 2.5 4.6 ± 2.3 0.36 
5. Satiety 26.5 ± 1.5 26.5 ± 1.5 0.98 
6. Contentedness 22.4 ± 2.0 20.8 ± 2.2 0.33 
7. Irritability 2.7 ± 0.8 2.3 ± 0.7 0.65 
8. Sleepiness 10.1 ± 1.6 10.9 ± 1.4 0.57 
9. Mental alertness 17.1 ± 2.1 19.8 ± 2.1 0.07 
Data expressed as arithmetic mean ± SEM. 
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Figure 5.1. Mean change in postprandial adiponectin, leptin, and ghrelin concentrations, by treatment group. 
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Figure 5.2 Mean change in postprandial insulin and glucose concentrations, by treatment and COMT genotype. 
Figure 5.2a. Insulin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2b. Glucose  
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Chapter 6 - Dissertation Summary
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The studies detailed in Chapters 3, 4, and 5 demonstrate that daily 
supplementation of 1315 mg decaffeinated GTE (843 mg as EGCG) was not associated 
with reductions in energy intake, body weight, BMI, or waist circumference over 12 
months in overweight and obese postmenopausal women. Similarly, GTE was not 
associated with overall reductions in adiposity or improvements in BMD, though GTE 
may be more beneficial for body fat reduction in individuals with higher BMI. GTE did 
not alter leptin, adiponectin, or ghrelin concentrations over 12 months or during the acute 
postprandial phase, and did not influence satiety after consumption of a high-
carbohydrate meal. However, GTE decreased fasting insulin concentrations after 12 
months in individuals with elevated baseline fasting concentrations. The high-activity 
form of the COMT enzyme may be associated with elevations in insulin and reduction in 
adiponectin concentrations over time, which is a metabolic profile associated with 
increased risk for type 2 diabetes and the metabolic syndrome. In correlation with this, 
COMT genotype influenced the post-meal glycemic response in a small sample of 
overweight and obese women, in that participants with the high-activity COMT genotype 
randomized to GTE showed increased insulin release as compared to those randomized to 
placebo or those with the low-activity form of COMT.  
These results suggest that daily supplementation of GTE may be beneficial for 
overweight and obese postmenopausal women with a higher degree of visceral adiposity 
and increased circulating insulin concentrations. Women with the high-activity form of 
COMT may see particular benefit. Therefore, GTE could be a safe and effective dietary 
supplement for those at risk for – or already diagnosed with - metabolic syndrome or type 
2 diabetes. Since these conditions are strongly associated with increased risk for breast 
cancer, it is possible that breast cancer risk could be reduced through decreasing the 
incidence and prevalence of these metabolic derangements. Additional research remains 
to be done to confirm these findings in clinical high-risk populations, to determine 
possible interactions with medications used to treat type 2 diabetes, and to fully elucidate 
the influence of COMT on the chronic and acute glycemic response.  
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I. MGTT Recruitment Letter 
 
Dear Ms. __________________, 
Congratulations on your normal screening mammogram. 
Are you interested in contributing to research on breast cancer prevention?  Up to one in 
eight American women are diagnosed with breast cancer during their lifetimes, and we are 
studying ways to prevent this disease. Our most recent study is investigating the possible 
breast cancer preventive effects of green tea consumption.   
We’re looking for healthy postmenopausal women whose normal mammograms show that 
they have relatively dense breasts. Your recent normal mammogram showed that you have 
relatively dense breasts, making you eligible to participate in medical research at the 
University of Minnesota.  Reducing breast density has been shown to decrease the risk of 
breast cancer, and we are conducting research to find out if green tea will lower breast 
density.  
If you are willing to participate in this 1-year study, you will be compensated up to $450. You 
would need to take 4 capsules daily, either decaffeinated green tea capsules or placebo 
(inactive) capsules, provide a urine and/or blood sample once a month (takes about 20 
minutes), and have another mammogram in 1 year. You might need to wait for your next 
annual mammogram until the Green Tea Study is over, which could be up to 15-16 months 
from your initial mammogram. 
This is a wonderful opportunity for you to contribute to research on women’s health and 
breast cancer prevention!  If you are interested in participating, we need to hear from you 
within two weeks of your receiving this letter. Please call (612) 624-3412 or visit 
www.greenteastudy.umn.edu to complete a brief screening questionnaire.  You may also 
email the study staff at greentea@umn.edu.  We look forward to speaking with you! It is your 
decision whether or not to participate. For your convenience, if we don’t hear from you in the 
next few weeks we may call you.  
If you have any questions about breast density and cancer risk, please contact Carolyn 
Torkelson, MD, a breast specialist and research physician with the University of Minnesota 
Breast Center, at (612) 625-8718. 
Sincerely yours, 
        
Tim Emory, MD, Meghan McKeon, MD, and Jessica Kuehn-Hajder, MD 
University of Minnesota Medical Center, Fairview Southdale Medical Center, and 
Maple Grove Medical Center Breast Center Lead Interpreting Radiologists
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II. Telephone Screening Questionnaire 
 
Name of caller _____________________ Subject ID# ________________  
 
Phone (h) ___________________ (w) ___________________  
Email ____________________ 
Interviewer ________________________   Date _______/______/______   
 
Phone Interview Questions: Green Tea Study 
 
1. To verify your identity, what is your date of birth? _____/_____/_____ 
 
2. Is this your first time contacting the Green Tea Study? ____________ 
 
3. What is your age?  _______ (50-70) 
 
4. Do you use tobacco products? ______  **Includes nicotine cessation products** 
 
5. When was your last menstrual period? _____/_____/_____    (must be at 
least 1 yr ago) 
 
6. What was the location and date of your last mammogram? 
_____/______/______  
 
______________________________________________________________ 
7. Have you had breast cancer or proliferative breast disease? ________   
Proliferative breast disease, also called hyperplasia, is an overgrowth of breast cells 
diagnosed with a needle or surgical biopsy.  It is not a cancerous condition but usually 
requires more frequent breast exams to examine the breast tissue. 
8. Have you had ovarian cancer? ________   
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9. Have you been diagnosed with any other form of cancer in the last 5 years? 
______ 
 
10. Have you been on any of the following medications at any time during the 
past 6 months? 
The individual qualifies for the study if NONE of these drugs have been taken in the 
past 6 months. 
             Y/N 
• Hormone Replacement Therapy 
           (For menopause symptoms)       _______     
• Tamoxifen   
(For breast cancer treatment or risk reduction)   _______      
• Raloxifene   
           (Osteoporosis treatment or risk reduction, or 
           breast cancer risk reduction)  
          _______      
• Aromatase Inhibitors 
           Such as Arimidex, Aromasin, or Femara 
(For breast cancer treatment)     _______    
• Methotrexate or Enbrel                 
(For rheumatoid arthritis)       _______    
 
11. During the past 6 months, have you taken any medications regularly? 
_______ 
If yes, what are they?  
           
           
   
12. Do you have any chronic health problems? _______   
If so, what are they?  
            
             
 
**Per Protocol: if a subject has any of the conditions below they are not eligible to 
participate in the study. ** 
 
• Diabetes?   
 
• Hyperthyroidism?   
 
• Uncontrolled high blood pressure (hypertension)?    
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• Crohn’s or Ulcerative Colitis 
 
 
13.  How tall are you? ______  What do you weigh? _____   
 
Calculate BMI ________  (19-35)   BMI = m/kg2  (1 lb. = 2.2 kg; 1 in. 
= 0.0254 m) 
14. Has your weight changed in the past year? _______   
 
If so, how much? ______________ (<10 lbs past year) 
15.  Do you consume alcohol? _____  If so, how much? _________________ 
 (< 7 drinks/week; 1 drink = 5 oz. wine, 12 oz. beer, or 1.5 oz. 80-proof 
distilled spirits) 
16.  Do you consume tea?  _______  If so, what kind?  
________________________________ 
 
If you consume green tea, how often? __________ _____________ (Less 
than one cup/wk) 
17.  Are you able to come to the Human Nutrition Research Clinic on the St. Paul 
campus of the University of Minnesota, first thing in the morning, before 
breakfast?    YES NO 
 
18.  If you are interested in the study, can you commit to monthly visits to the 
Human Nutrition Research Clinic over the 12 months of the study?  For most 
visits, you will be able to come at the time of your choosing.  Three visits (at 
months 0, 6, and 12) will require you to have fasted since 10:00 the night 
before.  YES  NO 
 
19.  What is the best time to reach you? 
______________________________________ 
 
20.  Would you prefer to be contacted by phone or email? 
____________________
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Congratulations!  You have met the preliminary requirements to participate in our 
Green Tea and Breast Cancer Risk Reduction Study. 
~OR~ 
Thank you very much for your time and interest.  Unfortunately, you do not 
qualify for our study for the following reasons: 
            
             
Thank you again, and have a great day. 
• If caller meets requirements, describe the study to them. 
 
Our study will look at breast cancer risk through the use of biological markers 
such as breast density.  We will be providing women that meet our criteria with 
either a green tea extract or placebo (inactive capsule) every day for one year.  
We will be measuring several biological factors from your blood and urine that 
can help indicate your risk for breast cancer. 
Would you like to hear more information?     
Another variable involved in our study is the genetic difference between women.  
Differences in specific genes may affect how a woman responds to the green tea 
extract.  We will be conducting a genetic test at the screening visit to confirm your 
eligibility for this study.  We will also test you for exposure to the hepatitis B and C 
viruses and measure your liver function before you can participate in the study.  These 
are routine tests that require about 2 to 4 tablespoons of blood withdrawn from your arm.  
The blood will be drawn by nurses at the Human Nutrition Research Clinic at the 
University of Minnesota in St. Paul, The results will be available in 2-4 weeks, and you 
will be notified if you meet the criteria for our study.  At that point, you will be able to 
schedule appointments at the clinic for the entire year of the study at your convenience, 
keeping in mind that 3 appointments—at months 0, 6, and 12—will require you to have 
been fasting since 10 o’clock the night before, so these appointments will be in the 
morning (between 7:30 and 10).  If you do not meet the criteria for our study, you will be 
informed and compensated for your time. 
Would you like to hear more information?      
I will give you a brief description of the study.  If you would like to participate, we can 
schedule an orientation session to explain the study in more detail and answer all the 
questions you may have.  As part of a clinical trial, you will be randomly assigned to 
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consume either a green tea extract or placebo capsule twice a day for one year.  During 
one year, biological markers from your blood and urine associated with breast cancer 
risk will be evaluated throughout fourteen clinic visits at the Human Nutrition Research 
Clinic (HNRC) of the University of Minnesota. Each clinic visit can take 0.5-1.5 hours. 
During each clinic visit, your weight, blood pressure, heart rate, and respiratory rate will 
be measured. Your waist and hip circumferences will also be measured at the second 
and last (fourteenth) clinic visits. Each clinic visit involves drawing a little more than 1 
teaspoon to 4 tablespoons blood depending on the clinic visit. For 3 visits, at the month 
0, month 6, and month 12, you will need to have been fasting since 10 pm the night 
before your clinic visit. You will collect your entire 24 hour urine at the baseline, month 6, 
and 12 and will bring collected urine in provided jugs to the HRNC for the clinic visits 2, 
8, and 14.You will also complete a food frequency questionnaire, which is a survey 
about your eating habits that takes approximately 60 minutes. Your first routine 
mammogram will be compared with the mammogram that you are normally scheduled 
for during the following year, at the end of study. Finally, you will be asked to avoid 
drinking green tea during the study period so we will be able to assess the exact effect of 
consumed green tea extract. 
• Would you like to come to an orientation to learn more about participating in 
our study? 
 
Circle one of each of the following: 
 
   Status:       Preferred contact:     
Orientation session: 
 
 ELIGIBLE        EMAIL     
_____/_____/______ 
 
INELIGIBLE       PHONE     
_________________ 
 141 
 
III. MGTT Consent Form 
CONSENT FORM 
Study Title:  Green tea and reduction of breast cancer risk  
You are invited to be in a research study of how green tea extract consumption affects 
levels of biological factors (biomarkers) that may influence breast cancer risk. We ask 
that you read this form and ask any questions you may have before agreeing to be in the 
study. This study is being conducted by Mindy Kurzer, Ph.D., Jian-Min Yuan, M.D, Tim 
Emory, M.D., Carolyn Torkelson, M.D. of the University of Minnesota and Karen 
Swenson, Ph.D of Park Nicollet.   
 
The purpose of this study is to determine the effect of green tea consumption on breast 
cancer biomarkers, such as mammographic density and sex hormone levels, to further 
understand how green tea might reduce the risk for breast cancer.  Although there is 
research that indicates that green tea reduces risk for breast cancer, not much is known 
about how green tea reduces risk. We think that green tea might change the way women 
metabolize estrogen, a sex hormone. We also think that green tea may reduce oxidative 
stress. Both of these physical changes have been shown to reduce breast cancer risk. If 
we can show that green tea changes these factors for the better, it will help us to better 
understand how green tea reduces risk for breast cancer. In addition, we are going to 
evaluate specific genetic variations to find out whether these genetic variations influence 
your physiological responses to the protective effects of green tea on biomarkers of breast 
cancer risk.   
 
The genetic testing done in this study will measure genetic markers that are not related to 
breast cancer risk or risk of any other disease.  We will simply be examining genetic 
variations that may influence your physiological response to green tea consumption. 
Catechol-O-methyltransferase (COMT) is the main enzyme responsible for breakdown 
and excretion of the active compounds in green tea that we think are responsible for the 
cancer-preventive effects. Previous studies have shown that people with the low-activity 
COMT (which is more common) gene benefit more from possible anti-carcinogenic 
properties of green tea than people with the high-activity COMT gene (which is less 
common). We will also test two other genes that help break down these green tea 
compounds: SULT and UGT genes. You will not receive any results or counseling 
regarding the genetic testing.  No genetic markers related to disease risk will be 
evaluated. 
 
Procedures: 
We anticipate that we will screen up to 8,000 women to find the required 800 participants 
and place them into either the treatment or control group according to a process that will 
not be under your control or the study investigators’.  First, we will perform blood tests to 
confirm that you meet the study criteria and to evaluate your genetic variations in the 
COMT gene.  The results of these tests will determine whether or not you can continue 
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with the study.  Once we have determined that you are eligible to continue, the process 
used to place participants into groups will be random (like the flip of a coin). Half the 
participants will be placed in the treatment group and will consume two green tea extract 
capsules twice per day (two in the morning and two in the afternoon) for one year. The 
other half will be placed in the control group and will consume two placebo capsules 
twice per day for one year. Capsule assignments will be made by the University of 
Minnesota Medical Center/Fairview Investigational Drug Services (IDS) Pharmacy.  
Green tea extract and placebo capsules will be identical and will be administered to the 
subjects by a research staff member or nurse at the HNRC blinded to the contents in the 
capsules. Once you are placed into the treatment or control group it will not be possible 
to change groups.  Neither you nor the investigators will know which group you are in.  
 
Please note that even though you may initially qualify for participation, you may not be 
invited to participate in the study after the first blood tests are performed. 
If you agree to be in this study, we would ask you to do the following things:  
1. Go to the Human Nutrition Research Clinic (HNRC) at the Food Science and 
Nutrition Department of the University of Minnesota in Saint Paul, MN 10 times 
during a 12-month time period. All ten clinic visits will involve a blood draw. At 
five clinic visits, urine samples will also be collected.  Clinic visits 3, 4, 6 and 7 
have the option of being completed at Fairview Crosstown, Fairview Jonathan, 
Fairview Oxboro, Fairview Maple Grove and Fairview Farmington.  The visits 
are described in detail below. 
2. At the beginning of the study and at the 6th and 12th month, collect all urine for 24 
hours in jugs that will be provided.   
3. Go to the University of Minnesota Medical Center (UMMC)/Fairview Breast 
Center, Fairview Southdale Breast Center, or Fairview Maple Grove Breast 
Center for your routine annual mammogram at the end of the study. 
4. Allow a portion of the blood drawn at the first clinical blood draw (about 1 
tablespoon) to be used for DNA analysis. DNA will be isolated from your blood 
sample and stored. We will then analyze the gene variations, which will allow us 
to determine if these gene variations influence your response to green tea extract 
consumption.  
5. Keep your body weight stable during the study, and do not participate in any 
weight loss or weight gain studies or programs.   
6. Consume four capsules per day for one year, containing either green tea extract or 
placebo, as decided by the researchers on a full stomach only, two in the morning 
and two in the afternoon. 
7. Refrain from drinking more than one cup of green tea per week while 
participating in the study. 
8. Refrain from drinking more than 7 alcoholic beverages per week while 
participating in the study.  
 
Here is the list of measurements to be made in this study 
• Body weight 
• Height 
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• Waist and hip circumferences 
• Blood pressure, heart rate, respiratory rate and body temperature 
• Completing a Food Frequency Questionnaire 
• Completing a Health History  Questionnaire 
• Completing a Menopause-Specific Quality of Life questionnaire 
• Blood collections (a little more than 1- 4 tablespoon(s) depending on the clinic 
visit, 14 times) for evaluation of plasma F2-isoprostanes (marker of oxidative 
stress), insulin like growth factor –1 (IGF-1) and its binding proteins (these 
are biomarkers for breast cancer), reproductive hormones, liver enzymes, 
vitamin D, glucose, insulin, HbA1c (a blood test for determining your blood 
glucose over prolonged periods of time), C-peptide (a factor useful in 
assessing insulin function and secretion), HDL-Cholesterol, LDL-C, Total-C, 
TG (lipid factors), oxidized LDL-C (a risk factor for heart disease), hsCRP, 
IL-1β, IL-6, IL-8, TNF-α (proteins in blood involved in immune system 
regulation), prolactin (a hormone that affects growth of the mammary glands), 
adiponectin (a protein that regulates glucose and lipids metabolism), 
osteocalcin, pyridinolines, osteoprotegerin, CTX and NTX (biomarkers for 
bone metabolism), ghrelin and leptin (hormones involved in appetite and 
weight regulation), catechins (green tea bioactive compounds), HBsAg, anti-
HBc, anti-HCV (markers for hepatitis B and C), assessing DNA repair 
capacity and specific changes in the following genes that are related to 
metabolism of the green tea bioactive compounds: COMT, GSTM1, GSTT1, 
UGT, SULT, IGF-1, IGFBP-3, PIK3CB and HSD3B1  
• Urine collection (two spot urines at the clinic in 10% of the subjects and three 
24-hour complete collections for all subjects) for measurement of creatinine (a 
muscle metabolite), estrogens and catechins   
• Mammogram to evaluate the changes in your breast density from baseline 
visit to the end of the study. Breast density changes measured by the 
mammograms will be calculated by aid of a computer program. 
 
Detailed Description of Clinic Visits: 
Clinic visit 1  
This clinic visit will take place at the Human Nutrition Research Clinic (HNRC), Food 
Science and Nutrition, University of Minnesota Saint Paul, MN. Measurements taken at 
this visit (hepatitis B and C virus infection, liver function and COMT gene variations) 
will be used to make the final assessment of eligibility. A trained medical professional 
will weigh you, measure your height, take your blood pressure while you are resting and 
then draw 45mL (about 3 tablespoons) of blood. You will be sent home with a urine 
collection container and instructions should you meet all inclusion criteria and return for 
Visit 2 to be randomized into the study.  If you are found to be ineligible due to not 
fulfilling the criteria for inclusion in the study after this visit, you will be notified within 
one month, released from the study and thanked for your time.  This visit will take 
approximately 30 minutes. 
 
Clinic visit 2 
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This clinic visit takes place at the HNRC after checking your eligibility at the first clinic 
visit. You should not have had anything to eat or drink other than water for 10 hours prior 
to your clinic visit. A trained medical professional will weigh you, measure your height, 
take your blood pressure while you are resting and will draw 65mL blood (about 4 
tablespoons). After that, your waist and hip circumferences will be measured using a tape 
measure. You will also complete a health survey, a quality of life questionnaire and a 
food frequency questionnaire as part of this visit. At the end of this visit, you will be 
given your first 3 month supply of capsules and a study log for recording pills which you 
have taken. You will also bring the first 24-hour urine collection to the HNRC at this 
visit. This urine was collected the day before and kept refrigerated until delivery to the 
HNRC.  The visit will take approximately 30 minutes. 
 
Clinic visit 3 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 2. A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 4  
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 3. A trained medical professional will 
draw 5mL (about one teaspoon) of your blood.  This visit will take approximately 30 
minutes. 
 
Clinic visit 5  
This clinic visit takes place approximately one month after clinic visit 4. A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting.  The trained medical professional will draw 5mL of blood 
(about one teaspoon), and you will provide a urine sample. You will be asked to bring 
your empty or partially empty bottles of your capsules and study log to this visit. At the 
end of this visit, you will be given your next 3-month supply of capsules and materials to 
complete your 24 hour urine collection for clinic visit 8 in several months. This visit will 
take approximately 30 minutes.  
 
Clinic visit 6 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 5.  A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 7 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
within one month after clinic visit 6. A trained medical professional will draw 5mL 
(about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 8 
This visit takes place at the HNRC approximately one month after your clinic visit 7. You 
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will be asked to not eat or drink anything but water for 10 hours prior to your clinic visit 
and to bring your empty or partially empty bottle of capsules and study log.  A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting. A trained medical professional will draw 65mL blood (about 4 
tablespoons). You will also bring your 24-hour urine collection from the previous day. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC. You will be asked to bring your empty or partially empty bottles of your 
capsules and pill diary. As part of this visit, you will complete a quality of life 
questionnaire, and you will be given your next 3 month supply of capsules. This visit will 
take approximately 30 minutes. 
 
Clinic visit 9 
This visit takes place at the HNRC approximately three months after your clinic visit 8. 
This visit repeats the tests and measurements taken in clinic visit 5. A study staff member 
will weigh you, measure your blood pressure, body temperature and heart rate while you 
are resting. A trained medical professional will draw 5mL of blood (about one teaspoon). 
At this visit, you will also provide a urine sample. You will be asked to bring your empty 
or partially empty bottles of your capsules and study log. At the end of this visit, you will 
be given your last 3 month supply of capsules and materials to complete your 24 hour 
urine collection for clinic visit 10 in several months. This visit will take approximately 30 
minutes.  
 
Clinic visit 10 
This is your last clinic visit. This visit will be scheduled at the HNRC approximately 
three months after your clinic visit 9, during month 12 of your participation. You will be 
asked to not eat or drink anything but water for 10 hours prior to this visit and to bring 
your empty or partially empty bottle of capsules, study log and 24-hour urine collection. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC.  A study staff member will weigh you, measure your blood pressure, body 
temperature and heart rate while you are resting. Your waist and hip circumferences will 
be measured as well. A trained medical professional will draw 65mL of blood (about 4 
tablespoons). You will also complete a quality of life questionnaire and a food frequency 
questionnaire as part of this visit. This visit will take approximately 30 minutes. 
 
Specific procedures to be performed: 
 
Food Frequency Questionnaire  
At clinic visits 2 and 10 you will complete a questionnaire about your eating habits over 
the past year. This survey is given in a web-based format and should take about 60 
minutes.  
 
Menopause-Specific Quality of Life Questionnaire 
At clinic visits 2, 8, and 10 you will answer questions regarding your experience of 
certain physical, psychosocial, and sexual symptoms over the previous week. These 
questions are designed to assess your quality of life in association with your menopausal 
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experience. The required time to complete this questionnaire will be less than 15 minutes. 
 
Collection of 24-hour urine samples 
The day before clinic visits 2, 8 and 10, you will collect all urine for a 24-hour period in 
jugs that we provide to you. You will keep them refrigerated and bring them to the clinic 
at the time of your visit. 
 
Mammogram 
As part of your routine medical checkup, you will undergo one mammogram within one 
week of finishing the study.  Also, you might need to wait for your next annual 
mammogram until the Green Tea Study is over, which could be up to 15-16 months from 
your initial mammogram. 
 
Risks of Being in the Study: 
Participating in this study has the following risks: 
 
First, liver toxicity has been seen in a few subjects who used green tea extract as a weight 
reduction aid. The risk of toxicity from taking manufactured green tea extracts has been 
estimated to be about 1 case out of 83,812 treatments, although no toxicity has been 
reported in any clinical trials performed to date. To be cautious, we will measure liver 
enzymes 9 times throughout our study for possible toxicity and tolerance at each visit at 
the HNRC or a Fairview clinic. If your liver enzymes are elevated, you will be informed 
and released from the study. 
 
Second, as with any dietary supplement or pharmaceutical, there is a slight risk of 
stomach upset, nausea, vomiting, and diarrhea.  To prevent any of these digestive 
problems, we advise that you take the study supplement on a full stomach, after breakfast 
and after dinner.  There is also a slight risk of headache from consuming the study 
supplement.  If discomfort persists, you may contact the study coordinators. 
 
You may experience discomfort from hunger and feel inconvenienced by having stop 
eating 10 hours before the blood draws at visits 2, 8 and 10 of the study.   
 
Also, there is a small risk of infection and bruising at the needle puncture site when blood 
is taken. The risk is minimal as all needles and equipment are sterilized and the 
procedures are performed by trained phlebotomists: registered nurses and certified 
medical assistants at the HNRC or a Fairview clinic. You may also feel some pain, 
dizziness, or feel faint lasting a few seconds upon insertion of the needle used to draw the 
blood. 
 
Lastly, screening mammography is the best way to detect early breast cancers.  You are 
currently getting your mammograms approximately every 12 months.  If you participate 
in this study, your mammogram may be delayed by at most 3-4 months.  Some experts 
(U.S. Preventive Services Task Force, 2009) have suggested that this type of delay has 
little effect on the benefits of mammography.  If you wish to have your regular 
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mammogram on a yearly basis, we will ask you to have a second limited view research 
mammogram after you have been on the study for 1 year.  The additional limited view 
mammogram would be at no cost to you. 
   
Benefits of Being in the Study: 
There may be no direct reduction of breast cancer risk as a result of participation in this 
study. Additionally, upon your request we can send the first liver function test results 
conducted at your screening visit to you or your primary care physician. 
 
Costs:   
No charges will be made for the Human Nutrition Research Clinic (HNRC) any Fairview 
clinic visits while you are a participant in this study. 
 
Compensation  
You will also receive financial compensation of up to $450 for study participation:  $20 
for completing the first clinic visit, $70 for the next four clinic visits (clinic visits 2, 3, 4 
and 5), $100 for the next three clinic visits (6, 7, 8), $60 for clinic visit 9, and $100 for 
completing the last clinic visit (clinic visit 10). Finally, upon completion of all clinical 
research endpoints (visits, questionnaires and mammogram), you will receive another 
$100 at the end of the study.   
 
Participants found ineligible after completing the first clinic visit will receive $20.00.  
Participants who become ineligible during the study will receive pro-rated compensation. 
 
Care in the case of injury 
In the event that this research results in an injury, treatment will be available, including 
first aid, emergency treatment, and follow-up care as needed. Care for such injuries will 
be billed in the appropriate manner, to you or your insurance company. If you think that 
you have suffered a research-related injury, let the principal investigator or a study 
coordinator know right away Dr. Mindy Kurzer: (612-624-9789) or study coordinators: 
(612-624-3412). 
 
Your participation in the study may be terminated by the investigator without 
regard to your consent in the following circumstances: 
1. Failure to come to clinic visits after one reschedule 
2. Circumstances change so that you are no longer eligible  
 
Confidentiality: 
The information provided by you and the information taken from the measurements of 
your body will be held strictly confidential and used for the purposes of research only. 
The HNRC, whose staff has completed the federally required training with regard to 
confidentiality of health information in research, will maintain medical records with your 
name on them for the purposes of scheduling and billing procedures only. Any/all 
medical information gathered, test results, lab samples will NOT have your name on 
them. Instead, they will be labeled with a study ID number only. 
 148 
 
Laboratory results and other test results will not be included in the medical record. Your 
name will be associated with your study ID number on one list, to be kept in a locked file 
cabinet.  Your study ID number will appear on all other study records.  Representatives 
of the University of Minnesota or the National Institutes of Health may be given access to 
your records to assure that the study is conducted properly. 
 
All your study records will be kept private, in locked storage according to HIPAA 
standards. None of your information will ever be given to anyone, and your name will 
never be associated with your records on paper or on computer.  In any sort of report we 
might publish, we will not include any information that will make it possible to identify 
you as a subject of this study.  
 
With regard to your blood and urine samples:  
• We will send samples of your blood with only a code number on it to the 
University of Southern California (USC) to analyze it for biomarkers of breast 
cancer called IGF-1, binding proteins for IGF-1, as well as reproductive 
hormones. USC will be paid to do these tests .We will NOT tell USC researchers 
your name or give them any identifying information about you. Any excess blood 
will be destroyed when researchers have completed these tests.  
 
• We will send samples of your blood and urine with a code number on it to 
Rutgers University to analyze it for plasma and urine catechin levels. Rutgers 
University will be paid to do these tests. We will NOT tell Rutgers University 
researchers your name or give them any identifying information about you. Any 
excess blood and urine will be destroyed when researchers have completed with 
these tests.  
 
• We will store any remaining blood and urine in a freezer in the Food Science and 
Nutrition Building at the University of Minnesota (St. Paul campus). The vials 
will have your study ID on them and the date on which the blood was drawn. 
Your name will NOT be stored with your blood. We will store these vials for up 
to 5 years after the entire study is over. The freezer in which they are stored is 
kept behind a locked door. The only people who have access to this freezer are 
paid research staff members who have completed the federally required training 
with regard to confidentiality of health information in research. The purpose for 
storing these samples is to enable us to conduct additional tests regarding green 
tea health effects. The principal investigator will maintain ownership of these 
samples while they are stored. Samples will be destroyed within five years after 
the completion of the study. You will not receive any results from future tests 
conducted with these stored samples.  
 
• USC and Rutgers University labs do NOT have access to your name. There is one 
confidential list and file that links your ID to your name. These files will be kept 
in the locked file cabinet as described above. The only people who will have 
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access to this list are the principal investigator (Dr. Kurzer) and her research staff, 
who have completed the federally required training with regard to confidentiality 
of health information in research.   
 
Protected Health Information (PHI) 
Your PHI created or received for the purposes of this study is protected under the federal 
regulation known as the Health Insurance Portability and Accountability Act of 1996 
(HIPAA).  Refer to the accompanying HIPAA authorization for details concerning the 
use of this information.  
 
A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and 
employers of 15 or more persons to discriminate against you based on your genetic 
information. Health insurance companies and group health plans may not request your 
genetic information that we get from this research. This means that they may not use your 
genetic information when making decisions regarding insurability. Be aware that this 
new federal law will not protect you against genetic discrimination by companies that 
sell life insurance, disability insurance, or long-term care insurance. 
 
Voluntary Nature of the Study: 
Your decision whether or not to participate will not affect your current or future relations 
with the University. If you decide to participate, you may withdraw at any time without 
affecting those relationships.  In addition, you may request your blood and urine samples 
to be destroyed following your withdrawal from the study. The procedure to withdraw is 
to call Mindy Kurzer, Ph.D. at (612) 624-9789 or the study coordinators at (612) 624-
3412 and inform them that you wish to withdraw.   
 
New Information: 
If during the course of this research study, there are significant new findings discovered 
that might influence your willingness to continue, the researchers will inform you of 
those developments. 
 
 Contacts and Questions: 
The primary researcher conducting this study is Mindy Kurzer, Ph.D.  If you have 
questions, you may contact her at the Department of Food Science and Nutrition, 
University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55108. Phone: (612) 624-9789; 
email: mkurzer@umn.edu. You may also contact the study coordinators in the 
Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., 
St. Paul, MN 55108. Phone: (612) 624-3412; email: greentea@umn.edu. 
  
If you have any questions or concerns regarding the study and would like to talk to 
someone other than the researcher(s), you are encouraged to contact the Fairview 
Research Helpline at telephone number (612)672-7692 or toll-free at (866) 508-6961. 
You may also contact this office in writing or in person at University of Minnesota 
Medical Center/Fairview Riverside Campus, 2200 Riverside Avenue, Minneapolis, MN 
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55454. 
 
Statement of Consent: 
I have read the above information. I have asked questions and have received answers. I 
consent to participate in the study.  
 
________________________________________________________________________    
Signature of Participant                                                                                   Date 
 
________________________________________________________________________ 
Name of Participant (printed) 
 
________________________________________________________________________ 
Street Address          City       State      Zip code 
 
________________________________________________________________________    
Signature of Person Obtaining Consent                Date 
You will be given a copy of this form for your records. 
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IV. Health History Questionnaire 
 
Green Tea Study 
 
Name: _________________  Date: __________________ 
Date of Birth (mm/dd/yyyy): ____________________ 
Level of Education, please circle one: 
• Some high school (1) 
• High school graduate (2) 
• Some college (3) 
• College degree (4) 
• Masters/PhD/Professional (5) 
 
Ethnicity (Please circle one): 
• Hispanic (1) 
• Non-Hispanic (2) 
• Do not wish to provide (3) 
 
Race (Please circle one): 
• American Indian or Alaska Native (1) 
• Asian (2) 
• Native Hawaiian or Other Pacific Islander (3) 
• Black or African American (4) 
• White (5) 
• More than one race (6) 
• Do not wish to provide (7) 
 
*Please answer the following questions as accurately as possible.* 
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General Health 
1. How would you describe your overall health? 
 
Poor (1)  Good (2)  Very Good (3)  Excellent (4) 
 
2. Has your weight changed in the past year?    YES (1)      NO (2) 
 
A) If yes, how many pounds have you: Gained: _____ Lost: ____ 
 
B) Please explain the reason 
___________________________________________ 
 
3. Do you exercise regularly?          YES (1)     NO (2)     
 
4.                                                                                                                                                                         
A) How many days per week do you exercise?  
_________________________ 
 
B) How intense is your exercise: 
 
 Mild (1)  Moderate (2)   Maximal (3) 
5. Please indicate in the table below, how many hours  per week were spent on 
the listed activities:       
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6. Do you have any allergies (other than foods)  YES (1)     NO (2) 
 
A) If yes, please describe         
           
 
7. Are you a regular blood donor?    YES (1)     NO (2) 
A) If yes, how many times per year do you donate?  ________/per year 
 
8. Have you smoked at least 100 cigarettes in your lifetime? YES (1)     NO (2) 
 
 # of Hours Per Week: 
Sitting at work (1)  
Sitting or driving (e.g. car, bus) (2)  
Sitting or lying watching TV (3)  
Sitting at home reading (4)   
Sitting other (e.g. eating, computer) (5)  
Walking to work or for exercise (including golf) (6)  
Jogging (slower than 10 minutes/mile) (7)  
Running (10 minutes/mile or faster) (8)  
Bicycling (including stationary machine) (9)  
Lap swimming (10)  
Tennis (11)  
Squash or racquetball (12)  
Calisthenics (e.g. rowing, stair, elliptical machine, etc.) (13)  
Weightlifting or weight machine (14)  
Heavy outdoor work (e.g. digging, chopping) (15)  
Other (Please specify): (16)  
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9. Do you now smoke cigarettes?    YES (1)     NO (2) 
 
10. If you’ve stopped smoking:  
A) How long has it been since you quit?    _____(years) 
 
B) How frequently did you smoke? ____________ (# of days/week) 
 
C) On average, how many cigarettes did you smoke per day? 
____________ 
 
11. How many people living in your household regularly smoke at home (one 
cigarette or more on 4 days or more out of the week)? 
______________________ 
 
12.  Do you use recreational drugs?     YES (1)     NO (2) 
 
Food Consumption Patterns 
12. Are you on a special diet now?    YES (1)     NO (2) 
A) If yes, please circle one: 
 
• Gluten-free (1) 
• High Fiber (2) 
• Lactose Intolerance (3) 
• Low Fat (4) 
• Low Carbohydrate (5) 
• Low Sodium (6) 
• Vegetarian (7) 
• Other (8), please describe: ______________________ 
 
13. Have you significantly changed your eating habits in the past 5 years?   
 
YES (1)     NO (2)  
 
A) If yes, please describe when, why, and how eating habits changed 
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14.  Do you have any food allergies?    YES (1)     NO (2) 
A) If yes, what are they?        
  _____        
    
 
15. Are you a vegetarian?                YES (1)     NO (2) 
A) If you are a vegetarian, do you eat eggs?            YES (1)     NO (2) 
 
B) If you are a vegetarian, do you drink milk?  YES (1)     NO (2) 
 
16.   Do you consume soy milk, foods, or supplements of any kind?   YES (1)     
NO (2) 
A) If yes, what type of soy products do you consume? 
• Tofu (1) 
• Soy milk (2) 
• Soy burger (3) 
• Soy nuts (4) 
• Edamame (5) 
• Soy protein bar (6) 
• Others (7) 
 
B) How often do you consume them (if you consume more than one 
product, please take an average and circle only one option below? 
• Never /Hardly Ever (1) 
• Once a Week (2) 
• 2–3 Times a Week (3) 
• 4–6 Times a Week (4) 
• 1–3 Times a Month (5) 
• Once a Day (6) 
• 2+ Times a Day (7) 
 
17. Do you consume Tea?               YES (1)     NO (2) 
 
If yes, how many cups of the following do you consume each week? 
A) Green Tea (1):  __________________________/Per Week 
B) Black Tea (2):   __________________________/Per Week  
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C) Herbal Tea (3):  _________________________ /Per Week 
D) Other (4); Please Specify: _________________ /Per Week  
 
18. Do you consume alcohol?     YES (1)     NO (2) 
A) If yes, how many drinks* per week? 
________________________________ 
 
*1 drink = 12oz beer, 4oz wine, 1oz hard liquor 
Medical History 
19. Please indicate if you or a family member has ever been diagnosed with any 
of the following. If it is a family member, please indicate if it is first- , or 
second-degree relative.  
- Examples of first-degree relative: parent, offspring or sibling. 
- Examples of second-degree relative: grandparent, grandchild, uncle, aunt, 
nephew, or niece. 
 
Condition You 
First 
Degree 
Second 
Degree 
 Breast cancer (1) Y  /  N Y  /  N Y  /  N 
 Fibrocystic breast disease (2) Y  /  N Y  /  N Y  /  N 
 Uterine cancer (3) Y  /  N Y  /  N Y  /  N 
 Endometrial cancer (4) Y  /  N Y  /  N Y  /  N 
 Cervical cancer (5) Y  /  N Y  /  N Y  /  N 
 Colon cancer (6) Y  /  N Y  /  N Y  /  N 
 Any other cancer (7) Y  /  N Y  /  N Y  /  N 
 Endometriosis (8) Y  /  N Y  /  N Y  /  N 
 Pelvic inflammatory disease (9) Y  /  N Y  /  N Y  /  N 
Frequent bladder infections (>1 per yr) 
(10) Y  /  N Y  /  N Y  /  N 
 Frequent yeast infections (>1 per yr) 
Y  /  N Y  /  N Y  /  N 
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(11) 
 Diabetes (12) Y  /  N Y  /  N Y  /  N 
 Overactive/underactive thyroid (13) Y  /  N Y  /  N Y  /  N 
Other hormone related diseases (E.g. 
pituitary, fertility, adrenal, etc.) (14) Y  /  N Y  /  N Y  /  N 
 Eating Disorder (15) Y  /  N Y  /  N Y  /  N 
 High cholesterol (16) Y  /  N Y  /  N Y  /  N 
 High blood pressure (17) Y  /  N Y  /  N Y  /  N 
 Stomach/intestinal ulcers (18) Y  /  N Y  /  N Y  /  N 
 Diverticular disease (19) Y  /  N Y  /  N Y  /  N 
 Hemorrhoids (20) Y  /  N Y  /  N Y  /  N 
 Ulcerative colitis (21) Y  /  N Y  /  N Y  /  N 
 Chronic constipation (22) Y  /  N Y  /  N Y  /  N 
 Chronic diarrhea (23) Y  /  N Y  /  N Y  /  N 
 Liver disorder (Hepatitis, abnormal  
liver enzymes level, etc.) (24) Y  /  N Y  /  N Y  /  N 
 
20. Are there any other mental or physical health issues we should be aware of? 
 YES (1)     NO (2) 
 
A) If yes, please list.         
            
 
Medication/Dietary Supplement/Treatment History 
21. Are you currently taking any prescription medications? YES (1)     NO (2) 
 
A) If yes, please list type, amount, and frequency      
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22. Have you taken any additional prescription medications in the past 6 months?  
 
YES (1)     NO (2) 
A) If yes, please list type, amount, and frequency.     
            
 
23. Have you ever undergone chemotherapy?   YES (1)     NO (2) 
 
If yes, at what age and for how long where you on chemotherapy? 
  
A) Age:    B) Duration: ______________ (months) 
 
C) What was the reason for needing chemotherapy? ________________ 
 
24. Have you ever taken tamoxifen (1), raloxifene (2) or aromatase inhibitors (3)?  
YES (1)     NO (2) 
A) If yes, which one(s)?          
B) How long did you take it (years)?        
C) When did you discontinue taking it?        
 
25. Do you use any over-the-counter drugs, including pain relievers?  
 
YES (1)     NO (2) 
A) If yes, please list drugs and frequency of use    
          
           
 
26. Do you take vitamin and/or mineral supplements? YES (1)     NO (2) 
 
If yes, please list brands, amounts and frequency in the following table. 
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Type Brand Amount Frequency 
Multi-vitamin (1)       
Vitamin A  (2)       
Vitamin B (including any type of 
vitamin B)  (3) 
      
Vitamin C  (4)       
Vitamin D or Vitamin D plus Calcium  
(5) 
      
Vitamin E  (6)       
Calcium or calcium plus others (not 
including vitamin D)  (7) 
      
Fish oil  (8)       
Minerals (any)  (9)       
Others  (10)        
 
27. Do you take any herbal supplements?   YES (1)     NO (2) 
 
If yes, please list types, brands, amounts and frequency 
__________________ 
__________________________________________________________ 
 
28. Do you use any other complementary medicine therapies?  
YES (1)     NO (2) 
(homeopathy, acupuncture, meditation, massage, etc.) 
A) If yes, please describe. 
__________________________________________________________
__________________________________________________________ 
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OB/GYN History 
 
29. At approximately what age did you first get your period?   ______________ 
 
30. At approximately what age did your periods became regular (about once per 
month)?  ________________ 
 
31. Have you had your uterus removed?    YES (1)     NO (2) 
 
32. Have you had any of your ovaries removed?                   YES (1)     NO (2) 
A) If yes, please circle one:    1 Ovary      Both Ovaries 
 
B) What age did you have 1 or both ovaries removed:     
________________ 
      
33. When was your last menstrual period?  
Note: If you do not remember the exact date, please provide an estimated 
age. _____________________  
 
34. If you are not currently, taking hormone replacement therapy, have you ever 
taken it in the past?     YES (1)     NO (2) 
 
A) If yes, for how long (years)?      
 
B) At approximately what age did you begin?  ________________ 
 
C) At approximately what age did you stop hormone replacement 
therapy? 
   
 
D) What product(s) did you use?       
           
 
E) What dose(s)?         
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35. Have you ever used any other treatments for menopause?   
YES (1)     NO (2) 
 
A) If yes, what product(s) did you use?     
          
 
B) How often?          
 
 
At what age did you use these treatments?      
 
36. Have you ever taken birth control pills?   YES (1)     NO (2) 
 
A) If so, for how many years total?       
 
B) At approximately what age did you start taking them?      
 
C) At approximately what age did you stop taking them?    
 
D) What was the name of the birth control pill that you used?   
           
 
37. Please give your pregnancy history: 
 
A) Number of pregnancies _____ B) Number of live births _____ 
 
38. What was the outcome of your first pregnancy? (Please circle one) 
 
• Live birth (1)      
• Still birth (2)       
• Tubal pregnancy (3)       
• Miscarriage (4)  
• Induced abortion (5) 
 
39.  What year was your first child born?  ____________ 
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40.  What year was your youngest child born?  ____________ 
 
41. Did you breast feed one or more of your children? YES (1)     NO (2) 
 
42. If you have breast fed, how many months total?  __________________ 
 
Study Logistics 
43. Why do you want to be in this study?      
• Compensation (1) 
• Altruistic reasons (2) 
• Bored (3) 
• Referred by health care practitioner (4) 
• Personal health benefit (5) 
• Other (6): A) please, specify: 
________________________________________________________________
_____________________________________________________ 
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Appendix 2. Supplementary Materials for Body Composition Study (Chapter 4) 
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I. Consent Form  
 
CONSENT FORM 
Study Title: Green Tea Consumption and Reduction of Body Fat  
Your Body Mass Index (BMI) of ≥ 25 kg/m2 has qualified you to participate in a sub-
study of the Green Tea and Breast Cancer Risk Reduction Study. The purpose of this 
study is to determine the effect of green tea consumption on body fat, as a percentage of 
total body weight and total body fat mass.  
Procedures: 
We anticipate that we will screen up to 300 women to find the required 130 participants 
to complete this portion of the study. Each woman will undergo two dual-energy X-ray 
absorptiometry (DXA) scans. A DXA scan is a painless, non-invasive procedure that is 
used to evaluate bone density and can also be used to determine total body composition 
and fat content with a high degree of accuracy. The first DXA scan will be completed at 
the beginning of your participation in the study, to determine your baseline level of body 
fat. The second scan will be completed at the end of your 12 months of participation in 
conjunction with your final clinic visit. Completing scans at baseline and at the end of the 
study will allow us to determine if there were any changes to body fat mass and/or body 
fat percentage during the time that participants were consuming the green tea or placebo 
supplement. 
If you agree to be in this study, we would ask you to do the following things: 
1. Go to the Delaware Clinical Research Unit (DCRU), located on the East Bank of 
the University of Minnesota in Minneapolis, MN, twice during a 12-month time 
period to complete DXA scans.  
2. Comply with all guidelines detailed in the original consent form for the Green Tea 
Study, including not actively attempting to gain or lose weight during the study 
and not participating in any weight loss or weight gain studies or programs. 
 
Specific Procedures to be Performed: 
 On the day of the exam you may eat normally. You should wear loose, 
comfortable clothing, and you will be asked to remove some or all of your clothes 
and wear a gown during the exam. You may also be asked to remove jewelry, 
removable dental appliances, eyeglasses, and any metal objects or clothing that 
might interfere with the x-ray images.  
 Inform DCRU personnel if you have recently had a barium examination or have 
been injected with a contrast material for a computed tomography (CT) scan or 
radioisotope scan. You may have to wait 30 days before undergoing a DXA test. 
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 You must hold very still and may be asked to keep from breathing for a few 
seconds while the x-ray picture is taken to reduce the possibility of a blurred 
image. The DXA scan is usually completed within 10 minutes.  
 Plan to be at the DCRU for a total of 30 minutes. 
 
Risks of Being in the Study: 
DXA scans involve exposure to minimal amounts of ionizing radiation. The total of 2 
scans over the duration of the one-year study results in a cumulative ionizing radiation 
exposure (0.20 mrems) that is far less than that of one chest x-ray (40 mrems), and which 
is well within acceptable limits and poses minimal risk to subjects.  
Benefits of Being in the Study 
You will receive a written report detailing the results of your baseline and end-of-study 
DXA scans at the end of your participation. There may be no change in body fat as a 
result of participation in this study.  
Costs 
No charges will be made for visits to the DCRU while you are a participant in this study. 
Compensation 
You will receive financial compensation of up to $50 for study participation: $20 for 
completing the first DXA scan and $30 for completing the end-of-study DXA. 
Care in the Case of Injury 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If you 
think that you have suffered a research related injury, let the study physicians know right 
away. 
Dr. Carolyn Torkelson, MD: (612) 625-8718 
Dr. Mindy Kurzer: (612) 624-9789  Study Coordinators: (612) 624-3412 
Confidentiality  
The information provided by you and the information taken from the measurements of 
your body will be held strictly confidential and used for the purposes of research only. 
The DCRU, whose staff has completed the federally required training with regard to 
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confidentiality of health information in research, will maintain medical records with your 
name on them for the purposes of scheduling and billing procedures only. Any/all 
medical information gathered and test results will NOT have your name on them. Instead, 
they will be labeled with a study ID number only.  
Test results will not be included in the medical record. Your name will be associated with 
your study ID number on one list, to be kept in a locked file cabinet.  Your study ID 
number will appear on all other study records.  Representatives of the University of 
Minnesota or the National Institutes of Health may be given access to your records to 
assure that the study is conducted properly. 
 
Your study records will be kept private, in locked storage according to HIPAA standards. 
None of your information will be given to anyone, and your name will never be 
associated with your records on paper or on computer.  In any sort of report we might 
publish, we will not include any information that will make it possible to identify you as 
a subject of this study.  
 
Protected Health Information (PHI) 
Your PHI created or received for the purposes of this study is protected under the federal 
regulation known as the Health Insurance Portability and Accountability Act of 1996 
(HIPAA).  Refer to the accompanying HIPAA authorization for details concerning the 
use of this information.  
Voluntary Nature of the Study 
Your decision whether or not to participate will not affect your current or future relations 
with the University. If you decide to participate, you may withdraw at any time without 
affecting those relationships. The procedure to withdraw is to call the study coordinators 
at (612) 624-3412 and inform them that you wish to withdraw.   
New Information 
If during the course of this research study, there are significant new findings discovered 
that might influence your willingness to continue, the researchers will inform you of 
those developments. 
Contacts and Questions 
The primary researcher conducting this study is Mindy Kurzer, Ph.D.  If you have 
questions, you may contact her at the Department of Food Science and Nutrition, 
University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55108. Phone: (612) 624-9789; 
email: mkurzer@umn.edu. You may also contact the study coordinators in the 
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Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., 
St. Paul, MN 55108. Phone: (612) 624-3412; email: greentea@umn.edu. 
You may also contact the Fairview Research Helpline Office:  
Phone: (612)672-7690, or E-mail: research@fairview.org  
Fairview Research Administration, 2433 Energy Park Drive, St. Paul, MN 55108. 
Statement of Consent: 
I have read the above information. I have asked questions and have received answers. I 
consent to participate in the study.  
________________________________________________________________________    
Signature of Participant                                                                                   Date 
________________________________________________________________________ 
Name of Participant (printed) 
________________________________________________________________________ 
Street Address          City       State      Zip code 
________________________________________________________________________    
Signature of Person Obtaining Consent               Date 
You will be given a copy of this form for your records. 
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II. Physical Activity Questionnaire (Body Composition Study, Chapter 4) 
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Appendix 3. Supplementary Materials for Postprandial Feeding Study (Chapter 5) 
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I. Consent Form  
 
CONSENT FORM 
Study Title: Green Tea Consumption and Postprandial Response of Energy-
Related Hormones Sub-Study  
Your Body Mass Index (BMI) of ≥ 25 kg/m2 and catechol-O-methyltransferase (COMT) 
genotype has qualified you to participate in a sub-study of the Green Tea and Breast 
Cancer Risk Reduction Study. The purpose of this sub-study is to determine the effect of 
green tea consumption on energy balance through assessment of hormones related to 
satiety and energy balance after consumption of a standardized meal. Participation in 
this sub-study will allow us to better understand the mechanisms by which green tea 
consumption may alter energy balance and appetite-related hormones, which in turn 
may lower the risk of breast cancer as well as other obesity-related chronic diseases. Dr. 
Mindy Kurzer at the University of Minnesota is conducting this study. Participation in this 
sub-study is optional and will not affect your participation in the main study.  
Procedures: 
We anticipate that we will screen up to 300 women to find the required 150 participants 
to complete this portion of the study. Participants in this sub-study will first complete food 
diaries and satiety questionnaires. You will have a catheter placed by a certified 
phlebotomist or Registered Nurse in order to obtain blood samples before consumption 
of a standardized meal. Blood samples will be obtained immediately after consumption 
of the standardized meal and every 30 minutes for four hours for a total of 10 blood 
samples. This half-day clinic visit will occur in the last two months of the Green Tea 
Study (during months 11 or 12).  
If you agree to be in this study, we would ask you to do the following things: 
3. Go to the Delaware Clinical Research Unit (DCRU), located at: 717 Delaware 
Street on the East Bank of the University of Minnesota in Minneapolis, MN, or the 
Human Nutrition Research Clinic (HNRC), located at 1134 Eckles Avenue on the 
St. Paul Campus of the University of Minnesota in St. Paul, MN once during 
month 11 or 12 of the Green Tea Study. 
4. Comply with all guidelines detailed in the original consent form for the Green Tea 
Study, including not actively attempting to gain or lose weight during the study 
and not participating in any weight loss or weight gain studies or programs. 
 
Specific Procedures to be Performed: 
 During the week prior to the half-day visit, participants will record food intake on 
two assigned weekdays and one weekend day prior to the visit. Diet records will 
be reviewed during the clinic visit and later analyzed for nutrient content.  
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 Participants will be instructed to adhere to their normal energy intake and to 
refrain from exercise and alcohol the day before the test day.  
 Participants will arrive at the DCRU or HNRC between 7:00 AM and 8:00 AM in a 
fasted state (no food or beverages, other than water, for 12 hours prior to arriving 
at the clinic). 
 Baseline satiety questionnaires will be completed, a certified phlebotomist or 
Registered Nurse will place a catheter in the antecubital region of the arm, and 
fasting blood will be drawn for assessment of energy-related hormones.  
 Participants will consume a standardized breakfast consisting of a bagel with 
cream cheese, orange slices or orange juice, and 2% milk or low-fat yogurt. 
Participants will be required to eat all of the breakfast.  
 Blood will be drawn immediately after consumption of the breakfast and every 30 
minutes over a period of 4 hours (for a total of 10 blood samples) for evaluation 
of change in the outcomes of interest.  
 Participants will complete additional satiety questionnaires approximately 2 and 4 
hours after eating the standardized breakfast. 
 
Risks of Being in the Study: 
Food diary collections involve inconvenience, but no risk.   There is a small risk of 
infection and bruising at the site where the catheter is placed. The risk is minimal as all 
needles and equipment are sterilized and trained phlebotomists, registered nurses and 
certified medical assistants perform the procedures. You may also feel some pain, 
dizziness, and faintness lasting a few seconds upon insertion of the catheter used to 
draw blood. 
Benefits of Being in the Study 
There may be no direct reduction of breast cancer risk or body weight as a result of 
participation in this study. 
Costs 
No charges will be made for the visit to the DCRU while you are a participant in this 
study. 
Compensation 
You will receive financial compensation of $100 for study participation. 
Care in the Case of Injury 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If you 
think that you have suffered a research related injury, let the study physicians know right 
away. 
 172 
Dr. Carolyn Torkelson, MD: (612) 625-8718 
Dr. Mindy Kurzer: (612) 624-9789 
Study Coordinators: (612) 624-3412 
 
Confidentiality  
The information provided by you and the information taken from analyses of your blood 
will be held strictly confidential and used for the purposes of research only. The DCRU 
staff has completed the federally required training with regard to confidentiality of health 
information in research. Any/all medical information gathered and test results will NOT 
have your name on them. Instead, they will be labeled with a study ID number only.  
Test results will not be included in the medical record. Your name will be associated with 
your study ID number on one list, to be kept in a locked file cabinet.  Your study ID 
number will appear on all other study records.  Representatives of the University of 
Minnesota or the National Institutes of Health may be given access to your records to 
assure that the study is conducted properly. 
 
Your study records will be kept private, in locked storage according to HIPAA standards. 
None of your information will be given to anyone, and your name will never be 
associated with your records on paper or on computer.  In any sort of report we might 
publish, we will not include any information that will make it possible to identify you as a 
subject of this study.  
 
Protected Health Information (PHI) 
Your PHI created or received for the purposes of this study is protected under the 
federal regulation known as the Health Insurance Portability and Accountability Act of 
1996 (HIPAA).  Refer to the accompanying HIPAA authorization for details concerning 
the use of this information.  
Voluntary Nature of the Study 
Your decision whether or not to participate will not affect your current or future relations 
with the University. If you decide to participate, you may withdraw at any time without 
affecting those relationships. The procedure to withdraw is to call the study coordinators 
at (612) 624-3412 and inform them that you wish to withdraw.   
New Information 
If during the course of this research study, there are significant new findings discovered 
that might influence your willingness to continue, the researchers will inform you of those 
developments. 
Contacts and Questions 
The primary researcher conducting this study is Mindy Kurzer, Ph.D.  If you have 
questions, you may contact her at the Department of Food Science and Nutrition, 
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University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55108. Phone: (612) 624-9789; 
email: mkurzer@umn.edu. You may also contact the study coordinators in the 
Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., 
St. Paul, MN 55108. Phone: (612) 624-3412; email: greentea@umn.edu. 
You may also contact the Fairview Research Helpline Office:  
Phone: (612)672-7690, or E-mail: research@fairview.org  
Fairview Research Administration, 2433 Energy Park Drive, St. Paul, MN 55108. 
Statement of Consent: 
I have read the above information. I have asked questions and have received answers. I 
consent to participate in the study.  
 
______________________________________________________________________  
Signature of Participant                                                                                Date 
______________________________________________________________________ 
Name of Participant (printed) 
______________________________________________________________________ 
Street Address      City        State      Zip code 
______________________________________________________________________  
Signature of Person Obtaining Consent            Date 
You will be given a copy of this form for your records. 
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II. Three-day Diet Record Instructions 
INSTRUCTIONS TO RECORD DIETARY INTAKE 
Use the forms provided to record all food and beverages (including water) consumed on 
two weekdays and one weekend day during the week prior to your half-day visit. We 
recommend filling it out each time you eat. Don’t trust your memory.  
Instructions: 
1. Record the time and type of meal (e.g. breakfast, lunch, afternoon snack) when the 
food or beverage is consumed. 
2. Record every item consumed.  Please be as specific as possible to aid with 
computer entry and food substitutions if necessary. This means including all snacks, 
beverages, and any condiments added to food before, during, or after preparation 
such as mustard, ketchup, mayonnaise, butter, margarine, salt, oils added in cooking, 
dressings on salads, jam, jelly, cream, and sugar. 
• Record all beverages consumed, including water.  Be sure to note if 
beverages such as coffee, tea and soda/pop are caffeinated and/or sweetened. 
Also, if consuming a mixed alcohol drink, remember to include a portion of 
both the alcohol and the mix (soda, juice, etc.) 
• Record vitamin, mineral, and/or herbal supplements taken.   
3. Record the amount of each item consumed.  It is important to record the amounts 
as accurately as possible, in household measurements (cups, teaspoons, and 
tablespoons) or by weight (grams and ounces for solids, fluid ounces for liquids). You 
may find the information on food labels helpful for converting amounts consumed to 
estimated measurement (i.e. a potato chip label may tell you that 16 chips is 
approximately one ounce).  Do not simply record the amount listed as one serving on 
your food record; instead, record the actual amount you consumed.   
4. For complex mixture foods (e.g. casserole, salad), record each ingredient separately, 
if possible. This will help you in the analysis if your item is not listed (e.g. tuna 
casserole).  
5. Record additional information, such as the method of food preparation, brand of 
food, etc. 
 
Below are examples of diet records. Note the type of information that is recorded. Please 
make sure that you collect all information on your foods eaten.  
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III. Nutrient Analysis of High-Carbohydrate Test Meal 
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IV. Visual Analog Scale for Satiety Assessment 
 
